societi
organ
nonprofit
scientif
organ
purpos
advanc
dissemin
knowledg
area
antivir
research
achiev
object
societi
organ
annual
meet
societi
th
year
exist
member
repres
countri
membership
applic
form
inform
pleas
contact
dr
ami
patick
secretari
isar
pfizer
global
r
depart
virolog
scienc
center
drive
san
diego
ca
phone
fax
email
amypatick
pfizercom
membership
applic
form
also
avail
confer
registr
desk
websit
wwwisaricarcom
enzym
pol
gene
hiv
identifi
import
viral
target
discoveri
antihiv
therapeut
agent
viral
target
hiv
revers
transcriptas
hiv
proteas
success
investig
develop
clinic
use
therapeut
agent
research
effort
drug
discoveri
third
enzym
pol
gene
hiv
integras
result
singl
fdaapprov
drug
nevertheless
integras
essenti
hiv
replic
remain
attract
target
discoveri
new
antihiv
agent
present
report
discoveri
conceptu
new
betadiketo
acid
construct
nucleobas
scaffold
potent
inhibitor
process
strand
transfer
step
recombin
hiv
integras
inhibitor
posit
control
compound
azt
test
pbmc
cellbas
microtit
antihiv
assay
clinic
isol
nsi
phenotyp
si
phenotyp
assay
cell
integras
inhibitor
found
highli
potent
vitro
antihiv
activ
efficaci
discoveri
remark
activ
molecul
repres
uniqu
set
diketo
acid
bear
nucleobas
scaffold
uncov
new
chapter
chemistri
biolog
integras
inhibitor
potenti
therapeut
applic
berta
bosch
imma
clotetcodina
julia
blanco
eduard
paul
gemma
coma
samandhi
francesc
mitjan
anuska
llano
margarita
bofil
bonaventura
clotet
jaum
piulat
jose
est
retrovirolog
laboratori
fundacio
irsicaixa
badalona
spain
laboratorio
de
merck
farma
barcelona
spain
macrophag
key
cell
hiv
infect
spread
insid
organ
macrophag
cultur
vitro
success
infect
differenti
cytokin
macrophag
coloni
stimul
factor
mcsf
monocyt
macrophag
differenti
process
mcsf
avintegrin
upregul
concomitantli
capac
hiv
gener
product
viru
infect
present
studi
show
antiav
antibodi
inhibit
infect
primari
macrophag
effect
replic
acut
infect
macrophag
dosedepend
effect
concentr
gml
absenc
cytotox
similarli
monoclon
antibodi
target
integrin
also
inhibit
infect
cell
type
reduc
detect
bal
provir
dna
acut
infect
macrophag
complet
ineffect
bal
product
chronic
infect
macrophag
suggest
inhibit
hiv
infect
earli
stage
viru
cycl
final
small
molecular
weight
antagonist
integrin
reduc
hiv
replic
subtox
concentr
therefor
result
suggest
avcontain
integrin
could
play
role
hiv
replic
macrophag
indic
small
molecular
weight
compound
may
develop
interfer
hiv
replic
macrophag
interact
av
integrin
andrew
vaillant
hong
lu
shuwen
liu
carol
lackmansmith
roger
ptak
jeanmarc
juteau
shibo
jiang
replicor
inc
laval
que
canada
f
lindsay
kimbal
research
institut
new
york
blood
center
new
york
ny
usa
southern
research
institut
frederick
md
usa
sequenc
independ
antivir
activ
phosphorothio
oligonucleotid
inhibit
block
interact
loop
previous
describ
activ
attribut
polyanion
activ
show
pson
fulli
omethyl
deriv
also
potent
inhibitor
membran
fusion
replic
sequenceindepend
sizedepend
optim
size
base
phosphorothio
depend
manner
independ
stabil
pson
interact
heptad
repeat
region
fusion
inhibitori
activ
pson
close
correl
abil
bind
heptad
repeat
block
sixhelix
bundl
format
critic
step
process
fusion
target
cell
requir
pson
interact
also
found
depend
phosphorothio
suggest
looppson
interact
may
also
hydrophob
compon
increas
hydrophob
longer
base
pson
may
contribut
inhibitori
activ
fusion
entri
longer
pson
greater
hydrophob
potent
block
hydrophob
interact
involv
sixhelix
bundl
format
shorter
pson
base
novel
antivir
mechan
action
long
pson
import
implic
therapi
infect
envelop
virus
type
fusion
protein
chri
meier
soenk
jessel
bastian
reichardt
olaf
ludek
jan
balzarini
univers
hamburg
institut
organ
chemistri
hamburg
germani
rega
institut
medic
research
katholiek
universiteit
leuven
leuven
belgium
carbocycl
nucleosid
analogu
like
abacavir
show
interest
antivir
properti
therefor
interest
conveni
stereoselect
access
class
compound
potenti
antivir
agent
use
new
converg
synthet
strategi
start
chiral
cyclopentenol
enantiomer
pure
carbocycl
thymidin
carbadt
obtain
key
intermedi
variat
posit
pathway
allow
entri
dand
lconfigur
nucleosid
analogu
howev
use
approach
mixtur
side
product
avoid
format
product
high
yield
howev
present
side
product
recov
stereoselect
hydrobor
lead
one
intermedi
use
well
synthesi
carbocycl
nucleosid
condens
carbocycl
moieti
differ
pyrimidin
purin
nucleobas
achiev
mitsunobu
reaction
variou
analogu
prepar
via
strategi
eg
dand
lcarbabvdu
nucleosid
analogu
known
antivir
activ
addit
carbocycl
carbocycl
isonucleosid
access
reaction
sequenc
new
nucleosid
analogu
test
antivir
activ
particularli
carbadt
found
potent
antihiv
activ
deriv
show
toxic
howev
exclud
nonact
compound
relat
miss
phosphoryl
monophosph
order
prove
nucleosid
convert
cyclosalphosph
trimest
transfer
nucleotid
detail
chemistri
enzymat
antivir
activ
data
present
case
nucleotid
releas
system
show
improv
antivir
activ
compar
parent
nucleosid
michela
pollicita
candac
pert
mariateresa
polianova
alessandro
ranazzi
michael
ruff
carlofederico
perno
stefano
aquaro
univers
rome
tor
vergata
itali
georgetown
univers
washington
dc
usa
monocytesmacrophag
mm
strateg
reservoir
commonli
infect
strain
attract
target
inhibit
mediat
entri
thu
antagonist
expect
power
new
class
receptorbas
therapeut
agent
infect
dalapeptid
tamid
dapta
octapeptid
deriv
region
abl
bind
dapta
act
select
viral
entri
inhibitor
displac
bind
dapta
activ
evalu
mm
infect
two
differ
strain
bal
presenc
sever
dose
compound
dapta
inhibit
replic
mm
compar
control
measur
gag
ag
releas
cell
cultur
supernat
concentr
nm
pcr
analysi
integr
provir
dna
cultur
mm
prove
dapta
abl
block
hiv
entri
prevent
hiv
infect
mm
moreov
capabl
differ
strain
produc
releas
infect
mm
affect
neuron
homeostasi
assess
neuroblastoma
cell
line
sknsh
express
sknsh
evalu
cell
morpholog
propidium
iodid
bind
fluorescenceactiv
cell
sort
fac
analysi
dapta
concentr
nm
strongli
inhibit
apoptosi
sknsh
respect
compar
control
unexpectedli
nonpeptid
antagonist
potent
activ
inhibit
apoptosi
compar
control
result
suggest
develop
new
compound
dapta
could
import
synergist
combin
antiretrovir
treatment
prevent
central
nervou
system
hivinfect
consequ
neural
damag
mechan
dapta
inhibit
may
includ
suppress
strain
brain
direct
inhibit
replic
mm
relat
damag
bind
pradimicin
prma
antifung
nonpeptid
benzonaphtacenequinon
antibiot
specif
inhibit
human
immunodefici
viru
hiv
cell
cultur
markedli
suppress
varieti
differ
clade
pbmc
primari
macrophag
sever
siv
strain
laboratori
cell
line
rang
effect
concentr
gml
cytostat
concentr
gml
prma
also
inhibit
syncytium
format
persist
cell
uninfect
sup
cell
prma
behav
artifici
lectin
select
bind
mannosecontain
glycan
consequ
biacor
experi
reveal
bind
presenc
ca
prma
endow
high
genet
barrier
regard
drug
resist
develop
varieti
multipl
mutat
nglycosyl
site
requir
viru
loos
mark
sensit
drug
cluster
pattern
glycan
delet
occur
prma
drug
pressur
resist
spectrum
mode
action
uniqu
among
exist
antihiv
drug
warrant
pre
clinic
investig
acknowledg
research
support
flemish
fond
voor
wetenschappelijk
onderzoek
center
excel
ku
leuven
european
commiss
empro
jan
muench
ludger
knut
adermann
axel
schulz
michael
schindler
raghavan
chinnadurai
wolfgeorg
forssmann
frank
kirchhoff
depart
virolog
univers
ulm
alberteinstein
alle
ulm
germani
ipf
pharmaceut
gmbh
feodorlynenstrass
hannov
germani
varieti
compon
human
blood
might
influenc
replic
infect
individu
peptid
librari
deriv
hemofiltr
hf
aqueou
blood
solut
contain
essenti
circul
blood
peptid
molecular
mass
kda
includ
chemokin
defensin
cytokin
identifi
potent
natur
occur
factor
inhibit
replic
screen
hfderiv
peptid
librari
antivir
activ
activ
fraction
contain
peptid
correspond
ctermin
fragment
highli
abund
serin
proteinas
inhibitor
analysi
correspond
chemic
synthes
peptid
term
viru
inhibitori
peptid
virip
demonstr
inhibit
infect
variant
test
independ
subtyp
coreceptor
usag
notabl
virip
also
block
multiresist
variant
primari
isol
virip
specif
inhibit
env
function
affect
infect
virion
contain
siv
mlv
hcv
ebola
vsv
env
protein
antivir
activ
prove
highli
specif
virip
sequenc
sinc
structur
close
relat
peptid
inact
found
virip
inhibit
hemolysi
erythrocyt
induc
fusionpeptid
fp
nmr
spectroscopi
confirm
virip
interact
directli
synthet
fp
observ
evid
natur
occur
human
substanc
inhibit
infect
new
mode
action
ie
bind
highli
conserv
fp
furthermor
perform
structureactivityrel
studi
virip
analog
found
specif
amino
acid
chang
enhanc
antivir
potenc
virip
two
order
magnitud
experi
cell
cultur
anim
model
demonstr
virip
exert
cytotox
effect
thu
virip
deriv
might
becom
new
class
entri
inhibitor
stefano
aquaro
valentina
svicher
roberta
darrigo
ubaldo
viscocomandini
andrea
antinori
mario
santoro
giovanni
di
perri
sergio
lo
caputo
pasqual
narciso
carlofederico
perno
univers
rome
tor
vergata
itali
inmi
l
spallanzani
itali
univers
turin
itali
sm
annunziata
hospit
florenc
itali
investig
correl
viroimmunolog
paramet
hivinfect
patient
pt
receiv
ad
singl
activ
drug
fail
regimen
two
hundr
ten
sequenc
clinic
followup
patient
analyz
baselin
week
week
treatment
associ
mutat
viremia
vl
count
cul
assess
mannwhitney
test
addit
fail
antiretrovir
regimen
induc
week
signific
vl
decreas
log
stabl
last
week
prior
log
p
signific
increas
cul
decreas
last
week
prior
cul
p
vl
rebound
log
week
respect
increas
cul
week
resist
mutat
absent
bl
occur
shortli
treatment
usual
alon
common
sign
failur
pt
viroimmunolog
outcom
pt
vari
accord
pt
associ
increas
bl
cul
cul
week
cul
week
p
compar
without
respect
signific
correl
vl
observ
log
bl
week
contrast
pt
associ
loss
cul
bl
cul
week
p
without
signific
chang
vl
log
bl
log
week
mutat
observ
pt
never
found
bl
abrog
site
correl
increas
week
conform
chang
induc
highli
conserv
giv
motif
tightli
relat
loss
hivinduc
damag
immun
system
facilit
mechan
viru
loss
fusion
effici
immunemedi
exposur
new
epitop
applic
proteasertinhibitor
thu
import
innov
therapeut
strategi
spread
highli
pathogen
influenza
virus
human
asia
high
mortal
rate
among
infect
individu
major
public
health
concern
absenc
vaccin
antigen
match
pandem
viru
antivir
drug
play
import
role
present
studi
report
antivir
activ
neuraminidas
inhibitor
oseltamivir
lethal
influenza
viru
infect
ferret
appropri
anim
model
close
resembl
clinic
sign
human
influenza
inocul
young
adult
ferret
viral
dose
low
eid
influenza
viru
caus
high
fever
c
weight
loss
initi
anorexia
extrem
lethargi
death
anim
day
postviru
inocul
pi
oral
administr
oseltamivir
dose
mgkgday
day
twice
daili
initi
h
pi
inhibit
febril
respons
reduc
weight
chang
initi
importantli
complet
protect
ferret
lethal
infect
treatment
group
viru
replic
upper
respiratori
tract
ferret
prevent
wherea
untreat
anim
shed
viru
titer
log
eid
ml
day
pi
system
spread
viru
observ
untreat
ferret
viru
detect
multipl
intern
organ
includ
brain
treatment
oseltamivir
result
complet
inhibit
viru
replic
lung
small
intestin
day
pi
brain
treat
anim
viru
detect
one
two
anim
test
reduct
titer
sequenc
analysi
show
amino
acid
substitut
conserv
residu
na
subunit
virus
isol
ferret
intern
organ
treatment
result
suggest
oseltamivir
earlier
treatment
prevent
mortal
ferret
howev
studi
investig
optim
dose
treatment
durat
requir
achiev
protect
infect
highli
pathogen
influenza
virus
much
need
natalia
ilyushina
erich
hoffmann
rachel
salomon
robert
webster
elena
govorkova
st
jude
children
research
hospit
memphi
tn
usa
present
studi
test
mous
model
hypothesi
combin
chemotherapi
drug
target
differ
viru
protein
may
lead
potent
benefici
effect
appli
plasmidbas
revers
genet
techniqu
gener
two
recombin
virus
one
viru
possess
asparagin
posit
protein
found
natur
circul
viru
confer
resist
amantadin
recombin
viru
possess
serin
posit
sensit
amantadin
balbc
mice
administ
oseltamivir
mgkgday
amantadin
mgkgday
twice
daili
day
oral
gavag
first
dose
given
h
inocul
viru
combin
treatment
mgkgday
oseltamivir
mgkgday
amantadin
given
schedul
singledrug
oseltamivir
produc
dosedepend
antivir
effect
recombin
virus
p
treatment
oseltamivir
dosag
mgkgday
significantli
inhibit
viru
replic
lung
brain
spleen
blood
mice
day
inocul
p
result
low
surviv
rate
singledrug
amantadin
show
dosedepend
effect
strain
notabl
risk
death
mice
receiv
mgkgday
amantadin
mgkgday
oseltamivir
similar
p
contrast
prophylact
treatment
mice
combin
oseltamivir
amantadin
complet
inhibit
viru
replic
anim
infect
p
compar
singledrug
usag
protect
anim
importantli
combin
chemotherapi
complet
protect
viru
spread
brain
mice
viru
detect
brain
treat
anim
day
inocul
neurolog
symptom
observ
result
suggest
combin
chemotherapi
provid
advantag
singleag
treatment
strategi
could
option
control
influenza
viru
infect
combin
novel
drug
explor
jean
reid
asburi
meera
raj
david
lawrenc
martin
petric
univers
british
columbia
vancouv
bc
canada
ge
healthcar
bioscienc
piscataway
nj
usa
british
columbia
center
diseas
control
vancouv
bc
canada
late
sever
acut
respiratori
syndrom
sar
becam
first
new
sever
easili
transmiss
human
diseas
emerg
centuri
although
abat
six
month
sar
serv
modern
paradigm
human
emerg
infect
death
report
countri
caus
agent
found
new
sarsassoci
coronaviru
sarscov
sequenc
sarscov
genom
first
report
bc
genom
scienc
center
full
set
viral
cellular
protein
compos
sarscov
virion
remain
unknown
approach
problem
util
twodimension
gel
electrophoresi
liquid
chromatographytandem
ms
lcmsm
identifi
viral
cellular
protein
purifi
sarscov
virion
obtain
human
infect
cell
human
liver
primat
monkey
kidney
infect
cell
interestingli
analysi
protein
purifi
sarscov
prepar
reveal
envelop
virion
contain
predict
viral
structur
protein
eg
spike
glycoprotein
nucleocapsid
protein
membran
glycoprotein
also
import
number
differenti
incorpor
host
cellular
protein
onto
newli
form
virus
unambigu
identifi
host
cellular
protein
sarscov
virion
lcmsm
protein
includ
member
annexin
superfamili
cytoskelet
protein
chaperon
vesicular
transport
protein
uracyldna
glycosylas
aldehyd
oxidoreductas
studi
provid
first
comprehens
compar
analysi
viral
cellular
protein
compos
infecti
particl
sarscov
obtain
human
primat
infect
cell
function
newli
identifi
hostspecif
protein
current
investig
use
rna
interf
system
contribut
structur
viral
product
replic
pathogen
discuss
acknowledg
support
earli
career
ubc
oper
grant
f
jean
cihr
petric
dale
barnard
craig
day
robert
montgomeri
kevin
bailey
matt
heiner
larri
lauridsen
robert
sidwel
kurt
berg
institut
antivir
research
utah
state
univers
logan
ut
usa
panum
inst
immi
ifnlab
copenhagen
denmark
sever
acut
respiratori
syndrom
sar
lifethreaten
respiratori
ill
caus
sarscov
approv
therapi
sar
drug
inhibit
sarscov
replic
vitro
includ
human
interferon
select
antiinflammatori
agent
chihrin
loufti
interferon
promis
potent
vitro
inhibit
sarscov
although
antiinflammatori
agent
activ
vitro
thought
might
efficaci
reduc
deleteri
inflammatori
respons
associ
viru
infect
sar
infect
human
exampl
troxerutin
flavenoid
antiinflammatori
properti
clinic
trial
treat
rhinoviru
rv
infect
amelior
rvinduc
inflamm
turner
et
al
apmi
therefor
troxerutin
test
inhibit
sarscov
replic
lung
infect
mice
use
mix
four
hydroxyethylrutosid
includ
troxuretin
addit
mous
interferonalpha
use
model
compound
human
interferonalpha
evalu
inhibit
viru
lung
titer
mous
interferonalpha
administ
ip
daili
begin
h
pre
viru
exposur
dose
iu
hydroxyethylrutosid
mix
mgkg
administ
ip
use
schedul
reduc
viru
replic
lung
mice
detect
limit
hydroxyethylrutosid
mix
given
mice
drink
water
mgml
like
equival
ip
dose
mgkg
assum
mice
drank
freeli
viru
lung
replic
also
complet
inhibit
treatment
appear
well
toler
sinc
group
mice
gain
weight
also
report
efficaci
variou
combin
two
dose
drug
administ
ip
use
dose
regimen
describ
data
support
supposit
interferon
might
use
therapi
treat
human
sar
infect
hydroxyethylrutosid
investig
potenti
therapi
acknowledg
support
contract
virolog
branch
niaid
nih
treatment
option
human
respiratori
syncyti
viru
rsv
limit
effect
vaccin
yet
avail
neutral
polyclon
antibodi
respigam
tm
medimmun
human
monoclon
antibodi
synagi
tm
medimmun
licens
prophylact
use
ribavirin
approv
antivir
rsv
efficaci
controversi
use
limit
treatment
highrisk
patient
clear
need
new
antirsv
therapeut
improv
efficaci
easeofus
mani
earli
effort
identifi
antirsv
compound
focus
block
process
fusion
develop
cellbas
screen
platform
identifi
antivir
inhibit
rsv
transcript
replic
assay
requir
infect
wildtyp
viru
base
rsv
subgenom
replic
system
babi
hamster
kidney
cell
express
essenti
viral
replic
protein
n
p
l
readout
express
report
gene
lacz
subgenom
rna
screen
apath
small
molecul
librari
yield
compound
hit
rate
valu
select
index
si
valu
seventytwo
compound
demonstr
antivir
activ
wildtyp
rsv
strain
cytopath
effect
inhibit
assay
si
antirsv
compound
repres
nine
differ
chemic
class
two
compound
thienopyrimidin
shown
desir
pharmacokinet
profil
chosen
efficaci
test
cottontail
rat
model
infect
sar
studi
identifi
pharmacophor
compound
initi
preliminari
studi
character
mechanismofact
virolog
assay
discuss
acknowledg
support
nih
previous
report
bicycl
furano
pyrimidin
nucleosid
analogu
bcna
exquisit
potent
select
inhibitor
varicella
zoster
viru
vzv
subnanomolar
activ
palkylphenyl
substitut
analogu
lead
compound
compound
enter
preclin
develop
fermavir
pharmaceut
report
first
chromatographyfre
synthesi
agent
scale
multigramm
amount
preclin
characteris
addit
keen
address
potenti
solubl
bioavail
issu
highli
lipophil
agent
synthesi
polar
analogu
two
categori
sidechain
ether
new
analogu
right
phosphat
potenti
solubl
prodrug
report
data
new
famili
meet
final
note
applic
phosphoramid
protid
approach
famili
seri
bcna
protid
design
intracellular
phosphat
deliveri
form
bypass
essenti
vzv
thymidin
kinasemedi
first
phosphoryl
step
graciela
andrei
joo
van
den
oord
pierr
fiten
ghislain
opdenakk
erik
de
clercq
robert
snoeck
rega
institut
medic
research
katholiek
universiteit
leuven
leuven
belgium
patholog
depart
uz
leuven
leuven
belgium
varicella
chickenpox
primari
infect
caus
vzv
character
viremia
skin
lesion
reactiv
latent
viru
result
skin
lesion
characterist
herp
zoster
shingl
keratinocyt
one
main
target
cell
product
infect
vivo
vzv
human
epitheli
cell
repres
relev
model
studi
vzv
pathogenesi
evalu
antivir
compound
organotyp
epitheli
raft
cultur
permit
full
differenti
keratinocyt
via
cultur
cell
collagen
matrix
airliquid
interfac
previous
shown
suscept
cultur
infect
vzv
depend
stage
differenti
raft
quantifi
activ
refer
antivzv
compound
measur
viral
dna
load
realtim
pcr
quantit
pcr
vzv
dna
perform
use
specif
primer
mgbprobe
gene
singlestrand
dna
bind
protein
taqman
method
two
seri
raft
cultur
infect
wildtyp
oka
strain
day
differenti
treat
serial
dilut
test
compound
day
postdifferenti
one
seri
cultur
process
histolog
one
viral
dna
quantif
acyclovir
acv
penciclovir
pcv
brivudin
bvdu
gml
foscarnet
pfa
gml
cidofovir
cdv
gml
inhibit
viral
dna
content
result
agreement
histolog
examin
raft
cytopath
effect
observ
concentr
expect
cdv
pfa
inhibit
replic
thymidinekinas
defici
tk
strain
correl
degre
protect
determin
histolog
examin
viral
quantif
could
also
demonstr
cdv
pfa
strain
sinc
anim
model
avail
vivo
evalu
antivir
agent
vzv
organotyp
cultur
may
consid
valuabl
ex
vivo
model
evalu
efficaci
new
antivzv
antivir
jaeseon
hwang
oliv
kregler
john
c
drach
leroy
b
townsend
elk
bogner
institut
klinisch
und
molekular
virologi
erlangen
germani
depart
biolog
materi
scienc
school
dentistri
interdepartment
graduat
program
medicin
chemistri
colleg
pharmaci
univers
michigan
ann
arbor
mi
usa
dna
packag
key
step
viral
matur
involv
bind
cleavag
viral
dna
contain
specif
dnapackag
motif
process
mediat
group
specif
enzym
call
terminas
previous
demonstr
hcmv
terminas
compos
two
subunit
larg
one
encod
small
protein
differ
function
larg
subunit
mediat
sequenc
specif
dna
bind
atp
hydrolysi
requir
duplex
nick
inhibitor
target
andor
attract
altern
hcmv
antivir
sinc
mammalian
cell
dna
replic
involv
cleavag
concatamer
dna
screen
sever
member
benzimidazol
ribonucleosid
class
replic
inhibitor
order
determin
compound
capac
block
atpas
activ
larg
terminas
subunit
analysi
bioluminometr
atpas
activ
assay
identifi
bdcrb
one
compound
benzimidazol
btcrb
inhibitori
effect
although
btcrb
bdcrb
inhibitor
atpas
activ
two
compound
dbdcrb
inhibit
viru
replic
plaquereduct
assay
thu
indic
differ
mode
action
addit
electron
microscopi
thin
section
observ
presenc
btcrb
bcapsid
dens
bodi
form
furthermor
spheric
capsid
accumul
perinuclear
cisterna
indic
block
nuclear
egress
therebi
provid
addit
evid
closelyrel
benzimidazol
dribonucleosid
may
differ
antivir
mode
action
human
cytomegaloviru
hcmv
caus
signific
morbid
mortal
varieti
immunocompromis
patient
current
avail
antihcmv
drug
interfer
dna
replic
howev
drug
highli
toxic
preclud
longterm
use
human
interrupt
hcmv
viral
entri
larg
unexplor
antivir
drug
develop
strategi
potenti
ideal
tractabl
goal
hcmv
believ
reli
upon
format
coil
coil
viral
glycoprotein
gb
gh
promot
virushost
membran
fusion
peptid
encompass
heptad
repeat
sequenc
two
protein
inhibit
viral
infect
explor
nonnatur
oligomer
molecul
foldam
design
mimic
element
put
segment
gb
effort
led
discoveri
oligom
acid
block
hcmv
infect
scaffold
offer
sever
advantag
design
proteinprotein
interact
inhibitor
amen
modular
synthesi
resist
proteolyt
degrad
display
larg
tailor
molecular
surfac
potent
inhibitor
block
hcmv
infect
micromolar
ic
cellbas
assay
compound
show
specif
hcmv
rel
close
relat
virus
mechanist
studi
suggest
inhibitor
interfer
membran
fusion
hcmv
particl
host
cell
current
effort
focus
understand
greater
detail
origin
observ
biolog
activ
explor
foldam
scaffold
base
inhibitor
design
develop
specif
fusion
inhibitor
herpesvirus
previou
report
indic
herp
simplex
viru
hsv
activ
nuclear
factorkappab
nfkb
product
infect
nonsteroid
antiinflammatori
drug
nsaid
signific
inhibitori
effect
nfkb
therefor
two
nsaid
indomethacin
aspirin
assay
antiherpet
effect
util
tool
studi
role
nfkb
infect
report
indomethacin
aspirin
inhibit
replic
noncytotox
dose
vero
cell
um
indomethacin
mm
aspirin
reduc
titer
respect
electromobl
shift
assay
reveal
activ
nfkb
inhibit
nsaid
dose
coincid
reduct
titer
investig
pathway
nfkb
inactiv
protein
level
ikbalpha
cytoplasm
nfkb
inhibitor
examin
ikbalpha
protein
present
uninfect
sampl
decreas
time
hsv
sampl
regardless
chemic
treatment
suggest
local
nfkb
nucleu
immunohistochemistri
studi
verifi
compon
dimer
nfkb
complex
transloc
nucleu
infect
cell
presenc
absenc
nsaid
final
direct
effect
viral
gene
activ
assay
realtim
rtpcr
analysi
indomethacin
aspirin
reduc
mrna
essenti
hsv
immediateearli
gene
respect
result
signific
decreas
protein
transcript
analysi
reveal
synthesi
mrna
thymidin
kinas
hsv
earli
gene
unaffect
chemic
treatment
howev
mrna
glycoprotein
c
hsv
late
gene
undetect
indomethacin
aspirin
treat
sampl
cumul
data
indic
indomethacin
aspirin
block
replic
ii
vitro
antiherpet
effect
nsaid
may
resid
abil
block
nfkb
activ
within
nucleu
impair
activ
essenti
hsv
gene
increas
speciesspecif
constraint
preclud
studi
human
cytomegaloviru
hcmv
anim
necessit
use
rodent
cmv
model
human
diseas
howev
suscept
anim
cmv
clinic
use
antivir
unpredict
exampl
guinea
pig
cmv
gpcmv
uniqu
valuabl
viru
model
congenit
cmv
infect
highli
resist
ganciclovir
gcv
medic
relev
dose
use
molecular
virolog
approach
test
hypothesi
gcv
suscept
could
confer
gpcmv
insert
human
phosphotransferas
gene
gpcmv
genom
gpcmv
genom
clone
bacteri
artifici
chromosom
e
coli
modifi
sitespecif
recombin
use
shuttl
plasmid
target
locu
carri
gene
hcmv
strain
town
result
chimer
viru
replic
compet
found
contain
hcmv
southernblot
sequenc
analys
northernblot
reveal
hcmv
transcript
express
late
gene
kinet
westernblot
use
hcmv
polyclon
antibodi
detect
protein
virusinfect
cell
chimer
viru
gcvsuscept
compar
wildtyp
gpcmv
ic
chimer
viru
also
exhibit
increas
sensit
maribavir
mbv
exhibit
reduct
compar
wildtyp
viru
presenc
mbv
ic
studi
vivo
pathogenesi
chimer
viru
cyclophosphamideimmunocompromis
strain
two
guinea
pig
challeng
intraperiton
result
evid
dissemin
infect
mortal
ganciclovir
treatment
mgkgday
result
reduc
weight
loss
mortal
compar
placebo
studi
confirm
key
role
cmv
antivir
therapi
demonstr
human
gpcmv
gener
alter
antivir
suscept
genit
herp
infect
global
health
problem
impact
hivaid
epidem
strategi
prevent
transmiss
includ
treatment
infect
subject
suppress
shed
prophylaxi
vaginallyappli
microbicid
examin
vitro
vivo
activ
rep
fulli
degener
mer
phosphorothio
oligonucleotid
infect
human
cervic
cell
vagin
murin
model
rep
broadspectrum
antiherpet
activ
potent
vitro
activ
hcmv
vzv
ebv
vaillant
et
al
submit
public
concentr
rep
inhibit
infect
present
entir
experi
synchron
infect
assay
demonstr
unlik
sulfon
polyanion
clinic
trial
primarili
block
hsv
attach
rep
act
multipl
step
inhibit
bind
entri
postentri
gene
express
vivo
studi
mice
treat
intravagin
rep
pb
control
variou
time
prior
vagin
challeng
lethal
dose
strain
log
pfu
rep
prophylaxi
provid
protect
mice
infect
diseas
protect
signific
challeng
min
treatment
p
addit
treatment
analog
rep
activ
mediat
immun
stimul
least
activ
rep
suggest
direct
antivir
activ
stimul
innat
immun
mechan
action
vivo
util
analog
protect
signific
challeng
min
treatment
p
trend
toward
protect
administ
min
prior
challeng
p
summari
treatment
rep
analog
superior
resist
low
ph
nucleas
degrad
effect
rep
experi
protect
mice
viral
infect
diseas
test
ph
resist
rep
analog
gel
formul
current
underway
acknowledg
support
contract
virolog
branch
niaid
nih
phosphorodiamid
morpholino
oligom
pmo
design
hybrid
highli
conserv
region
includ
aug
translat
start
site
hcv
call
evalu
efficaci
toxic
pharmacokinet
properti
inhibit
translat
initi
aug
start
site
nm
ugml
show
posit
cooper
pmo
retain
activ
presenc
point
mutat
hcv
genom
cell
incub
normal
human
serum
nh
hcv
infect
human
serum
hcv
replic
observ
rtpcr
produc
robust
inhibit
hcv
dose
sequencespecif
manner
studi
conduct
vivo
hcv
infect
trimera
mous
xtl
show
reduct
viral
titer
dose
depend
approxim
mice
undetect
viral
titer
remain
mice
show
log
reduct
viral
titer
mgmouseday
consecut
day
fraction
bioavail
sq
dose
approxim
appar
elimin
half
life
rat
nonhuman
primat
human
h
respect
volum
distribut
rang
lkg
cmax
linearli
relat
dose
mgm
phase
studi
healthi
volunt
daili
sq
dose
mg
complet
seriou
advers
event
observ
treatment
infect
patient
current
plan
inhibit
hcv
polyprotein
synthesi
anticip
contain
therapeut
benefi
proteas
inhibitor
polymeras
inhibit
hcv
infect
progress
fibrosi
reduc
liver
function
hepatocellular
carcinoma
death
current
standard
treatment
hcv
infect
involv
treatment
pegyl
interferon
combin
nucleosid
analogu
ribavirin
treatment
regimen
effect
cure
approxim
popul
therefor
signific
unmet
clinic
need
exist
hcv
therapi
virusencod
polymeras
proven
excel
molecular
target
chemotherapeut
intervent
numer
viral
mediat
diseas
case
hiv
hbv
herp
viru
infect
deoxynucleosid
analogu
act
chain
termin
agent
shown
invalu
clinic
util
analog
appropri
ribonucleosid
analogu
might
expect
inhibit
essenti
rna
polymeras
encod
hcv
describ
prepar
nucleosid
analogu
inhibitor
hcv
polymeras
design
nucleosid
analog
potenti
antihcv
agent
chose
investig
effect
substitut
ribonucleosid
deriv
reason
incorpor
ribonucleosid
contain
substitu
disrupt
elong
grow
rna
could
effect
either
steric
hindranc
via
conform
chang
carbohydr
moieti
investig
sever
analogu
present
particular
interest
azidocytidin
show
good
activ
genotyp
subgenom
replicon
measur
cytotox
cytostat
behavior
addit
shown
triphosph
azidocytidin
potent
highli
select
inhibitor
joanna
e
boerner
sue
choilai
tiongyip
michael
p
cooreman
teresa
compton
kai
lin
novarti
institut
biomed
research
technolog
squar
cambridg
usa
current
drug
discoveri
effort
hepat
c
viru
hcv
focu
develop
specif
inhibitor
two
viral
enzym
polymeras
proteas
howev
resist
viral
mutant
like
emerg
therapi
compromis
effect
inhibitor
altern
complementari
strategi
target
host
factor
also
essenti
viral
replic
cyclophilin
famili
peptidylprolyl
isomeras
cellular
target
cyclosporin
csa
present
opportun
report
recent
cyclophilin
b
bound
hcv
polymeras
stimul
rnabind
activ
function
block
presenc
csa
watashi
k
et
al
molecular
cell
csa
deriv
suitabl
candid
hcv
therapi
bind
cyclophilin
higher
affin
csa
lack
immunosuppress
activ
associ
csa
use
hcv
replicon
system
demonstr
exhibit
potent
antihcv
activ
vitro
moreov
combin
specif
nonnucleosid
inhibitor
hcv
polymeras
led
synergist
antivir
effect
signific
increas
cytotox
resist
clone
inhibitor
obtain
vitro
howev
much
difficult
gener
resist
polymeras
inhibitor
also
crossresist
two
inhibitor
final
addit
hcv
polymeras
inhibitor
drastic
reduc
emerg
resist
compar
polymeras
inhibitor
alon
taken
togeth
novel
mechan
action
favor
pharmacokinet
safeti
profil
repres
promis
clinic
candid
treat
hepat
c
provid
rational
specif
combin
therapi
nucleosid
analog
identifi
specif
inhibitor
hcv
replic
subgenom
hcv
replicon
cell
competit
inhibitor
cmp
incorpor
hcv
polymeras
transient
replicon
system
inhibit
hcv
rna
replic
driven
genotyp
polymeras
similar
potenc
compar
driven
genotyp
polymeras
inhibit
nativ
hcv
replicas
recombin
genotyp
similar
potenc
contrast
inhibit
human
dna
polymeras
alpha
beta
gamma
includ
revers
transcriptas
activ
dna
polymeras
beta
gamma
highli
sensit
inhibit
azttp
signific
inhibit
observ
human
rna
polymeras
ii
iii
deriv
hela
cell
addit
function
relat
nativ
influenza
viru
rna
depend
rna
polymeras
rdrp
activ
vitro
inhibit
concentr
mm
suggest
high
select
hcv
rdrp
thu
identifi
potent
highli
select
inhibitor
hcv
polymeras
mediat
rna
synthesi
guangxiang
luo
zhaohui
cai
chen
zhang
kyungsoo
chang
jieyun
jiang
microbiolog
immunolog
molecular
genet
univers
kentucki
colleg
medicin
lexington
ky
usa
studi
hepat
c
viru
hcv
replic
search
specif
antivir
agent
hcv
infect
hamper
lack
effici
stabl
cell
cultur
system
hcv
infect
propag
success
construct
stabl
human
hepatoma
cell
line
contain
chromosom
integratedgenotyp
hcv
cdna
constitut
produc
secret
high
titer
infecti
viru
cultur
media
transcript
express
fulllength
hcv
rna
genom
control
cellular
pol
ii
polymeras
promot
end
hepat
delta
viru
ribozym
end
result
hcv
rna
express
replic
effici
shown
presenc
high
level
hcv
protein
well
hcv
rna
stabl
cell
line
hcv
secret
stabl
cell
line
infecti
determin
antibodi
neutral
blockag
put
hcv
receptor
inhibit
hcv
replic
interferon
find
demonstr
establish
stabl
cell
cultur
system
infecti
hcv
product
propag
allow
studi
entir
hcv
infecti
cycl
stabl
hcvsecret
cell
line
pursu
develop
high
throughput
screen
effect
hcv
inhibitor
addit
establish
novel
power
hcv
replic
system
mous
hepatocyt
mous
embryo
fibroblast
mef
hcv
rna
found
replic
effici
pkr
pkr
mef
cell
demonstr
hcv
rna
replic
mef
cell
power
system
studi
hostviru
interact
use
divers
geneknockout
anim
interestingli
hcv
rna
replic
effici
pkr
cell
pkr
cell
suggest
role
pkr
control
hcv
rna
replic
howev
ifn
inhibit
hcv
rna
replic
pkr
cell
efficaci
similar
pkr
cell
suggest
pkrindepend
antivir
mechan
clearli
pkrdepend
pkrindepend
antivir
mechan
import
control
hcv
replic
mediat
ifninduc
antihcv
respons
studi
set
stage
develop
transgen
mous
model
hcv
replic
open
new
avenu
studi
hcv
host
interact
mef
deriv
divers
geneknockout
anim
andrea
cuconati
haitao
guo
gael
westbi
anand
mehta
timothi
block
institut
hepat
viru
research
drexel
institut
biotechnolog
virolog
research
doylestown
pa
usa
high
level
hepat
b
surfac
antigen
hbsag
bear
noninfecti
particl
serum
infect
individu
thought
play
role
suppress
hepat
b
viru
hbv
specif
immun
respons
titer
hbvspecif
antibodi
lymphocyt
current
hbv
therapeut
directli
reduc
viral
antigenemia
group
focus
enhanc
immun
respons
inhibit
viral
antigen
secret
infect
hepatocyt
therapeut
goal
use
hbv
vaccin
treatment
acut
chronic
infect
highthroughput
screen
small
molecul
librari
druglik
compound
undertaken
discov
novel
inhibitor
hbsag
secret
use
stabli
hbvtransfect
human
hepatoma
cell
line
develop
htscompat
elisa
protocol
detect
hbsag
secret
cultur
media
screen
result
initi
posit
hit
hit
rate
subsequ
retest
activ
toxic
mtt
assay
narrow
number
confirm
nontox
hit
current
categor
twelv
chemic
seri
previous
report
trio
relat
pyrazolopyridin
measur
measur
nascent
structureact
relationship
sar
suggest
central
moieti
molecul
essenti
activ
aromat
side
group
contribut
potenc
among
recent
confirm
inhibitor
two
current
investig
includ
isobutylacetamid
nanomolar
carbothiamid
micromolar
measur
secret
hbv
l
antigen
cellular
marker
indic
pyrazolopyridin
specif
inhibitor
viral
antigen
isobutylacetamid
carbothiamid
inde
specif
measur
intracellular
viral
dna
indic
none
molecul
inhibitor
replic
report
studi
potenc
specif
potenti
mechan
action
novel
antihbv
compound
background
entecavir
etv
potent
competit
inhibitor
hepat
b
viru
hbv
polymeras
activ
versu
three
enzymat
function
includ
prime
minu
plu
strand
dna
synthesi
virolog
rebound
due
etv
resist
etvr
observ
lamivudin
resist
lvdr
hbv
requir
least
one
addit
chang
revers
transcriptas
domain
rt
residu
substitut
surround
dntp
bind
site
primer
grip
rt
object
work
character
etvr
mechan
use
cell
cultur
vitro
enzym
molecular
model
studi
method
hbv
cell
cultur
assay
use
transfect
cell
quantit
releas
immunocaptur
hbv
nucleocapsid
gradientpurifi
intracellular
nucleocapsid
use
vitro
rt
assay
homolog
model
base
rt
structur
use
model
resist
chang
hbv
result
reduc
etv
suscept
etvr
hbv
observ
cultur
enzymat
vitro
kinet
studi
show
variou
etvr
substitut
lvdr
hbv
select
reduc
etvtriphosph
etvtp
bind
k
rt
without
markedli
chang
affin
dgtp
k
inhibit
ddgtp
etvr
rt
also
display
reduc
enzymat
activ
k
cat
rel
wildtyp
etvr
hbv
appear
growth
impair
model
studi
suggest
novel
etvtp
bind
pocket
hbv
rt
becam
constrain
etvr
chang
chang
primer
grip
region
rt
uniqu
resist
primarili
seen
synthesi
minu
strand
dna
etvr
chang
absenc
lvdr
substitut
greatli
reduc
impact
etv
suscept
confirm
model
suggest
etvr
impart
lvdr
chang
summari
etv
provid
high
genet
barrier
resist
requir
addit
chang
residu
along
preexist
lvdr
substitut
kinet
paramet
molecular
model
indic
etvr
substitut
select
affect
etvtp
bind
reduc
replic
capac
hbv
nonhuman
primat
nhp
model
classic
lesion
smallpox
use
test
efficaci
intraven
iv
cidofovir
treatment
cynomolgu
macaqu
infect
high
dose
pfu
iv
variola
produc
artifici
primari
viremia
treat
cidofovir
h
postinfect
pi
later
treatment
time
evalu
treatment
h
pi
halt
increas
peak
blood
viral
genom
titer
measur
quantit
taqmanmgb
realtim
pcr
less
cdvtreat
anim
compar
placebo
histor
number
pox
lesion
provid
best
correl
human
smallpox
clinic
sever
cdv
treatment
model
significantli
reduc
maximum
pox
lesion
count
number
size
skin
lesion
untreat
anim
contribut
significantli
total
viral
burden
lesion
contain
genomesg
better
understand
role
viral
burden
diseas
progress
major
organ
system
serial
sampl
studi
undertaken
untreat
anim
h
pi
viral
replic
spleen
exceed
genomesg
liver
bone
marrow
yield
genomesml
comparison
titer
tissu
rang
genomesg
blood
yield
genomesml
h
suggest
liver
spleen
marrow
may
initi
site
replic
level
viru
bone
marrow
reach
peak
approxim
genomesg
day
decreas
quantiti
consist
blood
viral
load
blood
increas
time
peak
around
day
genomesml
viru
also
detect
intestin
skelet
muscl
late
infect
test
abil
success
treat
cdv
h
pi
despit
earli
extens
organ
infect
acceler
nhp
variola
model
suggest
treatment
could
effect
reduc
viremia
mortal
onset
symptom
human
smallpox
demonstr
protract
diseas
cours
work
involv
variola
viru
conduct
whosanct
cdc
atlanta
laboratori
earl
kern
kathi
keith
robert
jordan
denni
hrubi
debra
quenel
depart
pediatr
univers
alabama
school
medicin
birmingham
al
usa
siga
technolog
inc
corval
usa
although
cidofovir
cdv
approv
investig
new
drug
emerg
treatment
smallpox
lack
oral
activ
dose
limit
toxic
dictat
need
continu
develop
better
therapeut
agent
potenti
bioterror
diseas
report
previous
lowmolecular
weight
compound
inhibit
replic
orthopoxvirus
vitro
protect
mice
infect
vaccinia
ectomelia
viru
present
studi
util
cowpox
viru
cv
vaccinia
viru
vv
infect
vitro
vivo
evalu
efficaci
treatment
orthopoxviru
infect
plaqu
reduct
assay
human
foreskin
fibroblast
cell
cv
vv
inhibit
um
vivo
studi
administ
daili
oral
gavag
mice
use
mgkg
day
begin
h
intranas
inocul
vv
cv
highli
effect
p
prevent
mortal
due
vv
cv
even
treatment
delay
h
postinfect
dose
durat
day
adequ
vv
infect
mice
durat
day
longer
requir
efficaci
cv
infect
mice
given
daili
day
mgkg
daili
h
postcv
inocul
mortal
significantli
alter
dosag
level
time
point
determin
effect
treatment
viru
replic
target
tissu
mice
inocul
cv
vv
treat
daili
mgkg
variou
day
postinfect
tissu
harvest
assay
viru
cv
vvinfect
mice
treatment
success
reduc
viru
titer
log
liver
spleen
kidney
littl
effect
note
lung
tissu
result
indic
signific
activ
vv
cv
infect
vitro
vivo
may
potenti
chemotherapeut
agent
treatment
human
orthopoxviru
infect
cidofovir
hpmpc
broadspectrum
antivir
agent
use
vistid
treat
aidsrel
cmv
retin
current
cidofovir
particular
interest
potenti
therapi
orthopox
viru
infect
includ
smallpox
import
limit
cidofovir
analog
nucleotid
drug
therapeut
role
low
oral
bioavail
poor
transport
cell
principl
bioavail
drug
improv
structur
modif
target
transport
express
human
intestin
effect
transport
prodrug
must
cleav
endogen
enzym
parent
compound
present
synthet
studi
novel
cidofovir
cyclic
cidofovir
chpmpc
prodrug
incorpor
amino
acid
small
peptid
compar
differ
drugamino
acid
linkag
strategi
compound
evalu
transportermedi
uptak
cellular
plasma
hydrolysi
result
compar
similar
studi
carri
seri
peptidomimet
conjug
foscarnet
trisodium
salt
phosphonoform
acid
pfa
antivir
agent
also
low
oral
bioavail
poor
cell
penetr
question
address
studi
wnvreactiv
antibodi
improv
diseas
sign
hamster
model
viru
demonstr
brain
hypothesi
base
high
activ
human
monoclon
antibodi
mous
model
administ
later
infect
oliph
et
al
nat
med
studi
viru
demonstr
brain
hamster
day
postvir
inject
dpi
cell
cultur
assay
quantit
rtpcr
immunohistochem
stain
wnv
neuron
eighti
percent
hamster
treat
ip
dpi
mgkg
human
monoclon
antibodi
surviv
wnv
diseas
wherea
placebotr
hamster
surviv
p
administ
dpi
surviv
test
hypothesi
effect
deliv
directli
brain
instead
peripher
administr
antibodi
deliv
brain
dpi
use
convectionenhanc
deliveri
cannula
implant
brain
detect
cn
none
detect
kidney
surviv
hamster
compar
placebotr
anim
p
addit
proof
major
hamster
wnv
cerebrospin
fluid
marker
cn
infect
protect
administ
ip
dpi
human
monoclon
antibodi
therefor
possibl
treatment
postexposur
wnvinfect
human
develop
sign
neuroinvas
diseas
acknowledg
support
contract
virolog
branch
niaid
nih
grant
rocki
mountain
region
center
excel
nih
hemorrhag
fever
virus
seriou
worldwid
health
concern
well
potenti
biolog
weapon
lassa
fever
viru
particular
annual
infect
sever
hundr
thousand
individu
west
africa
export
pathogen
outsid
region
either
intent
unintent
present
seriou
risk
develop
countri
world
cdc
niaid
identifi
lassa
fever
viru
categori
prioriti
pathogen
indic
highest
degre
threat
public
health
arenavirusspecif
antivir
drug
current
approv
use
human
purpos
siga
biodefens
program
develop
safe
effect
drug
prevent
treat
diseas
caus
categori
virus
end
larg
divers
librari
small
molecul
compound
screen
use
viral
pseudotyp
assay
identifi
inhibitor
target
essenti
lassa
surfac
glycoprotein
gp
thu
block
viral
entri
host
cell
twentysix
compound
identifi
qualiti
hit
defin
potenc
select
chemic
tractabl
antivir
activ
authent
lassa
fever
viru
assess
cell
cultur
collabor
colleagu
usamriid
number
potent
antivir
compound
relat
analog
exhibit
inform
chemic
structurebiolog
activ
relationship
sar
two
potenti
lead
compound
seri
emerg
studi
effect
concentr
less
nm
lassa
fever
viru
less
nm
lassa
gppseudotyp
viru
character
vivo
properti
compound
underway
vitro
antivir
potenc
select
anim
pharmacokinet
develop
process
present
inhibitor
repres
import
step
toward
develop
small
molecul
antivir
drug
lassa
fever
viru
sven
enterlein
pramila
walpita
allison
groseth
heinz
feldmann
ramon
flick
univers
texa
medic
branch
depart
patholog
galveston
tx
usa
nation
microbiolog
laboratori
public
health
agenc
canada
winnipeg
man
canada
nipah
niv
viru
famili
paramyxovirida
recent
emerg
human
anim
pathogen
caus
sever
enceph
fatal
rate
sinc
treatment
vaccin
avail
crossspeci
spread
observ
viru
classifi
biosafeti
level
agent
avoid
contain
studi
cisact
signal
target
antivir
strategi
use
optim
plasmiddriven
minigenom
rescu
system
without
need
recombin
vaccinia
viru
well
newli
establish
rna
polymeras
ibas
approach
minigenom
rescu
base
transfect
minigenom
nivcat
plasmid
encod
three
nucleocapsid
protein
n
nucleoprotein
l
polymeras
p
phosphoprotein
measur
enzymat
cat
assay
use
establish
plasmidbas
minigenom
rescu
system
screen
potenti
antivir
compound
first
step
tri
determin
optim
strategi
deliveri
small
hairpin
sh
interf
rna
molecul
compar
three
shrna
deliveri
system
anoth
agentreston
ebolaviru
famili
filovirida
plasmidmedi
pol
ii
pol
iiidriven
shrna
iii
exogen
produc
shrna
abil
induc
gene
silenc
interestingli
besid
vitrogener
pol
iiidriven
shrna
pol
transcript
show
effici
inhibit
minigenom
rescu
howev
effici
deliveri
method
transfect
vitro
transcrib
shrna
present
result
comparison
base
effici
approach
also
first
result
shrna
target
either
niv
n
p
l
gene
leadertrail
noncod
region
interfer
minigenom
replic
conform
data
live
viru
experi
condit
includ
filovirus
includ
ebola
viru
marburg
viru
among
notori
human
pathogen
caus
sporad
outbreak
sever
hemorrhag
fever
unfortun
therapeut
agent
avail
treat
infect
virus
antivir
screen
method
determin
effect
compound
viral
replic
involv
work
infecti
viru
obvious
practic
biosafeti
level
agent
develop
antivir
screen
method
base
cellbas
infectionindepend
ebola
subgenom
replic
system
express
easili
measur
enzym
depend
rna
replic
transcript
factor
ebola
viru
use
system
screen
synthet
compound
librari
antivir
activ
ebola
viru
identifi
number
inhibitor
also
use
identifi
peptid
inhibitor
direct
antiebola
viru
activ
mani
inhibitor
confirm
viral
replic
assay
use
gfpexpress
zair
strain
ebola
viru
fiftytwo
small
molecul
inhibitor
least
six
class
compound
valu
low
micromolar
rang
good
select
sever
compound
promis
chemic
biolog
pharmacolog
profil
pursu
potenti
antifiloviru
drug
current
prepar
test
compound
mous
model
ebola
viru
also
begun
lead
optim
program
improv
antivir
potenc
select
aryl
sulfonamid
compound
acknowledg
support
nih
human
papillomaviru
hpv
difficult
viru
target
tradit
antivir
method
due
small
size
small
number
obviou
therapeut
target
resist
propag
vitro
nevertheless
antivir
compound
reduc
hpv
dna
load
potenti
prevent
carcinogen
progress
infect
patient
end
develop
approach
dramat
reduc
hpv
episom
dna
load
keratinocyt
vitro
target
viral
dna
sequenc
pyrroleimidazol
polyamid
contain
fluoresc
probe
aid
cell
local
studi
design
recogn
ori
fluoresc
compound
rapidli
local
nucleu
cultur
keratinocyt
follow
addit
cultur
media
compound
test
abil
alter
keratinocyt
episom
dna
content
two
compound
caus
dosedepend
reduct
episom
measur
taqman
tm
realtim
pcr
control
vehicletr
cell
maintain
copi
per
cell
compound
reduc
dna
level
copi
per
cell
h
incub
compound
altern
taqman
tm
amplicon
within
gene
produc
ident
result
multiplex
taqman
tm
realtim
pcr
reaction
follow
ratio
dna
human
apo
gene
also
demonstr
dramat
loss
dna
copi
confirm
initi
observ
final
cell
treat
polyamid
h
polyamidecontain
media
remov
episom
level
follow
day
day
day
remov
polyamid
day
subcultur
cell
viral
episom
level
remain
approxim
lower
control
sampl
day
day
remov
polyamid
viral
dna
level
begin
recov
still
remain
significantli
lower
control
sampl
togeth
result
demonstr
target
hpv
origin
replic
dnabind
compound
dramat
reduc
episom
dna
level
small
interf
rna
sirna
potent
tool
gene
downregul
minim
stabl
cell
improv
efficaci
sirna
replac
nonbridg
oxygen
phosphodiest
linkag
natur
rna
group
result
boranophosph
uniqu
properti
includ
enhanc
nucleas
resist
alter
hydrogen
bond
phosphat
differ
interact
metal
ion
increas
thermal
stabil
rna
rna
rna
dna
duplex
antiegfp
sirna
contain
boranophosph
modif
prepar
vitro
transcript
rna
polymeras
ribonucleosid
alphapborano
triphosph
well
normal
phosphorothio
sirna
confirm
presenc
boran
modif
maldim
sever
properti
boranomodifi
sirna
investig
doubl
strand
rna
boran
modif
maintain
aform
conform
characterist
accord
circular
dichroism
cd
spectra
boran
group
sirna
increas
thermal
stabil
enhanc
c
per
modif
sirna
boranomodif
shown
least
resist
rnase
digest
normal
one
modifi
sirna
use
downregul
egfp
express
hela
cell
cultur
found
boranomodifi
sirna
consist
effect
sirna
contain
correspond
phosphorothio
modif
boranosirna
effect
normal
sirna
provid
center
antisens
strand
heavili
modifi
boranosirna
potent
normal
phosphorothio
sirna
lower
concentr
final
silenc
activ
boranophosph
singlestrand
sirna
ssrna
compar
unmodifi
dssirna
borano
ssrna
excel
maximum
silenc
activ
highli
effect
low
concentr
silenc
activ
durabl
one
week
transfect
result
antihpv
sirna
discuss
boranophosph
modif
potenti
new
class
antivir
therapeut
agent
report
describ
antivir
structur
activ
relationship
led
discoveri
novel
ntrti
excel
resist
profil
toward
variant
contain
major
n
rti
resist
mutat
method
phosphonomethoxi
analog
purin
pyrimidin
dideoxydidehydro
dideoxi
dd
ribos
scaffold
prepar
antivir
activ
measur
wildtyp
n
rtiresist
recombin
virus
use
cytopath
assay
cell
mitochondri
toxic
assess
cell
measur
mitochondri
dna
content
result
scaffold
display
superior
antivir
activ
compar
dd
scaffold
adenin
superior
nucleobas
inhibit
replic
mean
chang
potenc
virus
contain
thymidin
analog
mutat
tam
respect
explor
limit
mitochondri
toxic
address
way
prepar
ii
fluorin
substitut
exhibit
substanti
reduc
potenc
toward
mutant
virus
exhibit
chang
potenc
virus
contain
tam
respect
cytotox
effect
measur
mm
cell
effect
mitochondri
dna
detect
cell
conclus
novel
phosphon
ntrti
antiretrovir
activ
toward
wildtyp
resist
mutant
strain
compar
fluorin
atom
significantli
improv
vitro
toxic
profil
retain
favor
resist
profil
subsequ
studi
monoamid
prodrug
strategi
appli
achiev
optim
vivo
pharmacokinet
properti
entri
inhibitor
antagonist
particular
becom
one
activ
pursu
treatment
hiv
within
pharmaceut
industri
recent
multipl
group
disclos
piperidinebas
antagonist
medicin
chemist
eye
might
appear
share
common
threepoint
pharmacophor
compris
tertiari
amin
phenyl
ring
carboxamid
sulfonamid
group
sever
case
pharmacophor
element
tether
togeth
flexibl
aliphat
chain
sought
improv
potenc
introduc
structur
novelti
class
compound
rigidifi
tether
herein
describ
stereoselect
synthes
sar
seri
antagonist
wherein
tether
replac
four
stereochem
isom
rigidifi
cyclopropyl
scaffold
regul
hiv
transcript
complex
multistag
process
requir
concert
action
viral
cellular
protein
discov
naminoimidazol
naim
uniqu
class
hiv
inhibitor
target
viral
transcript
level
prototyp
naim
prevent
reactiv
dormant
viru
inhibit
viral
mrna
product
latent
cell
line
upon
stimul
pma
tsa
extens
research
reveal
unabl
inhibit
nfb
activ
pathway
chromatin
remodel
viral
promot
known
crucial
viral
transcript
activ
focus
viral
transcript
process
chromatin
immunoprecipit
chip
experi
reveal
abl
inhibit
phosphoryl
ctermin
domain
ctd
rna
polymeras
ii
step
mediat
subunit
ptefb
recruit
viral
promot
tat
protein
sinc
find
inhibit
level
activ
tatmedi
transcript
tatexpress
cell
line
transient
transfect
ltrgfp
construct
infer
must
interfer
transcript
process
uniqu
mode
action
evid
point
toward
kinas
belong
cdk
famili
target
naim
result
antivir
action
level
retrovir
transcript
clara
e
sandra
franco
miguel
lui
centro
de
molecular
severo
ochoa
csicuam
madrid
spain
irsicaixa
hosp
univers
german
tria
pujol
badalona
spain
serser
insert
codon
togeth
substitut
reversetranscriptas
rt
code
region
known
confer
resist
zidovudin
azt
stavudin
phenotyp
resist
correl
increas
atpdepend
phosphorolyt
activ
inhibitortermin
primer
previous
shown
rt
deriv
clinic
isol
ss
rt
contain
insert
addit
mutat
relat
drug
resist
includ
show
increas
unblock
activ
aztand
primer
compar
rt
contain
insert
togeth
mutat
otherwis
wildtyp
sequenc
result
suggest
mutat
associ
complex
clinic
relev
rt
contribut
increas
atpmedi
excis
activ
confer
highlevel
resist
azt
phenotyp
assay
identifi
residu
increas
excis
activ
obtain
recombin
enzym
bear
ss
rt
residu
wildtyp
rt
residu
rt
residu
rt
ss
rt
rt
well
rt
variant
substitut
rt
rt
deriv
rt
addit
rt
contain
mutat
togeth
combin
background
also
obtain
atpmedi
excis
activ
aztand
primer
determin
effect
mutat
test
phenotyp
assay
use
recombin
rt
contain
mutat
addit
chang
ntermin
region
show
highest
atpdepend
phosphorolyt
activ
block
primer
give
valu
similar
report
ss
rt
result
consist
phenotyp
data
contrast
rt
display
lowlevel
activ
experi
reveal
three
amino
acid
chang
ntermin
region
polymeras
respons
increas
excis
activ
shown
rt
bear
mutat
seri
phenylsubstitut
thiazolobenzimidazol
sever
compound
identifi
select
inhibitor
coxsacki
b
viru
replic
vero
cell
structureact
relationship
establish
substitut
analog
emerg
potent
congen
compound
activ
six
coxsacki
b
strain
test
vitro
antivir
activ
one
select
compound
ie
assess
mtsbase
cytopath
effect
assay
ii
viru
yield
reduct
assay
iii
realtim
quantit
pcr
rtqpcr
iv
monitor
viral
antigen
express
assay
clear
concentrationrespons
effect
obtain
effect
concentr
gml
cytotox
concentr
vero
cell
gml
thu
result
select
index
detail
singl
cycl
timeofdrugaddit
studi
viral
replic
monitor
mean
rtqpcr
reveal
compound
interact
viral
replic
time
coincid
onset
intracellular
viral
rna
synthesi
viru
gener
cultur
viru
presenc
increas
drug
concentr
drugresist
viru
genotyp
allow
us
identifi
put
viral
molecular
target
class
compound
retrovirus
hiromichi
tanaka
kazuhiro
haraguchi
hiroki
kumamoto
takao
nitanda
masanori
baba
ginger
e
dutschman
yungchi
cheng
school
pharmaceut
scienc
showa
univers
tokyo
japan
center
chronic
viral
diseas
kagoshima
univers
kagoshima
japan
school
medicin
yale
univers
new
ct
usa
recent
research
program
develop
synthet
method
carbonsubstitut
nucleosid
led
new
strategi
ring
open
epoxynucleosid
organoaluminum
organosilicon
reagent
enabl
us
introduc
alkyl
alkenyl
alkynyl
group
posit
result
studi
ethynylstavudin
found
antihiv
activ
parent
compound
stavudin
compound
sever
addit
appeal
promis
antihiv
agent
much
less
toxic
variou
cell
also
mitochondri
dna
synthesi
better
substrat
human
thymidin
kinas
much
resist
catabol
thymidin
phosphorylas
activ
enhanc
presenc
major
mutat
known
nnrtiresist
hiv
confer
present
synthesi
sar
studi
analogu
modifi
mainli
sugar
portion
neg
charg
polym
np
possess
broad
immunoadjuv
antivir
activ
topic
use
vaccin
drug
microbicid
develop
effici
limit
revers
electrostat
kind
interfer
virusspecif
nanoobject
overcom
limit
purposemad
intramolecular
modif
np
studi
among
nontox
maleic
acid
copolym
npsa
dextran
chitin
deriv
npp
within
vari
alicycl
modifi
applic
configur
flexibl
alkyl
nonalicycl
control
ineffect
synergist
np
antivir
potenc
monocycl
ii
moder
activ
contrari
hardconform
framestructur
spheroid
iiivi
exhibit
abil
optim
macromolecular
paramet
supereffect
synergist
strength
diapason
np
antivir
action
unlik
small
molecular
iiiivcontain
prototyp
amantadin
rimantadin
deitiforin
etc
narrowlyeffect
inhibitor
mainli
influenza
virus
npcoupl
modif
becom
effect
also
mani
virus
includ
drug
resist
strain
antivir
re
focu
antihiv
potenc
iv
provid
elev
np
activ
avail
less
toxic
iii
speci
similarli
activ
iii
spatialoptim
contact
doubl
bond
due
exoconfigur
turn
best
synergist
amplifi
select
augment
frame
cycl
iiiiv
toward
vvi
result
essenti
enhanc
antivir
activ
stimul
toxic
recent
involv
investig
vii
cholesterollik
system
tool
novel
rafttarget
strategi
demonstr
capac
least
amplif
potenc
earlier
studi
show
esterif
cidofovir
hpmpc
alkoxyalkanol
increas
antivir
activ
two
log
promot
oral
bioavail
evalu
approach
purin
base
nucleosid
phosphon
synthes
sever
alkoxyalkyl
ester
acycl
purin
phosphon
diamino
purin
pmedap
purin
pmecprdap
purin
phosphon
report
activ
wide
rang
virus
human
immunodefici
viru
retrovirus
herpesvirus
poxvirus
hepat
b
viru
studi
sever
alkoxyalkyl
analog
acycl
nucleosid
phosphon
synthes
evalu
alkoxyalkyl
ester
inhibitori
unmodifi
compound
reduct
assay
cell
infect
exampl
hexadecyloxypropyl
hdp
oleyloxyethyl
ole
ester
pmecprdap
log
activ
unmodifi
pmecprdap
spite
increas
cytotox
cell
select
index
higher
unmodifi
compound
conclus
esterif
pmedap
pmecprdap
hexadecyloxypropylor
oleyloxyethylresidu
greatli
increas
antivir
activ
select
vitro
victor
kuzmin
eugen
muratov
anatoli
artemenko
ludmila
koroleva
vladimir
silnikov
v
lozitski
fedchuk
av
bogatski
physicalchem
institut
odessa
ukrain
institut
chemic
biolog
fundament
medicin
novosibirsk
russian
feder
ukrainian
mechnikov
research
antiplagu
institut
odessa
ukrain
chemic
ribonucleas
hold
promis
tool
studi
structur
rna
rnaprotein
complex
reactiv
group
conjug
intend
cleavag
particular
rna
therapeut
inactiv
viru
genom
rna
certain
mrna
promis
antivir
agent
drug
design
develop
new
medicin
direct
hiv
perman
actual
task
usag
modern
quantit
structureact
relationship
qsar
method
could
allow
us
solv
problem
effect
object
present
work
qsar
analysi
antivir
activ
variou
tetrapeptidesartif
ribonucleas
consequ
molecular
design
new
antivir
agent
qsar
approach
base
simplex
represent
molecular
structur
sirm
use
solut
formul
problem
usag
sirm
allow
us
develop
molecular
design
new
effect
antivir
agent
thorough
research
relationship
antivir
activ
rna
po
bond
cleavag
structur
artif
ribonucleas
carri
statist
characterist
pl
partial
least
squar
model
quit
satisfactori
r
q
base
model
molecular
fragment
posit
neg
influenc
explor
properti
determin
thu
exampl
guanidin
triethylenediamin
fragment
promot
antivir
action
give
possibl
realiz
base
elucid
rule
molecular
design
compound
high
level
antivir
activ
result
prognosi
verifi
experiment
investig
thu
quit
adequ
simplex
qsar
model
antihiv
activityartif
ribonucleas
structur
obtain
use
drug
design
cyclotriazadisulfonamid
cada
compound
specif
downmodul
receptor
express
surfac
lymphocyt
monocytesmacrophag
primari
receptor
util
hiv
infect
target
cell
cada
thu
inhibit
entri
hiv
vermeir
et
al
virolog
cada
chemotherapi
may
suscept
product
drug
resist
strain
virus
mechan
action
complet
differ
antihiv
drug
current
clinic
use
downmodul
antivir
potenc
cada
analog
describ
vermeir
et
al
mol
pharmacol
structur
modif
cada
made
increas
potenc
reduc
cytotox
improv
physic
properti
sever
head
group
analog
synthes
polar
group
good
leav
group
fig
antihiv
modul
activ
compound
studi
head
group
may
regener
doubl
bond
cada
elimin
reaction
potenti
produc
watersolubl
prodrug
isocada
isom
cada
synthes
cycliz
tbd
fig
structur
modif
may
reveal
relationship
symmetri
molecul
biolog
activ
two
new
fluorinecontain
analog
also
synthes
modifi
toluenesulfonamid
side
arm
fig
antihiv
modul
activ
new
cada
analog
summar
center
drug
discoveri
univers
georgia
athen
ga
usa
drug
discoveri
target
elus
viral
enzym
hiv
integras
result
singl
fdaapprov
drug
present
describ
molecular
model
studi
conceptu
novel
inhibitor
hiv
integras
also
possess
potent
vitro
antihiv
activ
dock
perform
catalyt
core
integras
repres
chain
c
pdb
structur
code
build
molecul
primari
model
done
sybyl
silicon
graphic
workstat
program
gold
genet
optim
ligand
dock
use
extens
evalu
dock
pose
compound
activ
site
hiv
integras
give
inform
key
residu
involv
recognit
bind
ligand
gold
function
consist
three
basic
compon
proteinligand
hbond
energi
proteinligand
van
der
waal
energi
ligand
intern
energi
postprocess
gold
output
done
program
silver
util
program
suppli
gold
evalu
hydrogenbond
interact
metal
coordin
van
der
waal
factor
comparison
purpos
addit
dock
perform
use
dock
protocol
notabl
sybyl
modul
flexx
data
obtain
relat
studi
includ
bind
pose
bind
affin
function
conform
consider
gold
function
score
present
explain
center
drug
discoveri
univers
georgia
athen
ga
usa
hiv
integras
essenti
hiv
replic
attract
target
drug
discoveri
aid
howev
research
effort
drug
discoveri
pertain
hiv
integras
result
singl
fdaapprov
drug
mechan
action
inhibit
hiv
integras
recent
explor
novel
class
diketo
acid
construct
nucleobas
scaffold
specif
arrang
function
hydrophob
group
scaffold
compound
inhibitor
key
step
hiv
integras
one
lead
compound
group
also
found
remark
vitro
antihiv
activ
howev
synthes
inhibitor
quit
challeng
present
describ
synthet
methodolog
specif
develop
laboratori
prepar
repres
exampl
integras
inhibitor
purif
approach
produc
highli
purifi
compound
biolog
studi
explain
structur
function
conform
data
obtain
extens
spectroscop
studi
discuss
repres
antihiv
integras
data
vitro
antihiv
screen
result
present
recent
report
synthesi
antivir
activ
ringexpand
fat
nucleosid
analogu
call
inhibit
hcv
hiv
vitro
ec
valu
rang
micromolar
concentr
less
littl
low
toxic
host
cell
part
present
subject
report
preliminari
find
mechan
antihiv
activ
compound
along
synthesi
antivir
activ
addit
analogu
view
fact
number
hiv
patient
also
suffer
hcv
major
coinfect
number
ultim
die
endstag
hcvrelat
complic
includ
liver
cirrhosi
hepatocellular
carcinoma
drug
dual
inhibitori
characterist
virus
highli
desir
time
marina
burshtein
alexand
serbin
alissa
bukrinskaya
di
ivanovski
institut
virolog
moscow
russia
health
research
develop
found
moscow
russia
introduct
amantadin
wellknown
effect
antiinfluenza
drug
modifi
enhanc
antivir
activ
chemic
linkag
watersolubl
polyanion
matrix
via
differ
spacer
group
group
use
compound
norbornen
deriv
norbornen
adamantan
analogu
antiinfluenza
activ
method
absenc
cytotox
effect
shown
mtt
test
estim
cytotox
dose
antivir
effect
compound
analyz
lymphoblastoid
cell
hela
cell
magi
cell
effect
compound
regist
immunoblot
cell
lysat
measur
bgalactosidas
activ
result
strong
inhibit
replic
observ
compound
ad
viru
express
even
compound
ad
viru
remov
h
infect
anti
effect
compound
gradual
decreas
ad
h
infect
inhibit
observ
compound
ad
h
infect
compound
impair
virion
structur
adamantan
norbornen
deriv
shown
also
inhibit
azt
resist
viral
strain
conclus
adamantan
norbornen
shown
activ
hiv
inhibitor
high
select
index
compound
promis
candid
investig
includ
preclin
studi
less
known
effect
intracellular
halfliv
mainten
antivir
activ
investig
question
develop
novel
vitro
antivir
persist
assay
measur
antivir
persist
tenofovir
tfv
abacavir
cbv
coupl
measur
halfliv
tfvdp
cbvtp
anabolit
method
cell
stimul
primari
tcell
incub
grade
concentr
tfv
cbv
h
h
extracellular
drug
remov
wash
cell
incub
without
drug
h
infect
iiib
bal
quantifi
day
inhibit
replic
due
intracellular
drug
persist
determin
rel
standard
decay
intracellular
dptp
tcell
measur
use
lcmsm
result
cell
valu
tfv
h
drug
remov
remain
unchang
rel
shift
wherea
cbv
shift
indic
less
persist
cbv
tcell
valu
tfv
also
show
minim
shift
rel
h
drug
remov
cbv
show
much
larger
rel
shift
quantif
lcmsm
intracellular
tfvdp
cbvtp
tcell
vitro
demonstr
tfvdp
longest
intracellular
halflif
two
drug
tfvdp
h
versu
cbvtp
h
conclus
novel
antivir
persist
assay
develop
studi
relationship
intracellular
nrti
halfliv
antivir
activ
cell
primari
activ
tcell
tfv
longest
persist
antivir
activ
tcell
tfvdp
also
longest
halflif
two
nrti
cbvtp
much
shorter
halflif
tfvdp
show
less
antivir
persist
although
drug
approv
qd
dose
halflif
intracellular
tfvdp
maintain
antivir
suppress
vitro
timefram
consist
qd
dose
karen
watson
traci
l
hartman
lu
yang
robert
w
buckheit
jr
imquest
bioscienc
inc
frederick
md
usa
isi
phosphorothio
oligonucleotid
molecular
structur
gquartet
possess
molecul
shown
potent
inhibitor
hiv
attach
cellcel
fusion
act
specif
interact
loop
map
studi
monoclon
antibodi
target
epitop
around
loop
use
defin
bind
site
isi
vitro
isi
inhibit
laboratori
clinic
strain
test
includ
repres
subtyp
virus
drug
resist
virus
includ
mdr
virus
virus
util
chemokin
receptor
serial
passag
viru
presenc
increas
concentr
oligonucleotid
result
select
drug
resist
viru
strain
combin
assay
result
addit
synergist
interact
approv
hiv
inhibitor
antivir
toxic
profil
isi
result
perform
human
clinic
trial
therapeut
use
oligonucleotid
treat
hiv
infect
antivir
properti
mechan
action
isi
suggest
may
excel
antihiv
topic
microbicid
isi
found
highli
activ
cervic
explant
model
hiv
infect
highli
signific
inhibit
strain
viru
activ
also
observ
cellfre
cellassoci
viru
transmiss
assay
well
acut
infect
inhibit
assay
microbicid
specif
combin
assay
signific
efficaci
observ
isi
use
combin
microbicid
compound
result
studi
suggest
isi
may
repres
new
novel
antihiv
topic
microbicid
karen
watson
traci
l
hartman
lu
yang
robert
w
buckheit
jr
imquest
bioscienc
inc
frederick
md
usa
though
varieti
compound
develop
antihiv
topic
microbicid
polyanion
molecul
surfact
natur
product
peptid
protein
heterocycl
virucid
agent
clinic
efficaci
studi
demonstr
abil
agent
impact
viru
transmiss
still
progress
estim
microbicid
effect
would
capac
prevent
million
new
infect
year
thu
one
challeng
hiv
drug
develop
discoveri
compound
inhibit
sexual
transmiss
infecti
organ
sexual
partner
rapid
mutabl
hiv
known
presenc
drug
resist
virus
wild
type
viru
popul
suggest
microbicid
develop
suffer
problem
exist
hiv
therapi
name
select
resist
viru
strain
bypass
microbicid
barrier
infect
target
cell
vagin
rectal
environ
even
presenc
microbicid
thu
like
haartlik
combin
drug
therapi
becom
effect
mean
inhibit
sexual
transmiss
hiv
evalu
wide
varieti
antihiv
antisti
compound
vitro
alon
combin
one
anoth
demonstr
certain
pattern
inhibit
addit
synergi
antagon
occur
variou
class
compound
recent
compar
combin
antihiv
activ
microbicid
compound
fresh
human
pbmc
infect
clinic
isol
hiv
combin
activ
test
agent
cemssbas
cultur
gener
two
assay
system
yield
similar
combin
assay
result
provid
rational
combin
use
compound
microbicid
set
combin
compound
evalu
microbicidelik
viru
transmiss
assay
combin
result
suggest
higher
level
synergi
viru
attach
revers
transcriptas
inhibitor
might
expect
microbicid
environ
compar
level
predict
system
therapeut
environ
result
combin
assay
variou
microbicid
present
onset
hiv
diseas
hiv
rna
continu
produc
face
treatment
haart
circul
reservoir
rt
inhibitor
almost
ineffect
postintegr
event
among
class
anti
drug
proteas
inhibitor
pi
uniqu
inhibit
product
chronic
infect
macrophag
progress
hiv
infect
role
monocytesderiv
macrophag
mm
confirm
repres
chronolog
first
cytotyp
viral
replic
restart
consequ
failur
interrupt
antivir
therapi
aim
work
evalu
rebound
product
pi
remov
chronic
infect
mm
moreov
verifi
effect
remov
viru
matur
infect
abil
trigger
apoptosi
uninfect
peripher
blood
lymphocyt
pbl
rebound
gag
protein
measur
start
h
drug
remov
yet
viru
infect
remain
log
lower
control
week
inhibit
replic
still
upon
amprenavir
respect
data
confirm
western
blot
electron
microscopi
show
product
releas
immatur
viral
particl
moreov
pi
amprenavir
indinavir
treatment
dramat
reduc
apoptosi
pbl
cocultur
chronic
infect
mm
kept
ratio
level
untreat
control
day
cocultur
taken
altogeth
find
suggest
wide
clinic
import
amprenavir
indinavir
relev
longlast
antivir
effect
persistentlyinfect
reservoir
hiv
even
case
drug
interrupt
andor
hiv
infect
restart
district
drug
find
suffici
concentr
moreov
result
strengthen
evid
uniqu
posit
util
pi
ongo
product
hiv
infect
weili
jin
salvator
santino
michael
wang
gilead
scienc
foster
citi
ca
usa
background
effect
inhibit
hiv
revers
transcriptas
rt
current
repres
crucial
object
antiretrovir
therapi
capravirin
secondgener
nonnucleosid
rt
inhibitor
nnrti
capabl
block
replic
certain
nnrtiresist
strain
hiv
recent
clinic
develop
studi
report
vitro
select
character
viral
resist
capravirin
method
viral
resist
select
experi
perform
cell
hiv
iiib
isol
increas
concentr
capravirin
virus
analyz
genotyp
popul
sequenc
singl
genom
sequenc
sg
recombin
virus
nnrti
mutat
gener
provir
dna
clone
phenotyp
analys
perform
cell
result
capravirin
resist
select
initi
nm
ec
nm
capravirin
follow
nine
passag
presenc
increas
concentr
capravirin
mutat
emerg
rt
addit
passag
led
mutat
higher
concentr
nm
increas
capravirin
concentr
led
emerg
tripl
mutant
confer
resist
capravirin
sg
mix
viral
popul
differ
passag
show
present
genom
primari
mutat
acquir
sequenti
later
passag
sg
analysi
quadrupl
mutat
genom
also
observ
higher
capravirin
concentr
nm
recombin
virus
carri
mutat
produc
assess
suscept
capravirin
conclus
extens
vitro
passag
hivinfect
cell
presenc
capravirin
neither
mutat
rt
observ
instead
mutat
initi
acquir
follow
mutat
addit
mutat
tripl
mutant
genom
appear
enhanc
hiv
resist
capravirin
oluwafemi
olawuyi
adeyemi
falegan
medic
microbiolog
univers
colleg
hospit
ibadan
nigeria
dentistri
univers
colleg
hospit
ibadan
nigeria
issu
percentag
aidshiv
increas
everi
year
third
world
reinforc
factor
major
youth
third
world
know
hisher
hiv
statu
descript
self
develop
valid
reliabl
questionnair
r
use
collect
data
percentag
use
analyz
data
popul
studi
made
youth
femal
male
higher
institut
work
place
market
place
commun
street
nigeria
size
select
simpl
random
sampl
techniqu
mean
age
year
old
rel
risk
rr
calcul
ie
rr
indic
factor
risk
factor
confidenti
interv
ci
rr
signific
level
formula
ci
lower
limit
rr
ci
upper
limit
lesson
learn
seventi
percent
sampl
popul
know
hisher
hiv
statu
sexual
intercours
past
unprotect
intercours
protect
sex
sure
use
protect
mean
knowledg
hiv
statu
sexual
intercours
ten
percent
knowledg
hiv
statu
sexual
intercours
conclus
aidshiv
still
remain
killer
diseas
third
world
howev
lack
knowledg
individu
hiv
statu
remain
highest
risk
factor
spread
diseas
third
world
yuichiro
habu
jacob
barnor
norio
yamamoto
kahoko
hashimoto
naoko
miyanokurosaki
koichi
ishikawa
naoki
yamamoto
david
oforiadjei
hiroshi
takaku
depart
life
environment
scienc
chiba
institut
technolog
chiba
japan
high
technolog
research
center
chiba
institut
technolog
chiba
japan
japan
foundat
aid
prevent
depart
molecular
virolog
biorespons
tokyo
medic
dental
univers
tokyo
japan
aid
research
center
nation
institut
infecti
diseas
tokyo
japan
depart
virolog
noguchi
memori
institut
medic
research
accraghana
accra
ghana
bach
tech
corp
rna
interfer
rnai
potenti
strong
gene
interfer
tool
success
use
silenc
mani
pathogen
virus
includ
hiv
howev
mani
recent
report
shown
longterm
assay
cultur
involv
rna
virus
hiv
escap
mutant
breakthrough
silenc
effect
light
conundrum
propos
vector
design
target
multipl
gene
synergist
manner
may
address
problem
henc
design
chimer
rna
express
vector
express
vif
shrna
decoy
tar
rna
combin
vif
shrna
decoy
tar
rna
linker
dicer
abl
recogn
cleavag
second
gener
rnai
express
vector
system
synergist
effect
molecul
enhanc
inhibit
replic
longterm
transduc
pbmc
jurkat
cell
cultur
assay
week
prevent
viru
breakthrough
associ
sirnamedi
escap
variant
notabl
replic
similarli
suppress
control
cell
express
vif
shrna
week
increas
viru
replic
observ
afterward
hiv
viral
rna
extract
sequenc
point
indic
escap
mutant
cell
express
vif
target
hiv
confirm
substitut
base
vif
shrna
target
sequenc
hand
incid
mutat
observ
sequenc
viral
rna
cultur
express
vif
shrnadecoy
tar
rna
fourth
week
interestingli
viru
product
inhibit
longterm
effect
decoy
tar
rna
rnaprotein
interact
combin
shrna
decoy
tar
rna
secondgener
antihiv
shrna
may
provid
practic
basi
appli
sirnabas
gene
therapi
treatment
hivaid
introduct
design
effici
gene
therapi
aidshiv
novelti
aid
vaccin
designconcept
seen
fact
pol
gene
encod
nonstructur
protein
polyprotein
gener
three
enzym
revers
transcriptas
integras
proteas
clone
suitabl
retrovir
vector
adult
stem
cell
transfect
reinfus
circul
effect
counter
hiv
replic
antigen
variat
method
mrna
isol
adult
stem
cell
transcrib
cdna
revers
transcriptas
cdna
clone
suitabl
retrovir
vector
vacinia
carri
pol
gene
confer
resist
strong
revers
transcriptas
inhibitor
drug
adult
stem
cell
transfect
recombin
mixtur
reinfus
circul
hiv
infect
person
result
transfect
stem
cell
reinfus
provid
renew
sourc
better
empow
normal
blood
cell
type
would
disrupt
half
hiv
replic
circul
would
effici
induct
humer
cellular
mediat
immun
prolong
express
antigen
protect
immunolog
memori
gener
hiv
antigen
variat
conclus
aid
vaccin
design
would
lead
effici
prophylact
therapeut
therapi
aid
would
effect
take
care
problemat
factor
hiv
antigen
variat
long
main
obstacl
potent
aid
vaccin
develop
real
risk
interspeci
transmiss
andor
reassort
avian
swine
human
influenza
strain
drug
suscept
monitor
circul
avian
porzin
viru
strain
appear
warrant
effect
applic
antivir
drug
like
amantadin
studi
design
gain
insight
amantadin
suscept
avian
porcin
influenza
virus
isol
germani
viru
strain
isol
embryon
chicken
egg
passag
one
time
mdck
cell
plaqu
reduct
assay
appli
examin
viru
suscept
amantadin
genotyp
use
confirm
drug
resist
result
antivir
studi
porzin
isol
avian
isol
shown
amantadinesuscept
interestingli
three
amantadinesensit
porzin
strain
isol
porzin
influenza
virus
isol
later
drugresist
contain
aa
substitut
matrix
protein
addit
detect
two
strain
andor
well
known
amino
acid
substitut
confer
amantadin
resist
role
pig
intermedi
host
avian
human
influenza
virus
possibl
involv
genet
reassort
high
incid
natur
amantadineresist
porcin
influenza
virus
suggest
real
risk
emerg
amantadin
resist
human
virus
therefor
studi
ongo
evalu
circul
resist
phenotyp
pig
bird
human
recent
much
attent
devot
search
effect
chemotherapeut
agent
vaccin
erad
notori
diseas
present
chemotherapi
avail
combat
avian
flu
instanc
tamiflu
approv
treatment
usfda
develop
simpl
novel
molecul
potenti
antivir
activ
essenti
treat
avian
flu
viral
infect
isatin
versatil
lead
molecul
design
potenti
antivir
agent
deriv
report
possess
broad
spectrum
antivir
activ
methisazon
first
clinic
approv
treatment
pox
viral
infect
deriv
document
antiinfluenza
activ
base
upon
evid
present
work
initi
determin
antivir
activ
novel
isatin
deriv
avian
flu
mdck
cell
antivir
activ
studi
viru
yield
assay
cytotox
neutral
red
uptak
assay
uninfect
mdck
cell
five
compound
seri
inhibit
replic
avian
flu
viru
replic
mdck
cell
compound
activ
gml
gml
si
detail
studi
result
treatment
influenzainfect
mice
discuss
acknowledg
support
part
contract
virolog
branch
niaid
nih
argininerich
peptid
conjug
phophorodiamid
morpholino
oligom
arppmo
nucleas
resist
antisens
compound
hybrid
target
rna
sequencespecif
manner
result
disrupt
rna
function
eight
arppmo
design
basepair
variou
region
rna
evalu
hemagglutin
plaqu
assay
abil
inhibit
fluav
product
vero
cell
cultur
arppmo
target
aug
translat
start
site
np
segment
mrna
terminu
respect
vrna
highli
effect
reduc
influenza
viru
titer
order
magnitud
dosedepend
sequencespecif
manner
period
day
two
ppmo
target
translat
start
site
region
terminu
np
vrna
np
evalu
endpoint
dilut
elisa
assay
anoth
strain
well
arppmo
gener
specif
reduct
viru
level
regardless
viral
subtyp
methodolog
concentr
rang
np
ppmo
yield
similar
result
except
consider
lower
efficaci
strain
two
base
mispair
studi
plan
evalu
least
two
arppmo
anim
model
fluva
subtyp
macroheterocycl
compound
contain
crown
fragment
nitrogen
atom
show
largescal
biolog
activ
synthes
seri
azacrown
ether
deriv
also
studi
antiinfluenza
antiherpet
action
antihsv
action
studi
compound
test
use
cytomorpholog
method
cell
infect
strain
us
dose
ifucel
cell
incub
eagl
medium
contain
compound
dose
experiment
sampl
without
control
sampl
cell
fix
ethanol
stain
acridin
orang
solut
amount
infect
cell
dnacontain
viru
inclus
bodi
count
fluoresc
microscopi
antihsv
activ
compound
calcul
differ
percentag
infect
cell
treat
cell
cultur
percentag
infect
cell
untreat
cell
cultur
antiinfluenza
activ
studi
model
replic
ahong
strain
tissu
cultur
chorioallanto
membran
chicken
embryo
compound
use
dose
studi
antiinfluenza
action
two
deriv
showmen
neither
antihsv
antiinfluenza
activ
deriv
contain
ethoxycarbonylfrag
decreas
amount
cell
infect
respect
compound
inhibit
replic
influenza
viru
log
tid
show
antivir
activ
deriv
prove
activ
inhibitor
hsv
influenza
viru
reproduct
deriv
contain
decreas
amount
cell
infect
virusspecif
intranuclear
inclus
respect
first
compound
inhibit
replic
influenza
viru
log
tid
second
one
decreas
viru
amount
log
tid
result
studi
show
azacrown
ether
perspect
class
compound
search
new
antivir
agent
acknowledg
work
partial
support
stcu
grant
robert
w
sidwel
kevin
w
bailey
minhui
wong
donald
f
smee
dale
l
barnard
shanta
bantia
institut
antivir
research
utah
state
univers
logan
ut
usa
biocryst
pharmaceut
inc
birmingham
al
usa
cyclopentan
neuraminidas
inhibitor
peramivir
strike
inhibitori
effect
spectrum
influenza
virus
vitro
also
demonstr
signific
effect
influenza
b
viru
infect
administ
oral
mice
ferret
unfortun
clinic
trial
drug
administ
oral
success
probabl
due
low
blood
level
obtain
oral
administr
signific
plasma
drug
level
peramivir
persist
h
intramuscular
im
inject
importantli
howev
observ
peramivir
remain
tightli
bound
influenza
viru
neuraminidas
h
suggest
singl
im
intraven
iv
therapi
drug
may
highli
effect
influenza
infect
experi
press
indic
singl
im
peramivir
therapi
administ
h
viru
exposur
protect
mice
infect
influenza
viru
present
studi
peramivir
administ
im
iv
singl
inject
h
previru
exposur
separ
experi
mice
infect
influenza
viru
efficaci
compar
similar
dosag
oseltamivir
oseltamivir
carboxyl
run
parallel
dosag
mgkg
peramivir
administ
either
rout
significantli
prevent
death
lessen
arteri
oxygen
sao
declin
inhibit
develop
lung
consolid
inhibit
lung
viru
titer
lung
assay
perform
vari
time
viru
exposur
oseltamivir
oseltamivir
carboxyl
neuraminidas
bind
abil
seen
peramivir
less
efficaci
experi
delay
singl
iv
therapi
h
viru
exposur
also
significantli
inhibit
viru
infect
peramivir
appear
well
toler
toxic
control
anim
run
concomitantli
studi
data
indic
parenter
administ
peramivir
may
hold
promis
therapi
clinic
influenza
viru
infect
acknowledg
support
contract
virolog
branch
niaid
nih
hiroshi
saitoh
naoko
miyanokurosaki
hiroshi
takaku
depart
life
environment
scienc
faculti
engin
chiba
institut
technolog
chiba
japan
depart
life
environment
scienc
faculti
engin
high
technolog
research
center
chiba
institut
technolog
chiba
japan
background
influenza
viru
caus
widespread
infect
human
respiratori
tract
exist
vaccin
drug
therapi
limit
valu
recent
small
interf
rna
sirna
power
tool
sequencespecif
posttranscript
gene
silenc
potenti
therapeut
prophylact
applic
cancer
well
infecti
diseas
show
short
interf
rna
sirna
specif
conserv
region
viral
genom
potent
inhibit
influenza
viru
product
cell
line
influenza
viru
np
gene
potenti
target
rnai
technolog
hand
baculoviru
acmnpv
infect
varieti
mammalian
cell
facilit
use
viru
vector
gene
deliveri
viral
entri
cell
studi
describ
inhibit
influenza
viru
product
baculovirusmedi
shrna
express
vector
method
plasmid
vector
baculoviru
vector
use
studi
influenza
viru
b
np
gene
made
target
shrna
express
plasmid
vector
construct
control
human
pol
iii
promot
shrna
express
plasmid
shrna
express
baculoviru
vector
introduc
mdck
cell
h
later
cell
infect
either
bibaraki
viru
moi
h
postinfect
cultur
supernat
harvest
assay
determin
viru
titer
plaqu
assay
conclus
find
reveal
newli
synthes
np
protein
requir
influenza
viru
replic
provid
basi
develop
shrna
express
plasmid
prophylaxi
therapi
influenza
infect
human
julia
serkedjieva
ekaterina
krumova
tsvetanka
stefanova
nadja
nikolova
maria
angelova
institut
microbiolog
bulgarian
academi
scienc
sofia
bulgaria
semistandard
polyphenolrich
extract
pre
obtain
geranium
sanguineum
l
inhibit
reproduct
influenza
virus
type
b
vitro
ovo
protect
mice
mortal
experiment
influenza
viru
infect
serkedjieva
manolova
select
vitro
virusinhibitori
activ
pre
fairli
modest
contrast
signific
protect
vivo
thu
therapeut
effect
pre
need
explan
presum
might
attribut
combin
one
biolog
activ
known
natur
polyphenol
demonstr
previous
pre
manifest
strong
antioxid
radicalscaveng
activ
model
system
sokmen
et
al
current
studi
undertaken
investig
effect
plant
extract
level
antioxid
enzym
superoxid
dismutas
sod
catalas
kt
peroxidas
po
mice
lung
influenza
viru
infect
well
effect
pre
product
reactiv
oxygen
speci
ro
reactiv
nitrogen
intermedi
rni
alveolar
macrophag
influenza
viru
infect
mice
mice
challeng
intranas
ld
influenza
viru
pre
administ
instil
h
infect
dose
mgkg
establish
influenza
infect
induc
increas
sod
kt
po
product
day
infect
level
reach
placebo
control
applic
pre
brought
enzym
valu
control
level
influenza
infect
caus
also
signific
increas
h
product
alveolar
macrophag
gener
ro
rni
peak
day
pretreat
viral
challeng
reduc
excess
product
conclus
obtain
result
outlin
antioxid
radic
scaveng
properti
plant
extract
pre
benefici
modul
oxid
stress
respons
influenza
virusinduc
pneumonia
altern
mechan
action
might
contribut
overal
protect
effect
lethal
murin
experiment
influenza
infect
antivir
activ
natur
herb
extract
jisun
kwon
hyunjeong
lee
chiung
moon
jonghwan
kwak
younjeong
lee
changseon
song
avian
diseas
laboratori
colleg
veterinari
medicin
konkuk
univers
seoul
korea
hanyang
univers
seoul
korea
sungkyunkwan
univers
seoul
korea
nation
veterinari
research
quarantin
servic
seoul
korea
antivir
activ
one
tradit
korean
medic
herb
extract
influenza
viru
investig
effect
concentr
use
plaqu
reduct
assay
ugml
mean
cytotox
concentr
use
assay
mdck
cell
ugml
oral
gavag
treatment
balbc
mice
infect
influenza
viru
show
therapeut
effect
delay
clinic
sign
signific
inhibit
death
reduct
lung
viru
titer
identifi
lead
molecul
subject
fraction
purif
isol
activ
compound
antivir
activ
natur
herb
compound
discuss
result
suggest
possibl
candid
develop
new
antivir
medicin
influenza
therapi
hiroshi
takaku
takayuki
abe
hitoshi
takahashi
naoko
miyanokurosaki
depart
life
environ
sci
chiba
inst
tech
chiba
japan
high
tech
re
center
chiba
inst
tech
chiba
japan
re
inst
microbi
di
osaka
univers
osaka
japan
bach
tech
corp
background
baculoviru
autographa
californica
nuclear
polyhedrosi
viru
acnpv
long
use
biopesticid
tool
effici
recombin
protein
product
insect
cell
studi
examin
immun
recombin
baculoviru
express
influenza
viru
hemagglutinin
ha
lethal
influenza
infect
mice
protect
observ
mice
immun
intranas
recombin
baculoviru
also
wildtyp
baculoviru
baculoviru
also
shown
induc
secret
inflammatori
cytokin
murin
raw
macrophag
cell
line
result
vari
rout
immun
recombin
baculoviru
express
influenza
viru
hemagglutinin
protein
viru
lethal
influenza
infect
examin
mice
recombin
baculoviru
encod
hemagglutinin
gene
control
chicken
actin
promot
inocul
twice
week
apart
dose
pfu
per
mous
intramuscular
intraderm
intraperiton
intranas
rout
mice
intramuscularli
intraperiton
immun
recombin
exhibit
higher
level
product
serum
anti
ha
antibodi
immun
via
rout
protect
achiev
intranas
immun
surprisingli
mice
immun
wildtyp
baculoviru
intranas
rout
also
protect
lethal
influenza
viru
challeng
suffici
protect
mice
achiev
intranas
immun
pfu
either
recombin
wildtyp
baculoviru
evalu
reduct
viru
titer
product
inflammatori
cytokin
pulmonari
consolid
lung
result
indic
infect
baculoviru
induc
strong
innat
immun
respons
protect
mice
lethal
influenza
viru
infect
conclus
baculoviru
cpg
motif
induc
strong
innat
immun
respons
protect
mice
lethal
influenza
viru
b
infect
andrew
vaillant
anni
lebel
nathali
goyett
guy
boivin
jeanmarc
juteau
phil
wyde
replicor
inc
laval
que
canada
chuqchul
laval
univers
st
foy
que
canada
baylor
colleg
medicin
univers
texa
houston
tx
usa
potent
antivir
activ
phosphorothio
oligonucleotid
pson
observ
influenza
viral
infect
antivir
activ
sequenceindepend
size
depend
optim
activ
pson
base
length
depend
presenc
phosphorothio
modif
hydrophob
bind
studi
show
rep
mer
degener
pson
interact
neuraminidas
hemagglutinin
although
sialidas
activ
neuraminidas
affect
suggest
structur
interact
protein
requir
influenza
activ
target
compound
requir
hydrophob
suggest
alpha
helic
region
hemagglutinin
one
region
interact
antivir
activ
rep
conserv
mani
influenza
b
strain
suggest
potenti
therapeut
activ
avian
flu
newli
emerg
influenza
strain
rep
aerosol
excel
characterist
lung
deposit
aerosol
treatment
rep
well
toler
highli
effect
infect
influenza
prophylaxi
h
infect
result
demonstr
therapeut
potenti
aerosol
pson
influenza
infect
acknowledg
support
nih
contract
irina
v
alymova
sudhakara
babu
allen
portner
virolog
divis
depart
infecti
diseas
st
jude
children
research
hospit
memphi
tn
usa
biocryst
pharmaceut
inc
birmingham
al
usa
bcx
novel
select
inhibitor
human
parainfluenza
viru
infect
design
base
threedimension
structur
hemagglutininneuraminidas
hn
protein
newcastl
diseas
viru
compound
exhibit
strike
activ
parainfluenza
virus
vitro
vivo
efficaci
prophylaxi
lethal
synerg
parainfluenza
viru
streptococcu
pneumonia
mous
model
present
studi
conduct
determin
bcx
resist
variant
recombin
sendai
viru
whose
hn
gene
replac
human
parainfluenza
viru
type
rsev
hn
could
select
tissu
cultur
anim
purpos
viru
serial
passag
llcmk
cell
moi
presenc
increas
concentr
compound
infect
mice
treat
mgkgday
bcx
twice
five
day
treatment
start
h
infect
individu
clone
virus
analyz
presenc
mutat
one
mutat
globular
head
region
hn
protein
select
tissu
cultur
fifth
eleventh
passag
rsev
hn
sever
mutat
hn
gene
rsev
hn
select
anim
model
second
passag
viru
mice
treat
bcx
two
mutat
locat
cytoplasm
domain
hn
protein
mutat
found
globular
head
region
glycoprotein
nonconserv
aminoacid
residu
hn
protein
involv
substitut
isol
mutant
virus
stabl
five
passag
llcmk
cell
without
drug
develop
substitut
presenc
drug
display
resist
bcx
vitro
vivo
infect
mutant
alter
compar
wild
type
rsev
hn
viru
take
togeth
result
indic
prophylaxistreat
human
parainfluenza
viru
infect
bcx
may
lead
appear
clinic
signific
variant
virus
kiehoon
jung
michel
mendenhal
lawrenc
blatt
robert
w
sidwel
brian
b
gowen
institut
antivir
research
utah
state
univers
logan
ut
usa
intermun
brisban
ca
usa
hantaviru
pulmonari
syndrom
hp
acut
human
respiratori
diseas
remark
high
case
fatal
rate
etiolog
agent
member
bunyavirida
famili
genu
hantaviru
mapor
map
viru
recent
identifi
hantaviru
isol
western
venezuela
similar
phylogenet
hantavirus
known
caus
hp
southern
region
south
america
despit
lack
evid
map
product
infect
human
caus
hp
infect
hamster
close
resembl
diseas
manifest
associ
human
hp
hantavirus
gener
known
produc
littl
cytopath
effect
cpe
cultur
cell
line
unexpectedli
found
map
produc
remark
cpe
sever
vero
cell
line
facilit
evalu
known
antivir
agent
ribavirin
interferon
drug
highli
effect
reduc
cpe
determin
visual
examin
neutral
red
dye
uptak
associ
map
infect
sinc
much
observ
cpe
may
due
apoptosi
uninfect
bystand
cell
also
develop
quantit
q
rtpcr
assay
detect
copi
map
genom
sequenc
directli
assess
inhibit
viral
replic
data
obtain
use
qrtpcrbase
assay
consist
visual
cpe
reduct
neutral
reduptak
cytotox
find
develop
vitro
antivir
test
method
map
essenti
evolut
vivo
hamster
diseas
model
hp
latter
utmost
import
consid
current
need
effect
antivir
treatment
hp
lack
suitabl
model
requir
biosafeti
level
contain
facil
acknowledg
support
contract
virolog
branch
nation
institut
allergi
infecti
diseas
nation
institut
health
nucleosid
analogu
wide
use
antivir
anticanc
chemotherapi
class
drug
intracellular
convers
nucleosid
analogu
correspond
di
triphosph
target
cell
penetr
prerequisit
biolog
activ
structur
differ
natur
nucleosid
convers
often
ineffici
consequ
therapeut
efficaci
sometim
limit
free
phosphat
nucleotid
limit
util
therapi
account
poor
membran
permeabl
chemic
stabil
one
approach
improv
therapeut
potenti
nucleosid
analogu
deliveri
correspond
nucleotid
entiti
via
neutral
lipophil
prodrug
protid
nucleosid
aryl
phosphoramid
approach
develop
mcguigan
cowork
success
appli
number
differ
nucleosid
azt
dda
gener
structur
aryl
phosphoramid
encompass
two
mask
group
amino
acid
ester
aryl
moieti
bond
phosphat
group
order
appli
protid
technolog
nucleosid
potenti
antihepat
c
viru
hcv
activ
undertaken
studi
design
probe
effect
vari
natur
unnatur
amino
acid
ester
aryl
group
use
mask
group
target
phosphoramid
compound
synthesis
evalu
use
genotip
subgenom
hcv
replicon
prepar
varieti
arylphosphoramid
deriv
rang
substitut
nucleosid
includ
azidouridin
protect
variant
certain
nucleosid
phophoramid
observ
dramat
enhanc
replicon
activ
rel
parent
nucleosid
synthesi
biolog
activ
sar
compound
present
refer
mcguigan
cahard
balzarini
j
minireview
med
chem
identifi
seri
novel
anthranil
acid
deriv
potent
revers
inhibitor
hepat
c
viru
hcv
polymeras
essenti
enzym
viral
replic
micromolar
polymeras
inhibitor
belong
nphenoxyacetylanthranil
acid
chemotyp
xray
crystallographi
determin
inhibitor
bound
thumb
palm
region
adjac
activ
site
guid
crystallographi
subsequ
modif
hydrogen
bond
lipophil
region
inhibitor
result
greatli
improv
activ
sar
studi
reveal
second
potent
subseri
phenoxi
group
replac
anilino
group
analog
subseri
show
antivir
activ
cellbas
replicon
model
hcv
andrea
brancal
dimitrio
vlachaki
maria
chiara
barbera
romano
silvestri
colin
berri
johan
neyt
cardiff
univers
welsh
school
pharmaci
cardiff
xf
uk
universita
degli
studi
la
sapienza
dipartimento
di
studi
farmaceutici
roma
itali
cardiff
univers
cardiff
school
bioscienc
cardiff
uk
rega
institut
medic
research
ku
leuven
b
leuven
belgium
hepat
c
viral
infect
affect
million
peopl
worldwid
includ
million
unit
state
million
europ
viru
establish
chronic
infect
case
affect
individu
develop
cirrhosi
moment
neither
vaccin
effect
antivir
therapi
avail
effort
identifi
specif
antihcv
inhibitor
dramat
intensifi
last
year
mani
research
group
focus
interest
enzym
involv
viral
replic
among
enzym
viral
helicasentpas
proven
suitabl
target
develop
novel
antihcv
compound
compound
potent
inhibitor
hcv
helicas
although
mode
action
still
uncertain
propos
act
competit
inhibitor
rna
bind
start
hypothesi
prepar
seri
novel
compound
base
structur
benzimidazol
moieti
replac
differ
chemic
group
includ
neg
charg
carboxyl
moieti
mimic
phosphat
backbon
nucleic
acid
synthesi
enzym
inhibit
biolog
evalu
replicon
novel
compound
present
analyz
dale
r
cameron
migenix
inc
wesbrook
mall
vancouv
bc
canada
hepat
c
viru
hcv
lead
caus
liver
diseas
continu
attract
target
new
drug
develop
among
favour
approach
develop
new
hcv
drug
target
rnadepend
rna
rdr
polymeras
shown
essenti
enzym
replic
sever
publish
nonnucleosid
inhibitor
polymeras
clinic
develop
sever
publish
alloster
bind
pocket
protein
target
success
tradit
lead
identif
timeintens
costli
larg
infrastructur
requir
increasingli
push
toward
effect
computationalbas
screen
led
develop
virtual
screen
tool
tool
allow
investig
larg
quantiti
compound
silico
particular
properti
without
need
compound
synthesi
high
throughput
screen
moreov
techniqu
requir
modest
infrastructur
invest
effici
employ
openey
set
screen
tool
omega
roc
eon
concert
publicli
avail
hcv
inhibitor
inform
commerci
databas
identifi
novel
lead
inhibitor
coordin
proteininhibitor
complex
crystal
structur
util
target
avail
compound
databas
asinex
chembridg
util
testset
compound
filter
compound
conform
gener
use
omega
compar
templat
use
roc
postanalysi
eon
visual
analysi
maxim
particular
desir
bind
featur
minim
proteininhibitor
steric
clash
allow
list
potenti
hit
narrow
multipl
class
compound
identifi
procedur
sourc
subset
actual
compound
close
analog
test
enzymat
inhibit
activ
character
iter
process
result
identif
lead
compound
class
contain
multipl
activ
compound
one
reason
replicon
activ
conclus
readili
avail
structur
databas
inform
virtual
screen
tool
success
util
identifi
novel
inhibitor
hcv
rdr
polymeras
turn
serv
novel
lead
develop
new
therapi
treat
hcv
synthesi
antivir
activ
cytotox
novel
one
deriv
seri
novel
benzenesulphonamid
synthes
condens
benzo
sulphonamid
chemic
structur
assign
mean
spectral
analysi
ftir
pmr
ms
synthes
compound
screen
vitro
antivir
activ
human
pathogen
virus
hiv
hcv
hsv
vv
benzenesulphonamid
spsii
benzenesulphonamid
spsi
inhibit
replic
acut
infect
cell
concentr
approxim
gml
toxic
host
cell
concentr
gml
select
index
respect
huh
cell
spsi
inhibit
hcv
rna
synthesi
gml
cell
growth
gml
spsii
inhibit
virusinduc
cytopath
human
embryon
lung
hel
cell
infect
vaccinia
vv
concentr
gml
toxic
cell
concentr
gml
molecular
modif
seri
compound
may
help
optimis
antivir
activ
wengang
yang
yongnian
sun
avinash
phadk
milind
deshpand
mingjun
huang
achillion
pharmaceut
new
ct
usa
hcv
nonstructur
protein
catalyt
subunit
replic
complex
possess
motif
characterist
rnadepend
rna
polymeras
biochem
assay
use
recombin
use
investig
nonnucleosid
inhibitor
howev
inhibitori
effect
compound
often
vari
form
recombin
concentr
templat
andor
primer
use
assay
addit
alway
correl
obtain
repliconcontain
cell
observ
cast
concern
valid
cellfre
assay
report
explor
replic
complex
isol
crude
membran
fraction
repliconcontain
cell
compet
synthes
viral
rna
vitro
well
respons
inhibitor
optim
experiment
condit
two
speci
nascent
viral
rna
one
doublestrand
singlestrand
readili
detect
addit
nucleotid
inhibitor
block
synthesi
speci
presenc
nonnucleosid
inhibitor
howev
inhibit
mostli
singlestrand
rna
ssrna
synthesi
addit
replic
complex
isol
cell
contain
replicon
carri
resist
mutat
nonnucleosid
inhibitor
abl
synthes
amount
ssrna
vitro
regardless
presenc
absenc
inhibitor
demonstr
phenomenon
due
specif
inhibitori
effect
compound
combin
kinet
studi
ssrna
synthesi
inhibit
nonnucleosid
inhibitor
present
puls
period
conclud
ssrna
synthesi
catalyz
replic
complex
vitro
like
deriv
de
novo
initi
recent
report
synthesi
antivir
activ
ringexpand
fat
nucleosid
analogu
call
inhibit
hcv
hiv
vitro
ec
valu
rang
micromolar
concentr
less
littl
low
toxic
host
cell
part
ii
present
subject
report
preliminari
result
mechanist
studi
antihcv
activ
compound
along
synthesi
antivir
activ
addit
analogu
seri
light
fact
hcv
major
coinfect
patient
infect
hiv
number
ultim
die
endstag
hcvrelat
complic
includ
liver
cirrhosi
hepatocellular
carcinoma
drug
dual
inhibitori
characterist
virus
highli
desir
time
nigel
bourn
ronald
veselenak
richard
pyle
minkyung
yi
stanley
lemon
univers
texa
medic
branch
galveston
tx
usa
million
peopl
worldwid
estim
infect
hepat
c
viru
hcv
major
peopl
chronic
infect
establish
result
seriou
longterm
liver
damag
includ
progress
fibrosi
cirrhosi
hepatocellular
carcinoma
fact
hcv
believ
caus
case
liver
cancer
annual
worldwid
account
least
liver
transplant
us
current
treatment
option
limit
high
treatment
failur
rate
thu
real
need
new
treatment
option
amantadin
evalu
treatment
chronic
hcv
infect
number
clinic
studi
monotherapi
combin
therapeut
howev
result
trial
contradictori
time
clinic
potenti
amantadin
therapi
chronic
hcv
infect
remain
unclear
recent
studi
shown
small
hydrophob
hcv
protein
form
amantadin
sensit
ion
channel
provid
possibl
basi
antivir
activ
examin
abil
amantadin
reduc
hcv
replic
subgenom
fulllength
hcv
replicon
genotyp
strain
genotyp
strain
n
studi
amantadin
fail
reduc
viral
rna
replic
replicon
test
infecti
viru
assay
use
hcv
genotyp
strain
um
amantadin
fail
reduc
viral
rna
level
condit
test
howev
infecti
viru
studi
viral
inoculum
treat
amantadin
prior
infect
cell
monolay
amantadin
ad
cell
h
viru
adsorpt
signific
reduct
number
infecti
viral
foci
observ
h
incub
p
respect
result
suggest
even
absenc
direct
impact
rna
replic
amantadin
antivir
activ
current
evalu
amantadin
activ
infecti
hcv
genotyp
assay
defin
antivir
spectrum
activ
studi
fulli
defin
mechan
action
viru
life
cycl
also
underway
dominiqu
dugourd
raymond
siu
jeremi
fenn
migenix
inc
vancouv
bc
canada
celgosivir
alpha
glucosidas
inhibitor
develop
treatment
hepat
c
viru
hcv
infect
human
purpos
studi
evalu
vitro
antivir
activ
celgosivir
primari
activ
metabolit
castanospermin
combin
current
approv
therapi
ribavirin
interferon
surrog
model
hcv
bovin
viral
diarrhea
viru
bvdv
compound
alon
combin
test
bvdv
infect
madindarbi
bovin
kidney
mdbk
cell
synergi
analyz
use
isobologram
volum
synergi
measur
macsynergi
ii
tm
softwar
celgosivirinterferon
combin
significantli
synergist
celgosivirribavirin
combin
ribavirininterferon
combin
similarli
castanospermineinterferon
doubl
combin
synergist
castanospermineribavirin
combin
ribavirininterferon
combin
combin
celgosivirinterferon
castanospermineinterferon
led
signific
decreas
celgosivir
castanospermin
effect
celgosivir
castanospermin
reduc
addit
ribavirin
cytotox
doubl
tripl
combin
addit
less
addit
indic
combin
celgosivir
castanospermin
ribavirin
andor
interferon
gener
less
toxic
expect
result
indic
combin
celgosivir
interferon
interferon
ribavirin
may
effect
treatment
hcv
pegyl
interferon
plu
ribavirin
current
standard
care
treatment
chronic
hepat
c
viru
hcv
infect
regimen
result
sustain
virolog
respons
patient
associ
signific
treatmentassoci
toxic
number
approach
use
identifi
novel
therapeut
combin
better
toler
andor
efficaci
inhibitor
endoplasm
reticulum
er
shown
inhibit
viral
replic
secret
may
util
part
new
multidrug
treatment
cocktail
inhibitor
celgosivir
current
evalu
combin
pegyl
interferon
ribavirin
human
purpos
studi
evalu
antivir
effect
combin
celgosivir
castanospermin
primari
activ
metabolit
celgosivir
antivir
agent
divers
mechan
action
effect
combin
celgosivir
castanospermin
nucleosid
analogu
amantadin
anoth
iminosugar
nbutyldeoxynojirimycin
nbdnj
determin
cytopath
assay
use
hcv
surrog
viru
bovin
viral
diarrhea
viru
madin
darbi
bovin
kidney
cell
synergi
analyz
use
isobologram
volum
synergi
measur
macsynergi
ii
tm
softwar
volum
synergi
indic
castanospermin
nbdnj
combin
addit
celgosivir
nbdnj
combin
synergist
high
nbdnj
concentr
celgosivir
castanospermin
synergist
amantadin
volum
synergi
isobologram
analysi
confirm
synergist
interact
result
indic
celgosivir
could
consid
combin
regimen
contain
drug
directli
target
viral
replic
like
mechan
synergi
investig
depart
biotechnolog
yonsei
univers
seoul
korea
hepat
c
viru
hcv
envelop
viru
positivestrand
rna
genom
approxim
kilobas
major
caus
nona
nonb
hepat
lead
liver
cirrhosi
hepatocellular
carcinoma
combin
ribavirin
current
standard
therapi
treatment
hcv
infect
specif
antivir
therapi
avail
hcv
viral
genom
encod
singl
polyprotein
approxim
amino
acid
proteolyt
process
combin
host
viral
proteas
least
distinct
structur
nonstructur
protein
structur
protein
includ
c
nonstructur
ns
protein
includ
new
hcv
specif
therapi
smallmolecul
inhibitor
hcv
enzym
includ
protein
viral
rnadepend
rna
polymeras
rdrp
proteas
clinic
test
howev
rapid
emerg
drugresist
mutant
hamper
practic
clinic
applic
recent
shown
phosphoryl
hcv
rna
polymeras
protein
kinas
clike
regul
viru
rna
replic
hcv
rna
replic
inhibit
express
level
downregul
use
sirna
studi
investig
antihcv
effect
inhibitor
hcv
subgenom
replicon
system
treatment
replicon
cell
inhibitor
suppress
endogen
activ
inhibit
phosphoryl
hcv
rna
polymeras
result
suppress
hcv
rna
replic
dosedepend
manner
furthermor
inhibitor
combin
effect
inhibit
hcv
rna
replic
alon
inhibitor
show
cytotox
cellbas
drug
inhibit
studi
cellular
protein
rare
get
mutat
serv
cellular
target
therapeut
intervent
hcv
replic
specif
inactiv
activ
provid
opportun
interfer
hcv
rna
replic
haitao
guo
tianlun
zhou
jutao
guo
andrea
cuconati
anand
mehta
timothi
block
drexel
univers
colleg
medicin
doylestown
pa
usa
nucleon
inc
irvin
ca
usa
hepat
b
foundat
doylestown
pa
usa
million
peopl
worldwid
chronic
infect
hepat
b
viru
hbv
major
complic
chronic
hepat
b
develop
primari
hepatocellular
carcinoma
hcc
caus
estim
death
annual
current
clinic
treatment
nucleosid
analog
chronic
hepat
b
rare
cure
viru
infect
due
least
part
failur
elimin
viral
coval
close
circular
ccc
dna
nuclei
infect
hepatocyt
hbv
cccdna
essenti
viru
life
cycl
serv
templat
transcript
pregenom
rna
subvir
rna
speci
elimin
chronic
infect
consid
critic
longterm
therapi
howev
cccdna
previous
target
high
throughput
screen
small
molecul
librari
screen
compound
librari
antivir
drug
target
cccdna
set
develop
cellbas
assay
suitabl
high
throughput
screen
sinc
cccdna
timeconsum
assay
desir
use
viral
gene
product
could
serv
report
intracellular
cccdna
level
predict
secret
hbv
e
antigen
hbeag
cell
tetracyclin
induc
hbv
express
cell
line
would
cccdnadepend
larg
portion
precor
mrna
leader
sequenc
terminu
integr
viral
genom
delet
prevent
hbeag
express
transgen
could
restor
termin
redund
pregenom
rna
viral
dna
replic
subsequ
cccdna
format
experiment
result
show
follow
induct
produc
accumul
cccdna
becam
detect
day
hbeag
synthesi
secret
cultur
fluid
depend
upon
proport
level
cccdna
detect
therefor
secret
hbeag
cell
could
potenti
serv
conveni
report
high
throughput
screen
novel
antivir
drug
target
hbv
cccdna
kathi
aldern
jame
beadl
karl
hostetl
univers
california
san
diego
veteran
medic
research
foundat
san
diego
ca
usa
hpmpa
broad
spectrum
antivir
activ
orthopoxvirus
hbv
cmv
hsv
herp
group
virus
shown
hdp
hpmpa
greatli
enhanc
antivir
activ
virus
addit
hpmpa
nearli
inact
hiv
show
hdp
hpmpa
exhibit
log
less
unmodifi
hpmpa
cell
reduct
assay
evalu
metabol
basi
increas
antivir
activ
studi
compar
cellular
uptak
radiolabel
cdv
hpmpa
hdpester
convers
hpmpadiphosph
hpmpapp
cdvdiphosph
cdvpp
human
lung
fibroblast
use
hplc
partisil
sax
ion
exchang
chromatographi
cellular
uptak
hdpcdv
hdp
hpmpa
similar
howev
cell
expos
respect
drug
h
hpmpapp
appear
much
earlier
cdvpp
reach
level
sever
fold
greater
observ
hdpcdv
drug
wash
experi
carri
cell
expos
radiolabel
hdpcdv
hdp
hpmpa
h
cultur
medium
remov
replac
complet
medium
without
drug
level
hpmpapp
cdvpp
measur
hplc
everi
day
day
level
diphosph
declin
slowli
day
conclus
hdp
hpmpa
convert
diphosph
rapidli
hdpcdv
reach
higher
intracellular
level
may
explain
part
greater
antivir
activ
antivir
activ
oral
bioavail
cidofovir
cdv
enhanc
phosphon
esterifi
variou
straight
chain
alkoxyalkyl
group
length
chain
import
determin
antivir
activ
select
howev
case
rapid
metabol
inact
short
chain
metabolit
observ
enhanc
metabol
stabil
ester
synthes
cidofovir
alkoxyalkyl
ester
bear
methyl
group
penultim
carbon
alkyl
chain
enzymat
stabil
test
liver
fraction
variou
speci
mous
human
liver
fraction
compound
complet
stabl
min
straight
chain
hdpcdv
metabol
branch
alkoxyalkyl
ester
evalu
cell
infect
vaccinia
cowpox
ectromelia
virus
branch
methyl
analog
substanti
activ
cdv
equal
slightli
activ
straight
chain
analog
compound
retain
full
activ
compar
hdpcdv
compound
show
greater
activ
orthopoxvirus
compar
unbranch
analog
believ
structur
modif
alkyl
chain
slow
format
inact
metabolit
possibl
interf
oxid
may
result
better
pharmacokinet
potent
antivir
activ
orthopoxviru
infect
vivo
cidofovir
phosphonomethoxi
propyl
cytosin
hpmpc
broad
spectrum
antivir
agent
clinic
use
treatment
aidsrel
cmv
retin
cidofovir
limit
oral
bioavail
attribut
ioniz
phosphon
diacid
moieti
physiolog
condit
shown
mask
group
conjug
cyclic
form
drug
chpmpc
via
ser
side
chain
po
ester
linkag
xser
dipeptid
x
hydrophob
amino
acid
result
prodrug
afford
significantli
improv
biolog
avail
parent
drug
anim
model
describ
total
synthesi
novel
cyclic
cidofovir
prodrug
lval
lphe
use
altern
conjug
strategi
viz
via
ethylen
glycol
link
util
po
co
ester
bond
prepar
hpmpc
synthon
rglycidol
use
modif
literatur
procedur
brodfuehr
et
al
involv
reaction
trityl
r
glycidol
directli
unprotect
cytosin
achiev
regiospecif
open
epoxid
ring
follow
reaction
benzoic
acid
anhydrid
obtain
desir
nbenzoyl
intermedi
need
continu
synthesi
pybop
use
condens
agent
conveni
onepot
convers
hpmpc
chpmpc
subsequ
esterf
latter
ethylen
glycolmodifi
amino
acid
prodrug
convert
drug
cellular
hff
tissu
liver
intestin
homogen
show
enhanc
oral
bioavail
evalu
rat
model
suggest
compound
may
use
understand
effect
drug
deliveri
cidofovir
cdv
broadspectrum
antivir
agent
use
treat
aidsrel
cytomegaloviru
cmv
retin
cmv
infect
cdv
good
vitro
activ
orthopox
virus
includ
smallpox
howev
use
limit
drug
low
oral
bioavail
poor
transport
cell
order
improv
oral
bioavail
group
synthes
seri
dipeptid
amino
acid
prodrug
cyclic
analog
cidofovir
ccdv
current
project
examin
cytotox
antivir
activ
prodrug
show
compound
cytotox
divers
activ
hcmv
orthopox
virus
vaccinia
cow
pox
inhibitori
concentr
rang
greater
respect
two
viru
type
vitro
situ
perfus
studi
establish
permeabl
prodrug
enhanc
transport
mediat
least
part
intestin
dipeptid
transport
also
found
bioavail
prodrug
depend
upon
prodrug
structur
achiev
eightfold
increas
bioavail
parent
compound
vivo
drug
stabil
experi
show
gastrointestin
liver
homogen
ccdv
prodrug
enzymat
hydrolyz
parent
compound
clear
work
biolog
benign
dipeptid
moieti
strateg
link
drug
mask
anion
properti
significantli
enhanc
intestin
transport
ccdv
creat
possibl
oral
bioavail
form
ccdv
low
toxic
acknowledg
support
fund
tsrl
inc
univers
michigan
nih
grant
lawrenc
trost
bernhard
lampert
lloyd
frick
merrick
almond
georg
painter
chimerix
inc
durham
nc
usa
dmpk
advisor
chimerix
inc
durham
nc
usa
foscarnet
pyrophosph
analog
approv
treatment
cmv
retin
acyclovirresist
herp
infect
immunocompromis
patient
activ
highli
drug
resist
strain
howev
clinic
util
foscarnet
limit
requir
control
intraven
infus
associ
high
risk
renal
impair
seizur
caus
alter
plasma
miner
electrolyt
lipid
conjug
shown
increas
vitro
activ
improv
oral
bioavail
reduc
toxic
sever
antivir
drug
requir
intraven
administr
poor
bioavail
case
foscarnet
conjug
methylbatyl
alcohol
decreas
appar
ec
valu
esterifi
produc
order
increas
solubl
protect
decarboxyl
foscarnet
moieti
passag
stomach
present
result
preliminari
toxicolog
toxicokinet
studi
methylbatyl
alcohol
conjug
foscarnet
methyl
ester
rat
given
oral
dose
mgkg
daili
day
clinic
sign
toxic
bodi
weight
food
consumpt
compar
control
serum
biochemistri
hematolog
coagul
paramet
urinalysi
normal
gross
find
necropsi
effect
organ
weight
find
histopatholog
examin
wide
rang
tissu
importantli
chang
serum
biochemistri
paramet
histopatholog
examin
indic
renal
impair
serum
electrolyt
chang
associ
foscarnet
oral
dose
result
signific
plasma
exposur
c
max
gml
biolog
activ
deesterifi
form
conclus
absorb
oral
administr
convert
good
preliminari
toxic
profil
result
support
develop
treatment
drug
resist
hiv
infect
zhiqian
wu
juli
breitenbach
ulrika
erickson
john
hilfing
john
drach
gordon
amidon
depart
pharmaceut
scienc
colleg
pharmaci
univers
michigan
ann
arbor
mi
usa
school
dentistri
univers
michigan
ann
arbor
mi
usa
tsrl
inc
ann
arbor
mi
usa
vaccinia
viru
surrog
model
system
studi
pox
virolog
develop
antivir
therapeut
potent
anti
vaccinia
viru
activ
variou
shortcom
vidarabin
make
good
candid
improv
util
prodrug
strategi
vidarabin
polar
nucleosid
drug
low
membran
permeabl
rapid
degrad
adonesin
deaminas
monoest
prodrug
vidarabin
variou
amino
acid
promoieti
lvalin
lisoleucin
lphenylalanin
laspart
acid
lprolin
synthes
evalu
stabil
permeabl
activ
vaccinia
viru
prodrug
exhibit
differ
hydrolysi
rate
cell
homogen
min
lisoleucyl
lvalyl
monoest
prodrug
exhibit
compar
bioconvers
rate
uptak
well
permeabl
valacyclovir
commerci
market
oral
amino
acid
ester
prodrug
prodrug
potent
activ
vaccinia
viru
resist
preliminari
anim
studi
show
lisoleucyl
vidarabin
result
increas
circul
vidarabin
level
result
suggest
may
possibl
use
amino
acid
prodrug
strategi
improv
vidarabin
anti
vaccinia
viru
agent
vidarabin
adenin
araa
origin
investig
antitumor
agent
later
found
activ
herp
simplex
viru
hsv
type
first
fdaapprov
drug
treatment
system
hsv
infect
although
replac
acyclovir
analog
applic
vidarabin
remain
altern
therapi
acyclovirresist
hsv
varicellazost
viru
infect
despit
proven
efficaci
vidarabin
suffer
limit
includ
metabol
adenosin
deaminas
ada
inact
hypoxanthin
homolog
arah
ii
low
lipophil
membran
permeabl
iii
poor
aqueou
solubl
thu
limit
option
parenter
peror
deliveri
recent
interest
vidarabin
trigger
discoveri
activ
vaccinia
vv
cow
pox
cpv
virus
cidofovir
plaqu
reduct
assay
activ
enhanc
combin
deoxycoformycin
pentostatin
potent
inhibitor
ada
therebi
provid
signific
superior
cidofovir
result
earlier
studi
substitut
vidarabin
analog
lipper
et
al
mol
pharmacol
determin
minim
metabol
vidarabin
synthes
amino
acid
substitut
prodrug
gave
significantli
potent
antipox
viru
agent
found
amino
acid
ester
prodrug
vidarabin
activ
vv
noncytotox
concentr
use
cell
homogen
purifi
enzym
intact
cell
system
show
prodrug
resist
inactiv
ada
prodrug
also
enhanc
transport
potenti
like
target
intestin
dipeptid
transport
final
oral
deliveri
prodrug
small
intestin
result
increas
vidarabin
plasma
level
compar
unsubstitut
vidarabin
properti
make
prodrug
vidarabin
good
candid
oral
bioavail
antipox
viru
agent
stabl
presenc
ada
acknowledg
support
fund
tsrl
inc
univers
michigan
ulf
goerbig
ann
baum
jan
balzarini
chri
meier
univers
hamburg
institut
organ
chemistri
hamburg
germani
rega
institut
medic
research
katoliek
universiteit
leuven
leuven
belgium
cyclos
pronucleotid
system
design
intracellular
deliveri
therapeut
activ
nucleosid
monophosph
part
recent
work
cyclos
approach
interact
cyclos
nucleotid
cholinesteras
investig
known
organophosph
may
act
irrevers
inhibitor
cholinesteras
suicid
mechan
case
cyclos
nucleotid
cholinesteras
inhibit
could
lead
unwant
side
effect
possibl
therapeut
applic
two
type
cholinesteras
found
human
highli
specif
physiolog
import
acetylcholinesteras
ach
much
unspecif
butyrylcholinesteras
bche
unknown
physiolog
import
fortun
inhibit
ach
observ
varieti
differ
cyclos
nucleotid
contrast
bche
inhibit
found
case
antihivact
monophosph
first
cyclos
deriv
combin
three
desir
properti
success
intracellular
deliveri
nucleotid
suffici
hydrolyt
stabil
strongli
reduc
inhibitor
activ
toward
bche
promis
properti
compound
combin
mask
develop
antivir
activ
nucleosid
analogu
like
dda
azt
acyclovir
contribut
present
synthesi
hydrolysi
stabil
inhibit
behaviour
toward
bche
antihiv
data
new
compound
hen
jessen
wolfgang
fendrich
tilmann
schulz
jan
balzarini
chri
meier
univers
hamburg
institut
organ
chemistri
hamburg
germani
rega
institut
medicin
research
katholiek
universiteit
leuven
leuven
belgium
cyclosalpronucleotid
use
deliveri
antivir
activ
nucleotid
cell
via
ph
trigger
select
hydrolysi
distinguish
intraand
extracellular
environ
enzymecleav
side
chain
introduc
aromat
moieti
pronucleotid
enrich
compound
insid
cell
behavior
describ
lockin
effect
mani
differ
cyclos
pronucleotid
design
show
differ
hydrolysi
properti
antivir
data
origin
natur
cyclosalmoieti
well
nucleosid
examin
differ
analyt
tool
high
accuraci
sensit
need
structur
close
possibl
lead
compound
requir
met
intrins
fluoresc
nucleosid
coupl
differ
cyclos
mask
group
analysi
purinetyp
nucleosid
isoda
high
intrins
fluoresc
properti
chosen
convert
isoa
isodda
pyrimidinetyp
seri
fluoresc
nucleosid
k
synthes
well
dideoxycompound
dm
k
nucleosid
transform
differ
cyclosalpronucleotid
test
suitabl
fluoresc
analysi
fact
improv
sensit
factor
compar
uvdetect
found
compound
pmol
detect
compound
fluoresc
absorb
spectra
record
determin
absorpt
emiss
maxima
new
compound
lack
activ
strain
howev
compound
show
low
cytotox
import
usabl
fluoresc
probe
cell
due
analyt
sensit
simpl
model
uptak
studi
could
carri
employ
utub
two
aqueou
phase
separ
unpolar
organ
solvent
simul
diffus
barrier
properti
aqueou
phase
vari
enzymedriven
enrich
lockin
modifi
intrins
fluoresc
cyclosalpronucleotid
pass
diffus
barrier
could
simul
nicola
gisch
jan
balzarini
chri
meier
univers
hamburg
institut
organ
chemistri
hamburg
germani
rega
institut
medic
research
katholiek
universiteit
leuven
leuven
belgium
cyclosalpronucleotid
effici
deliv
therapeut
activ
nucleosid
monophosph
human
cell
lockin
cyclosalpronucleotid
socal
second
gener
cyclosalcompound
design
trap
compound
intracellular
cleavag
esterasecleav
moieti
one
disadvantag
lockin
compound
high
chemic
stabil
lead
delay
drug
deliveri
therefor
conceptu
differ
enzymat
activ
cyclosalpronucleotid
develop
concept
lipophil
donor
substitu
attach
aromat
ring
convert
polar
acceptor
substitu
intracellular
enzymat
cleavag
consequ
liber
acceptor
group
lead
strong
decreas
hydrolysi
stabil
rapid
format
charg
intermedi
result
phosphodiest
intermedi
nucleotid
releas
subsequ
concept
synthesi
character
vitro
antivir
evalu
third
gener
cyclosalpronucleotid
present
toma
cihlar
richard
mackman
adrian
ray
dean
boojamra
lijun
zhang
deborah
grant
hon
hui
jennif
vela
neil
parkin
yolanda
lie
kirsten
white
michael
miller
gerri
rhode
manoj
desai
gilead
scienc
foster
citi
ca
usa
monogram
bioscienc
san
francisco
ca
usa
background
n
rti
current
use
backbon
antiretrovir
combin
therapi
howev
longterm
benefit
limit
advers
effect
resist
develop
drugdrug
interact
suboptim
efficaci
treatmentexperienc
patient
therefor
search
novel
nucleotid
analog
improv
pharmacolog
profil
method
dideoxydidehydroadenosin
select
broad
rang
nucleosid
phosphon
analog
phosphoramid
prodrug
technolog
previous
explor
tenofovir
appli
result
identif
ethylalaninyl
phenyl
ester
result
exhibit
potent
activ
primari
lymphocyt
tcell
line
ec
nm
low
cytotox
cc
observ
multipl
cell
type
includ
renal
cell
diphosph
metabolit
shown
act
obligatori
dna
chain
termin
competit
inhibitor
revers
transcriptas
rt
k
unlik
ddi
neither
prodrug
inhibit
mitochondri
dna
replic
cell
phenosens
assay
retain
full
activ
variant
mutat
rt
virus
thymidin
analog
mutat
show
reduc
suscept
shift
smaller
test
nrti
follow
oral
dose
mgkg
dog
bioavail
prodrug
exceed
result
high
intracellular
level
prolong
retent
h
diphosph
blood
lymphocyt
conclus
prodrug
exhibit
favor
vitro
pharmacolog
profil
includ
less
resist
due
rt
mutat
approv
nrti
possess
good
vivo
pharmacokinet
properti
thu
repres
attract
develop
candid
potenti
clinic
efficaci
treatmentna
nrtiexperienc
patient
martin
mcdermott
gabriel
birku
ruth
wang
holli
macarthur
xiaohong
liu
nilima
kutti
toma
cihlar
craig
gibb
swami
swaminathan
arnold
fridland
william
lee
gilead
scienc
inc
foster
citi
ca
usa
alkylalaninyl
phenyl
ester
prodrug
tenofovir
tfv
propyl
adenin
novel
nucleotid
analog
dideoxydidehydroadenosin
respect
exhibit
potent
vitro
activ
favor
resist
profil
low
cytotox
compar
tenofovir
disoproxil
viread
prodrug
significantli
stabl
plasma
deliv
greater
level
activ
diphosph
metabolit
pbmc
vitro
vivo
initi
step
intracellular
activ
hydrolysi
alanin
carboxyest
unknown
hydrolyt
enzym
isol
identif
enzym
human
pbmc
report
result
major
enzym
capabl
cleav
purifi
human
pbmc
separ
esteras
abl
cleav
alpha
napthyl
acet
ana
increas
specif
activ
prodrug
hydrolas
achiev
sdspage
analysi
show
presenc
promin
protein
band
kda
identifi
ingel
tryptic
digest
msm
sequenc
result
peptid
lysosom
carboxypeptidas
cathepsin
ec
cata
biochem
properti
purifi
prodrug
hydrolas
match
cata
recombin
cata
isol
prodrug
hydrolas
display
nearli
ident
suscept
hydrolas
inhibitor
substrat
prefer
panel
tenofovir
phosphoramid
prodrug
incub
enzym
c
h
difluorophosphon
result
label
ident
kda
protein
catalyt
subunit
label
band
react
polyclon
antibodi
specif
human
cathepsin
final
follow
incub
approxim
lower
intracellular
concentr
tfv
metabolit
detect
fibroblast
patient
express
nonfunct
cat
cat
acel
compar
normal
control
fibroblast
cat
cell
center
drug
deliveri
nanomedicin
univers
nebraska
medic
center
omaha
ne
usa
nucleosid
triphosph
ntp
biolog
activ
form
mani
antivir
nucleosid
analog
capabl
effici
block
product
viral
nucleic
acid
infect
cell
describ
novel
microparticul
formul
encapsul
ntp
drug
deliveri
antivir
therapi
respiratori
infect
polym
network
poloxagel
consist
crosslink
poloxam
cation
polym
molecul
design
synthes
character
load
ntp
interact
cell
poloxagelntp
formul
could
obtain
simpl
mix
aqueou
solut
ntp
aqueou
dispers
poloxagel
subsequ
lyophil
drug
load
equal
weight
form
phosphat
group
ntp
complex
amino
group
polycation
backbon
poloxagel
formul
could
store
room
temperatur
mani
month
without
degrad
ntp
particl
size
aqueou
poloxagelntp
dispers
low
hydrodynam
diamet
rate
passiv
drug
releas
physiolog
solut
load
drug
period
formul
effect
consum
mani
type
cell
signific
amount
drug
poloxagel
detect
cellular
interior
h
incub
presenc
cellular
membran
drug
releas
poloxagelntp
formul
dramat
increas
attribut
effect
trigger
releas
bound
ntp
result
competit
interact
polycation
backbon
poloxagel
phospholipid
cellular
membran
mucoadhes
properti
poloxam
may
addit
enhanc
bind
poloxagel
airwayslung
epithelium
triphosph
ribavirin
synthes
use
phosphoryl
tri
imidazolyl
phosphat
conveni
onepot
approach
formul
differ
poloxagel
ribavirin
triphosph
prepar
character
prospect
antivir
formul
prophylact
therapeut
treatment
respiratori
infect
includ
influenza
viru
aerosol
rout
applic
antivir
formul
associ
problem
discuss
edwin
gong
ebrima
gibb
joel
oger
depart
pharmacolog
therapeut
univers
british
columbia
vancouv
bc
canada
neuroimmunolog
lab
ubc
hospit
depart
medicin
univers
british
columbia
vancouv
bc
canada
ifnalpha
ifnbeta
current
employ
treatment
mani
viral
diseas
especi
chronic
hepat
ifnbeta
also
employ
treatment
multipl
sclerosi
ms
chronic
often
debilit
diseas
central
nervou
system
howev
protein
therapeut
longterm
ifn
therapi
lead
develop
bind
neutral
antibodi
ifn
thu
lead
deceas
clinic
effect
ifn
order
measur
bioavail
ifn
level
neutral
antibodi
develop
realtim
rtpcr
taqman
assay
quantit
express
mxa
ifninduc
protein
mrna
nucleotid
sequenc
mxa
deposit
genebank
align
pair
primer
hybrid
probe
design
base
conserv
region
hous
keep
gene
gapdh
use
calibr
rel
quantit
rna
standard
gener
vitro
transcript
clone
mxa
gene
plasmid
vector
reaction
paramet
optim
assay
valid
use
pbmc
ms
patient
treat
ifnbeta
evalu
ifn
bioavail
total
rna
extract
pbmc
quantit
detect
onestep
rtpcr
mxa
gapdh
result
calcul
ct
method
show
differ
signaltonois
ratio
sampl
neutral
antibodi
sampl
untreat
ms
patient
healthi
donor
approxim
indic
assay
reliabl
method
determin
ifn
bioavail
v
lozitski
kravchenko
v
larionov
research
antiplagu
institut
odessa
ukrain
nation
univers
odessa
ukrain
transderm
deliveri
td
drug
novel
method
treatment
diseas
td
carri
help
transderm
therapeut
system
tt
multilay
plaster
contain
activ
ingredi
td
number
advantag
prolong
drug
action
drug
concentr
maintain
therapeut
rang
trauma
patient
skin
use
td
remov
tt
skin
immedi
stop
drug
enter
organ
firstpass
effect
liver
reduc
mani
highli
activ
drug
irrit
gastrointestin
tract
administ
oral
other
short
halflif
timethes
drug
downsid
mention
use
tt
previou
research
elabor
tt
contain
rimantadin
ttscr
studi
efficaci
experiment
influenza
mice
establish
transderm
deliveri
rimantadin
effect
oral
administr
aim
work
increas
efficaci
ttscr
solv
task
studi
influenc
permeabl
enhanc
antiinfluenza
efficaci
ttscr
experiment
infect
appli
tt
adhes
hydrogel
matrix
polyvinyl
alcohol
consist
base
plastif
improv
administr
activ
substanc
skin
induc
irrit
ttscr
mgmous
appli
shaven
back
experiment
anim
tt
group
addit
contain
one
permeabl
enhanc
mgmous
dmso
mgmous
octanol
mgmous
papain
tt
appli
shaven
back
mice
stay
day
infect
day
challeng
mice
group
infect
intranas
influenza
viru
highli
pathogen
challeng
carri
use
four
anim
viru
dilut
within
rang
death
anim
record
day
result
show
proteolyt
enzym
papain
increas
antiinfluenza
efficaci
ttscr
log
tid
dmso
octanol
demonstr
activ
mikhail
dobrikov
serguei
vinogradov
barbara
ramsay
shaw
depart
chemistri
duke
univers
durham
nc
usa
center
drug
deliveri
nanomedicin
colleg
pharmaci
univers
nebraska
omaha
ne
usa
nucleosid
revers
transcriptas
inhibitor
nrti
wide
use
antivir
chemotherapi
nrti
requir
stepwis
phosphoryl
respect
nucleosid
triphosph
inhibit
viral
dna
synthesi
howev
emerg
revers
transcriptasedepend
drug
resist
limit
effect
treatment
nrti
analogu
show
sever
uniqu
physicochem
biolog
properti
enzymat
studi
indic
rpisom
ddndp
better
substrat
cellular
ndp
kinas
parent
ddndp
ii
neither
isom
substrat
mammalian
pyruv
kinas
show
poor
inhibitori
properti
enzym
iii
rp
ddntp
isom
better
inhibitor
drugand
multidrugresist
viral
revers
transcriptas
poor
substrat
dnadepend
dna
polymeris
iv
incorpor
viral
dna
boranoddnmp
residu
resist
atpdepend
remov
viral
dna
parent
ddntp
bypass
ineffici
phosphoryl
nrti
sever
prodrug
analogu
previous
synthes
effici
deliveri
system
analogu
base
nanos
cation
polymer
gel
nanogel
propos
select
inhibit
drugand
multidrug
resist
viral
rt
poorer
inhibit
intracellular
kinas
dna
polymeras
analogu
specif
deliveri
infect
cell
complex
nanogel
particl
suggest
new
approach
design
power
antivir
drug
acknowledg
work
support
nih
grant
br
develop
highthroughput
cellbas
assay
address
critic
need
antivir
drug
treatment
influenza
consider
demand
screen
high
volum
compound
target
develop
microtit
plate
format
assay
assay
inhibit
influenzainduc
cytopath
effect
cpe
mdck
cell
assess
use
celltiterglo
luminesc
cell
viabil
assay
promega
reagent
measur
amount
atp
present
cell
directli
proport
number
metabol
activ
cell
valid
studi
execut
establish
optim
cell
densiti
viral
concentr
dmso
toler
compound
dilut
incub
time
virusinduc
cpe
effect
control
drug
concentr
addit
paramet
assay
variabl
reagent
read
stabil
edg
effect
stabil
also
investig
valid
current
initi
use
assay
screen
chemic
librari
report
find
librari
screen
addit
aforement
valid
believ
approach
also
provid
mechan
discoveri
new
antivir
lead
influenza
well
avian
flu
fundacio
irsicaixa
hospit
universitari
german
tria
pujol
badalona
spain
develop
bacteriophag
lambda
base
genet
screen
use
isol
character
sitespecif
proteas
genet
screen
system
base
bacteriophag
lambda
cicro
regulatori
circuit
encod
repressor
ci
specif
cleav
initi
lysogenictolyt
switch
adapt
simpl
safe
rapid
genet
screen
system
predict
activ
phenotyp
human
immunodefici
viru
type
proteas
cours
viral
infect
antiretrovir
therapi
specif
target
proteas
insert
lambda
phage
ci
repressor
target
specif
cihiv
repressor
evalu
coexpress
repressor
proteas
construct
upon
infect
escherichia
coli
cell
express
two
construct
encod
repressor
proteas
lambda
phage
replic
effici
cell
express
proteas
assay
respond
appropri
wellknown
proteas
inhibitor
use
search
new
proteas
inhibitor
high
level
specif
system
modest
differ
catalyt
effici
quantifi
also
use
character
differ
mutant
viral
proteas
demonstr
broad
applic
proteas
assay
use
viral
proteas
cognat
cleavag
site
includ
hepat
c
viru
hcv
proteas
sever
acut
respiratori
syndrom
sar
coronaviru
cov
scov
proteas
compar
proteas
assay
method
assay
follow
advantag
safe
highli
sensit
highli
specif
easi
quantif
rapid
gener
differ
proteas
cleavag
substrat
use
molecular
clone
express
system
may
use
develop
screen
method
identifi
viral
proteas
inhibitor
also
use
character
cellular
viral
infecti
agent
proteas
differ
activ
specif
karen
watson
todd
b
parsley
robert
w
buckheit
jr
imquest
bioscienc
inc
frederick
md
usa
viru
transmiss
rapid
resist
select
assay
develop
order
quickli
evalu
biolog
properti
antiinfect
test
compound
ration
priorit
develop
transmiss
assay
specif
evalu
abil
test
agent
suppress
clear
viru
replic
cultur
serial
passag
viru
presenc
fix
concentr
test
compound
alon
combin
growth
expans
viru
infect
cultur
shown
occur
replic
origin
infect
cell
absenc
viru
spread
direct
viru
cell
infect
cell
cell
transmiss
order
steril
cultur
test
compound
must
possess
abil
specif
potent
interfer
viru
replic
three
method
must
abl
inhibit
replic
resist
virus
preexist
viral
inoculum
rapidli
grow
presenc
fix
concentr
test
agent
twelv
pyrimidinedion
evalu
potenti
use
antihiv
therapeut
agent
topic
microbicid
evalu
abil
inhibit
viru
transmiss
defin
abil
rapidli
select
resist
viru
strain
compound
evalu
parallel
known
antihiv
agent
inhibit
viru
entri
revers
transcript
sustiva
azt
result
transmiss
assay
suggest
signific
biolog
differ
exist
antivir
compound
even
highli
relat
congen
class
pyrimidinedion
suggest
transmiss
rapid
resist
select
assay
measur
import
antivir
properti
antihiv
agent
biolog
studi
evalu
mechan
viru
growth
presenc
high
concentr
test
compound
describ
laur
kerstin
angner
anna
overbi
david
stein
patrick
iversen
ramon
flick
utmb
depart
patholog
galveston
tx
usa
avi
biopharma
inc
corval
usa
famili
bunyavirida
sever
member
genu
phleboviru
report
caus
diseas
human
livestock
among
rift
valley
fever
rvf
viru
import
humananim
pathogen
widespread
geograph
distribut
abil
produc
sever
human
diseas
make
viru
worldwid
public
health
concern
phosphorodiamid
morpholinooligom
pmo
class
dnalik
antisens
agent
typic
synthes
length
subunit
contain
purin
pyrimidin
base
attach
backbon
compos
six
member
morpholin
ring
join
phosphorodiamid
intersubunit
linkag
shown
effect
antivir
compound
differ
viru
famili
eg
coronavirida
flavivirida
pmo
bind
rna
prevent
translat
viral
rna
use
recent
develop
plasmidbas
minigenom
rescu
system
uukuniemi
phleboviru
model
viru
rvf
virus
screen
antivir
compound
base
morpholino
antisens
oligonucleotid
approach
antivir
compound
apprais
basi
report
gene
activ
fig
inhibitori
effect
compound
also
test
measur
reduct
viru
titer
fig
monitor
chang
viral
antigen
product
use
indirect
immunofluoresc
procedur
fac
analysi
analysi
genom
transcriptionrepl
rtpcr
inde
sever
pmo
could
identifi
interf
effect
low
bunyavir
minigenom
rescu
well
viru
prolifer
base
result
plan
confirm
antivir
activ
promis
compound
suitabl
anim
model
shown
fractal
approach
problem
viruscel
interact
give
uniqu
possibl
process
data
sequenc
direct
invers
fourier
transform
studi
carri
herp
simplex
viru
interact
sensit
cell
cultur
object
imag
system
bright
peak
form
result
laser
diffract
structur
element
viruscel
system
whole
viruscel
interact
inform
insert
comput
fastest
parallel
way
laser
intens
peak
form
speckl
imag
system
consider
could
transform
hierarch
system
circl
squar
accord
choic
research
conserv
valu
depend
true
intermolecular
interact
potenti
potenti
characterist
everi
stage
viruscel
interact
respons
given
structur
dynam
viruscel
system
uniqu
typic
form
fractal
cluster
correspond
system
imag
well
process
comput
techniqu
hierarch
fractal
design
viruscel
system
propos
first
time
give
univers
need
quantit
descript
possibl
combin
viru
correspond
sensit
cell
note
well
fractal
microscop
use
viruscel
dynam
system
imag
properti
requir
experiment
tool
monitor
includ
reliabl
reproduc
precis
devic
could
use
drug
design
biolog
test
stage
scope
time
effort
economi
compound
librari
screen
fractal
microscop
combin
qsar
drug
design
techniqu
make
antiherpet
drug
design
competit
compar
regular
approach
acknowledg
author
indebt
partial
support
stcu
grant
investig
experiment
fractal
properti
diffract
imag
obtain
laser
irradi
viruscel
system
shown
diffract
process
mathemat
equival
direct
fourier
transform
said
system
compon
model
simpl
geometr
figur
eg
circl
viral
famili
could
code
describ
quantit
averag
size
free
viral
particl
type
symmetri
propos
use
invers
fourier
transform
viruscel
system
order
get
real
enlarg
imag
virus
attack
sensit
cell
well
cell
structur
transform
caus
sequent
stage
viru
reproduct
process
set
bright
dark
spot
form
viruscel
system
diffract
imag
could
code
set
number
matrix
form
correl
vectorfunct
use
quantif
procedur
correl
function
use
present
polar
coordin
system
axial
symmetri
laser
beam
taken
main
physic
axi
full
inform
includ
imag
peak
diamet
color
index
transform
use
invers
fourier
techniqu
set
intersect
bright
dark
circl
full
vitro
dynam
structur
chang
viruscel
system
describ
chang
circl
diamet
area
intersect
shown
also
magnif
fractal
microscop
could
achiev
depend
laser
power
use
propos
fractal
microscop
could
appli
well
vivo
experi
requir
magnif
make
us
use
project
laser
output
exceed
mw
shown
fractal
microscop
base
invers
fourier
transform
could
appli
success
pharmaceut
antivir
drug
design
laboratori
clinic
trial
new
antivir
prepar
especi
effect
hierarch
qsar
research
acknowledg
author
grate
support
stcu
grant
previous
report
bicycl
furano
pyrimidin
potent
select
inhibitor
varicella
zoster
viru
vzv
subnanomolar
activ
palkylphenyl
substitut
analogu
compound
howev
highli
lipophil
poorli
solubl
water
report
seri
palkyloxyphenyl
compound
contain
phenol
ether
aim
enhanc
water
solubl
whilst
retain
antivir
activ
mcguigan
et
al
report
synthesi
characteris
antivir
evalu
novel
seri
palkyloxyphenyl
least
one
methylen
spacer
phenyl
ether
group
potenti
boost
pharmacokinet
profil
alkyl
chain
length
fix
retain
high
clogp
valu
paramet
previous
shown
correl
high
antivir
potenc
target
structur
prepar
pdcatalys
coupl
seri
parasubstitut
alkoxyphenyl
acetylen
deoxyuridin
give
intermedi
nucleosid
subsequ
cyclis
presenc
cui
give
desir
bicycl
system
antivir
activ
cytotox
solubl
compound
report
previous
report
novel
nucleosid
analogu
contain
unusu
furano
bicycl
pyrimidin
base
long
side
chain
discov
potent
exquisit
select
toward
varicella
zoster
viru
follow
discoveri
three
main
site
modif
identifi
explor
side
chain
bicycl
base
sugar
moieti
modif
side
chain
insert
phenyl
ring
led
potent
antivzv
nucleosid
date
nm
investig
modif
three
site
state
continu
herein
report
adjust
analogu
replac
furo
oxygen
sulfur
parent
nucleosid
bear
alkyl
side
chain
report
retain
antivir
activ
howev
bear
phenyl
alkyl
side
chain
shown
give
slight
reduct
antivzv
activ
modif
phenyl
ring
side
chain
includ
halogen
substitut
fluorin
particular
produc
intrigu
result
ortho
meta
substitut
show
antivzv
activ
para
analogu
complet
devoid
antivir
activ
report
studi
includ
di
tri
substitut
phenyl
analogu
final
also
investig
sugar
modif
includ
substitut
hydroxyl
group
previou
modif
replac
hydroxyl
group
result
loss
activ
vzv
present
new
substitut
analogu
provid
interest
biolog
result
previous
report
bicycl
furano
pyrimidin
potent
select
inhibitor
varicella
zoster
viru
vzv
subnanomolar
activ
palkylphenyl
substitut
analogu
srinivasan
et
al
sar
explor
via
substitut
phenyl
deriv
electron
withdraw
electron
donat
group
report
synthesi
characteris
biolog
evalu
novel
seri
mono
substitut
phenyl
deriv
order
probe
structur
activ
relationship
region
target
compound
synthesis
sonogashira
condit
seri
substitut
phenyl
acetylen
coupl
deoxyuridin
give
intermedi
nucleosid
subsequ
cyclis
presenc
cui
give
desir
bicycl
system
diseas
caus
herp
simplex
viru
hsv
wide
distribut
prophylaxi
treatment
infect
import
health
care
task
requir
also
search
design
develop
new
antiherpet
drug
overcom
drug
resist
toxic
side
effect
exist
drug
drug
select
simpli
base
result
empir
screen
effect
computerbas
technolog
may
help
optim
structur
antivir
compound
well
design
develop
new
drug
object
present
work
quantit
structureact
relationship
qsar
analysi
antivir
activ
variou
n
n
dispirotripiperazin
connect
consequ
drug
design
wellestablish
simplex
represent
molecular
structur
sirm
qsar
approach
use
fulfil
object
allow
molecular
design
new
effect
antivir
drug
thorough
investig
relationship
cytotox
hela
cell
gmk
cell
cc
gml
b
antiherpet
activ
strain
kupka
ic
gml
c
select
index
ratio
cc
ic
structur
n
n
deriv
dispirotripiperazin
conduct
statist
characterist
pl
partial
least
squar
model
quit
satisfactori
r
q
result
confirm
experiment
data
base
obtain
model
molecular
fragment
promot
interfer
antivir
activ
defin
addit
model
provid
possibl
predict
molecular
fragment
enhanc
antiherpet
activ
design
new
well
toler
highli
virusspecif
drug
summari
develop
simplex
approach
effect
instrument
predict
design
novel
effect
antiherpet
agent
sever
repres
seri
bear
bulki
aryl
group
recent
shown
possess
unexpect
activ
toward
unlik
common
antihsv
drug
compound
retain
activ
toward
kinasedefici
acyclovirresist
strain
therefor
unusu
mechan
antivir
action
assum
order
investig
mechan
discov
potent
analogu
synthes
sever
novel
deoxi
arabino
uridin
deriv
possess
differ
substitu
dinucleosid
contain
two
uridin
moieti
coupl
singl
polycycl
aromat
hydrocarbon
eg
pyren
repres
anoth
type
structur
variat
nucleosid
compound
well
possess
bright
fluoresc
use
biolog
evalu
cytomegaloviru
cmv
wide
spread
opportunist
pathogen
belong
beta
subfamili
herpesvirida
primari
infect
gener
asymptomat
result
life
long
latenc
howev
morbid
mortal
rate
posttransplant
greatli
increas
follow
reactiv
recrudesc
cmv
ganciclovir
gcv
cidofovir
cdv
success
suppress
cmv
viral
replic
immunocompromis
patient
although
sustain
use
drug
result
emerg
multidrug
resist
strain
viru
studi
use
plaqu
reduct
assay
determin
antivir
efficaci
two
ribonucleotid
reductas
inhibitor
didox
dx
acid
trimidox
tx
inhibit
wild
type
drugresist
strain
murin
cmv
smith
strain
result
present
demonstr
dx
tx
inhibit
viral
plaqu
format
dose
depend
manner
wild
type
resist
strain
increas
drug
dose
requir
cdv
gcv
respect
inhibit
plaqu
format
resist
strain
cdv
wt
r
mgcv
wt
r
compar
moder
increas
drug
dose
requir
dx
tx
achiev
inhibit
resist
strain
dx
wt
r
mtx
wt
r
correspond
increas
respect
work
current
underway
determin
possibl
mechan
antivir
action
toxic
profil
novel
virostat
patient
human
immunodefici
viru
hiv
infect
coinfect
herpesvirus
continu
problem
patient
receiv
antivir
hiv
therapi
sinc
treatment
affect
larg
number
drug
requir
multipl
infect
would
use
antivir
activ
hiv
herpesvirus
report
previous
alkoxyalkyl
ester
prodrug
cidofovir
cdv
sever
log
activ
herpesviru
replic
unmodifi
cdv
determin
strategi
would
effect
acycl
nucleosid
phosphon
activ
hiv
infect
hexadecyloxypropyl
hdp
ester
synthes
phosphonomethoxyethyl
cytosin
pmec
phosphonomethoxyethyl
phosphonomethoxyethyl
phosphonomethoxyethyl
pmedap
phosphonomethoxyethyl
pmecprdap
assay
activ
herpesviru
replic
overal
hdp
ester
activ
unmodifi
acycl
nucleosid
phosphon
indic
use
strategi
increas
antivir
activ
acycl
nucleosid
phosphon
one
activ
compound
hdppmecprdap
ec
valu
hff
cell
infect
hcmv
repres
increas
efficaci
parent
pmecprdap
anoth
promis
compound
hdppmedap
ec
valu
um
hff
cell
infect
hcmv
repres
increas
parent
pmedap
result
present
indic
modifi
acycl
nucleotid
antivir
activ
hiv
also
inhibit
replic
herpesvirus
evalu
activ
herpesvirus
problem
hivinfect
patient
human
herpesvirus
type
warrant
may
provid
new
therapeut
option
patient
coinfect
juli
breitenbach
katherin
z
borysko
jiri
zemlicka
john
c
drach
biolog
materi
scienc
school
dentistri
univers
michigan
ann
arbor
mi
usa
karmano
cancer
institut
wayn
state
univers
school
medicin
detroit
mi
usa
previous
describ
first
qiu
et
al
j
med
chem
second
gener
zhou
et
al
j
med
chem
methylenecyclopropan
purin
potent
select
activ
hcmv
strain
select
separ
resist
firstgener
analog
synadenol
synguanol
resist
sever
firstgener
purin
analog
similar
resist
observ
secondgener
guanin
analog
cyclopropavir
ic
plaqu
assay
respect
wildtyp
wt
synguanolresist
viru
likewis
delet
mutant
prichard
et
al
j
virol
resist
first
secondgener
compound
ic
wt
del
respect
synguanol
cyclopropavir
hcmv
strain
select
resist
synadenol
sequenc
two
mutat
identifi
hcmv
either
relat
mutat
alon
sensit
synadenol
synguanol
baldanti
et
al
antivir
re
hypothes
two
mutat
requir
resist
firstand
secondgener
analog
hypothesi
test
construct
three
strain
hcmv
hcmv
bac
one
mutat
expect
two
strain
singl
mutat
resist
ganciclovir
littl
resist
first
gener
compound
synadenol
synguanol
strain
somewhat
resist
secondgener
compound
cyclopropavir
less
observ
viru
two
mutat
studi
resist
construct
viru
two
mutat
underway
conclud
function
requir
activ
hcmv
like
two
mutat
requir
signific
resist
acknowledg
support
grant
nih
fund
univers
michigan
svitlana
zagorodnya
nadiya
nesterova
inna
alexeeva
larisa
palchikovskaya
galina
baranova
alexand
kobko
anna
golovan
zabolotni
institut
microbiolog
virolog
na
ukrain
kiev
ukrain
institut
molecular
biolog
genet
na
ukrain
kiev
ukrain
search
new
effect
prepar
capabl
inhibit
herpesvirus
reproduct
stipul
certain
resist
differ
group
chemic
prepar
new
triazin
bear
tricycl
base
nglycosid
deriv
structur
wide
use
potenti
antivir
agent
object
present
investig
studi
activ
triazin
bear
tricycl
base
no
well
nglycosid
deriv
epsteinbarr
viruslymphotrop
oncogen
viru
herpesvirida
famili
model
ebvinfect
vitro
use
line
lymphoblastoid
bcell
raji
infect
ebv
inhibit
reproduct
ebv
cell
cultur
determin
reduct
number
genomeequival
ebv
dna
cell
reveal
quantit
pcr
use
primer
reagent
r
russia
first
stage
investig
substanc
analysi
cytotox
cell
line
raji
studi
concentr
gml
concentr
inhibit
quantiti
live
cell
equal
substanc
gml
gml
minim
inhibit
concentr
mic
no
equal
gml
amount
genomeequival
dna
ebv
cell
reduc
henc
index
select
equal
triazin
bear
tricycl
base
no
nglycosid
addit
compound
also
test
transcript
replic
model
system
vitro
result
indic
base
nglycosid
deriv
effect
rna
dna
synthesi
differ
manner
r
sgarbanti
l
nencioni
g
c
nucci
u
benatti
magnani
e
garaci
palamara
depart
public
health
scienc
univers
rome
la
sapienza
rome
itali
depart
biopatholog
physiopatholog
optic
univers
rome
tor
vergata
rome
itali
depart
exp
medicin
biochemistri
section
univers
genova
genoa
itali
inst
biochemistri
univers
urbino
urbino
itali
depart
exp
med
biochem
scienc
univers
rome
tor
vergata
rome
itali
sever
studi
demonstr
differ
virus
induc
imbal
intracellular
redox
state
deplet
glutathion
gsh
main
intracellular
antioxid
imbal
intracellular
redox
state
repres
key
event
develop
viral
infect
inde
previou
data
show
treatment
gsh
prevent
decreas
intracellular
gsh
inhibit
replic
differ
rna
dna
virus
vitro
vivo
recent
data
demonstr
butanoyl
deriv
gsh
increas
hydrophob
properti
inhibit
vitro
replic
effici
gsh
reason
evalu
effect
topic
administr
kerat
rabbit
infect
corneal
epithelium
previous
scratch
inocul
pfuml
dissolv
salin
solut
mm
uley
administ
eyedrop
four
time
daili
ten
day
salin
solut
use
control
group
clinic
evalu
conjunctiv
corneal
involv
perform
use
fluorescein
sodium
eyedrop
slit
lamp
fit
cobalt
blue
filter
demonstr
treatment
effect
reduc
sever
progress
kerat
conjunct
moreov
treat
anim
conjunctiv
titr
assay
day
postinfect
significantli
reduc
compar
control
anim
mean
unitsml
versu
unitsml
n
group
accordingli
similar
result
obtain
measur
viru
titr
cornea
anim
versu
placebo
anim
mean
unitsml
versu
unitsml
n
per
group
result
highlight
antivir
activ
vivo
suggest
topic
treatment
could
consid
complementari
therapi
kerat
debra
quenel
deborah
collin
latisha
pettway
carol
hartlin
jame
beadl
w
wan
karl
hostetl
earl
kern
univers
alabama
school
medicin
birmingham
al
usa
depart
medicin
univers
california
san
diego
veteran
medic
research
foundat
san
diego
ca
usa
cytomegaloviru
cmv
caus
wide
varieti
clinic
manifest
immunocompromis
host
transplant
recipi
util
sever
combin
immunodefici
scid
mice
implant
human
fetal
tissu
subsequ
infect
hcmv
balbc
mice
infect
mcmv
evalu
new
antivir
therapi
cmv
infect
current
studi
use
two
model
determin
efficaci
phosphonomethoxi
propyl
adenin
hpmpa
hexadecyloxypropyl
hpmpa
hdp
hpmpa
octadecyloxyethyl
hpmpa
ode
hpmpa
hcmv
model
human
fetal
thymu
liver
thyliv
tissu
implant
kidney
capsul
mice
inocul
week
later
pfu
hcmv
tissu
sampl
obtain
variou
time
point
quantit
hcmv
titer
plaqu
assay
gener
replic
toledo
strain
hcmv
implant
tissu
increas
day
gradual
decreas
undetect
level
week
postinfect
determin
efficaci
compound
oral
treatment
vehicl
mgkg
hpmpa
hdp
hpmpa
ode
hpmpa
initi
h
infect
continu
day
cidofovir
cdv
mgkg
administ
ip
daili
posit
control
result
indic
hpmpa
hdp
hpmpa
ode
hpmpa
highli
effect
significantli
reduc
replic
compar
vehicl
control
mcmv
infect
mice
hdp
hpmpa
highli
effect
prevent
mortal
administ
oral
mgkg
begin
h
postvir
inocul
mgkg
treatment
delay
h
postvir
inocul
data
indic
compound
highli
efficaci
two
anim
model
cmv
infect
evalu
use
hcmv
infect
human
cytomegaloviru
cmv
ubiquit
asymptomat
infect
immunocompet
individu
lead
seriou
ill
immunocompromis
individu
transplant
recipi
neonat
aid
patient
thu
need
welltoler
potent
antivir
compound
activ
cmv
well
recogn
current
studi
evalu
vivo
activ
rep
fulli
degener
mer
phosphorothio
oligonucleotid
murin
cytomegaloviru
infect
mcmv
mice
rep
potent
vitro
activ
hcmv
vzv
ebv
vaillant
et
al
submit
public
initi
studi
infect
mice
treat
rep
compar
salinetr
infect
control
mice
compound
administ
intraperiton
consecut
day
mgkg
start
day
prior
infect
mice
infect
pfu
mcmv
day
h
posttreat
sera
collect
h
hpi
dpi
elisa
analysi
product
spleen
liver
collect
dpi
determin
viru
titer
dpi
viru
titer
spleen
liver
significantli
reduc
rep
treatment
compar
control
mice
splenomegali
observ
infect
mice
treat
rep
salin
treat
infect
mice
rep
treat
uninfect
mice
level
mice
treat
rep
peak
hpi
compar
hpi
salinetr
control
mice
data
suggest
immun
stimul
might
contribut
antivir
activ
pson
perhap
level
second
studi
compar
vivo
activ
rep
two
oligonucleotid
analog
activ
mediat
immun
stimul
suggest
direct
antivir
activ
rep
analog
predomin
therapeut
mechan
vivo
moreov
one
rep
analog
exhibit
even
greater
antivir
activ
rep
caus
splenomegali
addit
experi
underway
provid
insight
mechan
action
mcmv
infect
acknowledg
support
contract
virolog
branch
niaid
nih
kathi
keith
joseph
maddri
namita
bansal
kochurani
jacob
secrist
john
earl
kern
depart
pediatr
univers
alabama
school
medicin
birmingham
al
usa
southern
research
institut
birmingham
al
usa
seri
novel
antivir
agent
prepar
base
lead
compound
relat
acycl
nucleosid
phosphon
agent
consist
purin
nucleu
bear
pendant
phosphon
acid
group
design
strategi
twofold
follow
approach
hostetl
group
mask
partial
mask
anion
phosphon
lipophil
ester
andor
amino
acid
phosphonamid
prodrug
could
enhanc
cellular
uptak
cleav
intracellularli
investig
new
substitu
purin
proof
concept
phosphonomethoxyethyl
adenin
pmea
scaffold
employ
analog
pmea
substitut
purin
adenin
site
synthes
evalu
activ
orthopoxviru
infect
mani
substitu
previous
recogn
ncyclopropyl
shown
antivir
activ
structureact
relationship
investig
excit
find
introduct
sever
novel
moieti
purin
particularli
hydrazino
hydroxylamino
cyclopropylamino
group
result
sever
compound
excel
vitro
activ
exampl
octadecyloxyethyl
ode
cyclopropyl
pmea
ec
valu
ode
cyclopropyl
pmea
ec
valu
cowpox
vaccinia
virus
respect
use
plaqu
reduct
assay
hff
cell
condit
parent
molecul
pmea
complet
inact
two
compound
cc
valu
give
select
indic
studi
indic
sever
modif
pmea
scaffold
result
good
antivir
activ
orthopoxviru
infect
vitro
activ
compound
current
scale
evalu
anim
model
isatin
versatil
lead
molecul
design
potenti
bioactiv
agent
deriv
report
possess
inhibitori
activ
varieti
pathogen
virus
methisazon
one
first
synthet
antivir
agent
use
clinic
treatment
orthopox
viru
infect
presenc
thiosemicarbazon
howev
result
immunosuppres
attempt
replac
thiosemicarbazon
sulphonamid
order
modifi
antivir
activ
present
work
perform
evalu
antivir
activ
cytotox
novel
amino
n
benzen
sulphonamid
pox
virus
vaccinia
cowpox
viru
human
fibroblast
cell
activ
compar
cidofovir
cdv
among
compound
amino
n
benzen
sulphonamid
activ
compound
valu
mol
compar
cdv
mol
vaccinia
viru
compound
nontox
lm
use
neutral
red
uptak
assay
substitut
halogen
atom
posit
isatin
found
abolish
antivir
activ
compound
evalu
orthopox
infect
anim
determin
potenti
develop
effect
agent
treatment
infect
acknowledg
support
part
contract
virolog
branch
niaid
nih
usa
evgeni
belanov
svetlana
kotovskaya
nikolay
bormotov
sergey
balakhnin
olga
serova
nataliya
perova
zina
baskakova
galina
dzhumbaeva
valerii
charushin
oleg
chupakhin
state
research
center
virolog
biotechnolog
vector
koltsovo
novosibirsk
reg
russia
ural
state
technic
univers
yekaterinburg
russia
institut
organ
synthes
yekaterinburg
russia
studi
synthes
seri
fig
deriv
order
evalu
structur
featur
requir
antiorthopoxvirus
activ
deriv
test
cytotox
activ
vaccinia
cowpox
mousepox
monkeypox
experi
variola
virus
vero
cell
result
studi
structureact
relationship
reveal
compound
contain
phenyl
group
alkoxi
fluoro
substitut
benzen
ring
benzotriazin
show
antiorthopoxvirus
activ
antivir
activ
reduc
lost
substitut
substitut
thu
find
new
class
heterocycl
compound
antivir
activ
acknowledg
research
fund
istc
project
yali
chen
guang
yang
kadi
honeychurch
denni
hrubi
robert
jordan
siga
technolog
inc
sw
research
waysuit
corval
usa
recent
discov
highli
specif
potent
antiorthopoxviru
compound
via
high
throughput
screen
yang
et
al
j
virol
marker
rescu
resist
variant
local
compound
resist
gene
encod
major
orthopoxviru
envelop
protein
requir
extracellular
viral
particl
format
particip
wrap
intracellular
matur
viru
imv
membran
deriv
tran
golgi
late
endosom
compart
produc
intracellular
envelop
viru
iev
transport
cell
surfac
form
extracellular
viru
particl
gain
insight
mechan
action
examin
effect
product
extracellular
viral
particl
cell
infect
recombin
vaccinia
viru
contain
gfptag
protein
presenc
iev
particl
format
dramat
reduc
plaqu
format
almost
complet
inhibit
imv
particl
appear
retain
intracellular
vesicl
reveal
electron
microscopi
furthermor
prevent
intracellular
local
late
endosom
compart
measur
confoc
microscopi
contrast
affect
local
express
resist
viru
variant
intriguingli
compound
affect
intracellular
local
transfect
cell
result
suggest
inhibit
unknown
virusspecif
activ
requir
work
underscor
exquisit
specif
support
continu
develop
potenti
antiorthopoxviru
drug
guang
yang
chri
harver
denni
hrubi
robert
jordan
siga
technolog
inc
sw
research
way
suit
corval
usa
potent
oral
bioavail
antiorthopoxviru
compound
activ
vitro
vivo
frequenc
natur
occur
resist
variant
measur
fluctuat
analysi
found
marker
rescu
drug
resist
variant
local
chang
associ
reduc
compound
suscept
vaccinia
viru
gene
spectrum
mutat
confer
resist
determin
use
errorpron
pcr
procedur
increas
frequenc
compound
resist
rel
frequenc
natur
occur
resist
use
procedur
random
point
mutat
introduc
code
sequenc
errorpron
pcr
mutat
allel
transfer
wildtyp
viru
genom
marker
rescu
sequenc
analysi
input
errorpron
pcr
product
prior
marker
rescu
identifi
numer
nucleotid
chang
code
sequenc
creat
nonsens
mutat
viru
recombin
select
form
plaqu
presenc
drug
select
power
select
procedur
enrich
virus
produc
function
resist
protein
sequenc
analysi
compound
resist
allel
identifi
numer
silent
mutat
scatter
throughout
code
sequenc
point
mutat
lead
amino
acid
chang
cluster
around
amino
acid
posit
within
gene
seven
mutat
result
singl
amino
acid
chang
could
correl
reduc
compound
suscept
taken
togeth
result
suggest
mutat
least
posit
within
confer
resist
resist
mutat
cluster
amino
acid
domain
region
protein
unknown
function
sever
pyrimidin
analog
identifi
antivir
activ
cowpox
viru
cv
vaccinia
viru
vv
primari
human
foreskin
fibroblast
cell
molecul
contain
benzopyran
cyanovinyl
pyrazolon
moieti
posit
exhibit
signific
antivir
activ
virus
three
compound
seri
ec
valu
plaqu
reduct
assay
cv
vv
antivir
activ
compound
also
determin
herp
simplex
viru
hsv
plaqu
assay
two
compound
cyanovinyl
deriv
posit
ec
valu
wherea
substitu
posit
exhibit
weaker
activ
one
virus
analog
contain
benzopyran
substitu
effect
varicella
zoster
viru
vzv
yield
ec
valu
plaqu
reduct
assay
none
compound
activ
human
cytomegaloviru
interestingli
compound
much
less
effect
thymidin
kinas
tk
neg
strain
cv
suggest
activ
enzym
import
mechan
action
tk
defici
strain
hsv
also
compar
resist
compound
tk
depend
compound
cv
hsv
taken
togeth
lack
activ
cytomegaloviru
replic
suggest
activ
viral
tk
import
mechan
action
result
indic
pyrimidin
analog
larg
substitu
posit
substrat
distinct
tk
homolog
encod
herpesvirus
orthopoxvirus
suggest
may
effect
infect
virus
synthesi
test
addit
analog
warrant
help
identifi
potent
analog
vivo
test
depart
pediatr
univers
alabama
school
medicin
birmingham
al
usa
nmethanocarbathymidin
n
mct
conform
lock
nucleosid
analog
activ
herpesvirus
orthopoxvirus
vitro
compound
inhibit
replic
herp
simplex
viru
hsv
ec
valu
gml
vaccinia
viru
vv
cowpox
viru
cv
ec
valu
gml
respect
assay
use
thymidin
kinas
tk
neg
strain
cv
yield
ec
valu
greater
tk
posit
isol
similarli
tk
neg
strain
less
sensit
drug
wildtyp
strain
thu
antivir
activ
molecul
depend
type
tk
hsv
type
ii
tk
express
vv
cv
virus
suggest
substrat
diverg
form
enzym
drug
also
good
inhibitor
viral
dna
synthesi
virus
consist
inhibit
viral
dna
polymeras
activ
viral
tk
homolog
also
possibl
phosphoryl
form
drug
may
inhibit
enzym
thymidyl
synthetas
inhibit
viral
dna
synthesi
indirectli
interest
tk
depend
molecul
explain
rather
unusu
spectrum
activ
includ
orthopoxvirus
alphaherpesvirus
epsteinbarr
viru
ebv
human
herpesviru
sinc
virus
express
molecul
tk
activ
could
phosphoryl
thu
activ
drug
convers
nmct
ineffect
betaherpesvirus
encod
tk
homolog
compound
also
highli
effect
reduc
mortal
mice
infect
cv
vv
hsv
treatment
initi
h
infect
dose
low
mgkg
result
indic
n
mct
activ
vitro
vivo
mechan
action
suggest
molecul
may
effect
select
therapeut
orthopoxviru
certain
herpesviru
infect
warrant
develop
previous
report
isol
character
drugresist
mutant
obtain
follow
repeat
passag
vaccinia
viru
vv
lederl
strain
presenc
increas
concentr
cidofovir
cdv
cdvr
mutant
encod
two
mutat
relat
genet
polymorph
introduc
mutat
pathogen
strain
w
western
reserv
character
drugsuscept
profil
recombin
virus
pathogen
mice
recombin
virus
prove
resist
cdv
relat
compound
cyclic
cdv
propoxi
pyrimidin
viru
bear
substitut
prove
resist
cdv
singl
mutant
interestingli
mutant
differ
sensit
phosphonoacet
acid
paa
mutant
respect
hypersensit
resist
paa
contrast
doubl
mutant
show
chang
sensit
paa
compar
wildtyp
strain
unlik
mutant
show
two
threefold
decreas
suscept
toward
hpmp
purin
deriv
mutant
show
crossresist
hpmp
purin
deriv
note
process
select
cdvresist
mutant
presenc
increas
concentr
compound
mutat
appear
substitut
latter
mutat
occur
conjunct
test
virul
lethal
intranas
infect
model
mice
cdvr
recombin
virus
prove
attenu
suggest
cdvr
mutat
associ
reduc
pathogen
furthermor
found
cdv
dose
mgkgday
day
still
abl
protect
mice
term
bodi
weight
loss
intranas
challeng
recombin
viru
evalu
use
cpg
dna
antivir
therapi
amanda
phelp
linda
eastaugh
amanda
gate
david
ulaeto
arthur
krieg
defenc
scienc
technolog
laboratori
dstl
salisburi
wiltshir
uk
coley
pharmaceut
ltd
ottawa
ont
canada
present
licens
antivir
orthopoxviru
infect
variola
vaccinia
viru
vacv
although
stockpil
smallpox
vaccin
exist
util
postexposur
treatment
infect
live
viral
vaccin
administ
contraind
bacteri
dna
contain
unmethyl
motif
togeth
flank
region
stimul
innat
immun
respons
synthet
cpg
dna
mimic
immunostimulatori
activ
bacteri
dna
recognis
intracellular
tolllik
receptor
four
class
cpg
dna
differ
properti
elicit
distinct
initi
immun
respons
previou
studi
use
establish
lethal
respiratori
model
poxviru
infect
demonstr
class
b
cpg
dna
could
provid
protect
lethal
vacv
balbc
mice
administ
day
prior
challeng
order
evalu
efficaci
balbc
mice
challeng
intranas
vacv
treat
dose
rang
ugmous
treatment
administ
intranas
light
anaesthesia
either
day
challeng
day
postchalleng
efficaci
determin
percentag
bodi
weight
loss
postchalleng
optimum
surviv
rate
observ
treat
ug
day
postchalleng
challeng
surviv
rate
observ
treat
ug
day
postchalleng
challeng
delay
treatment
either
day
postchalleng
ineffect
indic
window
opportun
deliveri
within
day
multipl
dose
use
attempt
extend
window
opportun
deliv
twice
within
period
interestingli
consider
detriment
effect
actual
acceler
onset
diseas
ultim
death
work
requir
optimis
use
cpg
dna
potenti
antivir
therapi
evid
suggest
may
immens
util
part
coadministr
therapi
antivir
compound
area
work
current
investig
crown
copyright
dstl
depart
virolog
hebrew
univers
hadassah
medic
school
jerusalem
israel
pathogen
immunogen
lister
elstre
strain
vaccinia
viru
use
vaccin
smallpox
studi
mous
model
viru
reach
brain
inocul
intranas
inject
intracrani
dose
plaqu
form
unit
pfu
lethal
mice
lower
dose
viru
caus
mice
initi
loos
weight
complet
recov
thereaft
signific
level
protect
lethal
dose
wr
strain
achiev
mice
follow
immun
lister
strain
higher
dose
repeat
vaccin
procedur
requir
modifi
vaccinia
viru
ankara
mva
found
lister
vaccin
strain
appli
israel
compris
heterogen
viru
popul
isol
plaquepurifi
three
viru
variant
differ
plaqu
size
cell
cultur
name
llarg
plaqu
mmedium
plaqu
ssmall
plaqu
variant
isol
could
neutral
rabbit
antibodi
prepar
western
reserv
strain
vaccinia
viru
onestep
growth
curv
cell
quit
similar
howev
differ
pathogen
mice
follow
intranas
inocul
pfu
intracrani
inject
pfu
variant
virul
two
variant
resembl
pathogen
lister
strain
activ
also
determin
thymidin
kinas
tk
defici
vaccinia
viru
mous
monkey
cell
potenc
n
mct
similar
seen
wildtyp
viru
suggest
cellular
enzym
may
import
viral
tk
phosphoryl
compound
mice
intranas
infect
cowpox
vaccinia
virus
follow
h
later
intraperiton
treatment
n
mct
day
cidofovir
day
n
mct
treatment
mgkgday
result
surviv
cowpox
viru
infect
respect
compar
surviv
placebo
statist
signific
reduct
lung
viru
titer
day
occur
mgkgday
treat
mice
dose
spare
mice
lethal
vaccinia
viru
challeng
howev
mgkgday
treatment
significantli
reduc
day
viru
titer
lung
weight
mgkgday
treatment
reduc
lung
consolid
cidofovir
mgkgday
protect
anim
death
model
evalu
n
mct
may
limit
mice
base
upon
greatli
reduc
efficaci
cell
higher
anim
acknowledg
support
part
contract
virolog
branch
niaid
nih
chelsea
byrd
elena
sbrana
shuyuan
xiao
marina
siirin
robert
tesh
denni
hrubi
robert
jordan
siga
technolog
inc
corval
usa
univers
texa
medic
branch
galveston
tx
usa
potent
small
molecul
inhibitor
orthopoxviru
replic
shown
protect
mice
lethal
challeng
vaccinia
ectromelia
virus
report
result
preliminari
trial
show
efficaci
sever
monkeypox
viru
infect
ground
squirrel
model
ground
squirrel
infect
less
pfu
monkeypox
viru
develop
fulmin
diseas
resembl
human
hemorrhag
smallpox
sever
lethal
form
diseas
oral
administr
mgkg
per
day
day
protect
ground
squirrel
lethal
challeng
pfu
monkeypox
viru
compound
treat
anim
show
weight
loss
evid
diseas
blood
chemistri
valu
similar
uninfect
anim
contrast
placebotr
anim
show
elev
liver
enzym
alt
ast
level
anim
die
day
postinfect
treatment
h
protect
observ
h
group
protect
h
group
sever
patholog
chang
observ
organ
anim
receiv
placebo
especi
lung
liver
spleen
contrast
organ
anim
receiv
h
postinfect
appear
grossli
microscop
normal
thu
appear
promis
candid
continu
develop
therapeut
agent
sever
orthopoxviru
infect
ing
vliegen
guang
yang
denni
hrubi
erik
de
clercq
robert
jordan
johan
neyt
rega
institut
medic
research
ku
leuven
belgium
siga
technolog
inc
corval
usa
potent
inhibitor
replic
variou
orthopoxvirus
resist
cowpoxviru
map
mutat
homolog
vaccinia
viru
yang
et
al
j
virol
latter
encod
envelop
protein
requir
product
extracellular
viru
delet
result
viru
replicationcompet
cell
cultur
produc
smaller
plaqu
wildtyp
wrvac
wherea
intraven
iv
inocul
nmri
mice
pfu
wrvac
result
pox
tail
lesion
per
mous
inoculum
caus
lesion
p
athym
nude
nunu
scid
mice
inocul
iv
pfu
develop
tail
lesion
mean
day
death
nunu
mice
inocul
day
compar
day
wrvacinfect
mice
p
scid
mice
surviv
infect
next
studi
whether
abl
protect
mice
subsequ
infect
wrvac
mimic
human
vaccin
protocol
nmri
mice
infect
intracutan
ic
mean
scarif
lumbosacr
area
pfu
placebo
none
infect
mice
develop
lesion
inocul
site
one
week
later
anim
infect
ic
pfu
wrvac
placebo
anim
none
anim
develop
poxviru
lesion
second
set
experi
mice
inocul
ic
placebo
infect
one
week
later
pfu
wrvac
iv
rout
placebo
anim
develop
averag
pox
tail
lesion
lesion
develop
anim
p
third
set
experi
nmri
mice
inocul
iv
either
pfu
placebo
none
mice
develop
lesion
one
week
later
anim
inocul
iv
pfu
wrvac
placebo
group
develop
averag
lesion
compar
lesion
mice
p
may
thu
consid
sever
attenu
viru
may
potenti
use
smallpox
vaccin
ji
yuan
travi
lim
shuan
coughlin
dexin
qiu
zhen
liu
dave
stein
decheng
yang
jame
hogg
icaptur
centr
cardiovascular
pulmonari
research
univers
british
columbia
vancouv
bc
canada
avi
biopharma
inc
corval
usa
background
coxsackieviru
common
caus
viral
myocard
exist
drug
therapi
limit
valu
antisens
oligonucleotid
ason
design
pair
viral
rna
could
inhibit
viral
replic
howev
effect
tradit
ason
limit
due
poor
cellular
uptak
degrad
nucleas
phosphorodiamid
morpholino
oligom
pmo
contain
backbon
modif
make
pmo
resist
nucleas
addit
arginin
rich
peptid
conjug
end
oligom
improv
deliveri
cell
featur
make
pmo
ppmo
promis
candid
inhibit
infect
method
total
ppmo
target
distinct
region
viral
genom
one
scrambl
sequenc
design
chemic
synthes
fitc
label
ppmo
use
observ
distribut
confoc
microscopi
viral
protein
viral
titr
cell
viabil
measur
westernblot
plaqu
assay
mt
assay
respect
result
ppmo
show
increas
cellular
uptak
compar
nonconjug
pmo
among
ppmo
target
intern
ribosom
entri
site
utr
show
potent
abil
dosedepend
manner
infect
hela
cardiomyocyt
cell
treat
show
drastic
reduc
product
log
decreas
viral
titr
compar
control
cell
viabil
assay
reveal
treat
hela
cell
still
aliv
compar
controltr
cell
antivir
activ
still
exist
day
treatment
addit
cell
treat
postinfect
show
similar
inhibit
viral
replic
furthermor
specif
ppmo
demonstr
inabl
inhibit
rsv
infect
hela
cell
show
ppmo
effect
inhibit
viral
replic
vitro
provid
new
possibl
antivir
intervent
picornavirus
respons
variou
human
viral
diseas
includ
common
cold
enceph
mening
myocard
etc
specif
antivir
therapi
treat
prevent
viral
diseas
usag
modern
comput
technolog
may
help
solv
problem
effect
object
present
studi
quantit
structureact
relationship
qsar
analysi
antivir
activ
set
biphenyloxi
propyl
isoxazol
deriv
inhibit
replic
hela
cell
base
result
qsar
structur
new
potenti
antivir
agent
predict
use
consequ
molecular
design
qsar
approach
appli
base
simplex
represent
molecular
structur
sirm
relationship
antivir
activ
pleconarilsensit
clinic
isol
ic
gml
b
cytotox
hela
cell
cc
gml
c
select
index
si
ratio
cc
ic
structur
biphenyloxi
propyl
isoxazol
deriv
studi
systemat
quit
adequ
qsar
model
r
q
obtain
use
pl
partial
least
squar
method
paramet
studi
model
close
correl
experiment
data
structur
fragment
posit
neg
influenc
cytotox
well
antivir
activ
determin
base
model
exampl
qsar
analysi
antivir
activ
biphenyloxi
propyl
isoxazol
deriv
reveal
presenc
mnitrophenyl
ptrifluorophenyl
fragment
distinctli
neg
influenc
antivir
action
compound
strong
antivir
activ
contain
oxadiazol
fragment
moreov
data
allow
virtual
screen
molecular
design
new
welltoler
compound
strong
activ
ivanka
nikolova
roumena
petkova
bori
atanassov
stoyan
chakarov
angel
galabov
institut
microbiolog
bulgarian
academi
scienc
sofia
bulgaria
scientif
technolog
servic
ltd
sofia
bulgaria
institut
organ
chemistri
bulgarian
academi
scienc
sofia
bulgaria
analysi
rna
sequenc
disoxarilresist
mutant
coxsackieviru
carri
wildtyp
disoxarilsensit
strain
connecticut
two
disoxarilresist
mutant
one
produc
fl
cell
one
isol
brain
newborn
mice
infect
coxsackieviru
treat
disoxaril
disoxarildepend
mutant
strain
obtain
resist
strain
passag
cell
cultur
includ
present
studi
rtpcr
assay
primer
set
select
region
coxsackieviru
genom
code
capsid
protein
carri
parallel
compar
analysi
sequenc
result
fragment
disoxaril
mutant
studi
genbank
sequenc
origin
gene
coxsackieviru
perform
blast
align
tool
distinct
alter
locu
disoxarilresist
disoxarildepend
mutant
compar
sequenc
origin
genbank
name
delet
uug
ntt
insert
uuu
observ
highdegre
similar
resist
mutant
produc
cell
cultur
depend
strain
observ
similar
wild
strain
resist
mutant
obtain
mice
found
similar
strain
develop
cell
cultur
put
model
spatial
fold
target
protein
disoxaril
mutant
propos
ralitsa
vassilevapencheva
angel
galabov
previou
studi
present
new
approach
combin
applic
antiviralsconsecut
administr
partner
schedul
could
consid
especi
suitabl
treatment
enterovir
infect
develop
resist
rapid
due
extrem
high
viral
mutat
rate
approach
aim
restrict
resist
develop
experi
vivo
use
antivir
prove
high
effici
experi
cell
cultur
screen
variou
doubl
tripl
quadrupl
combin
carri
show
two
tripl
combin
name
disoxaril
win
compound
oxoglaucin
new
antivir
drug
develop
laboratori
classic
enterovir
inhibitor
disoxariloxoglaucinguanidinehydrochlorid
classic
enterovir
inhibitor
manifest
signific
effect
protect
newborn
mice
neurotrop
coxsackieviru
infect
current
studi
role
chronolog
arrang
antivir
includ
combin
investig
experi
carri
tripl
combin
disoxariloxoglaucinguanidinehydrochlorid
found
optim
treatment
cours
start
disoxaril
treatment
cours
quit
success
disoxaril
follow
guanidinehydrochlorid
effect
tripl
combin
start
oxoglaucin
follow
guanidinehydrochlorid
moder
cours
start
guanidinehydrochlorid
prove
ineffect
furthermor
studi
viru
sensit
inhibitorspartn
valu
phenotyp
characterist
brain
isol
eg
size
plaqu
pathogen
mice
recent
contribut
develop
new
antipicornaviru
agent
led
discoveri
deriv
whose
vitro
anticoxsackieviru
activ
depend
natur
substitu
para
posit
phenyl
ring
particularli
compound
phenyl
phenyl
exhibit
interest
antivir
activ
high
select
index
present
studi
investig
mechan
action
compound
studi
time
addit
experi
suggest
compound
exert
differ
interfer
earli
step
viral
replic
cycl
fact
compound
effect
ad
within
h
end
adsorpt
period
reduct
observ
ad
adsorpt
period
wherea
reduct
viru
titer
observ
ad
adsorpt
period
reduct
observ
compound
ad
period
time
influenc
compound
viru
adsorpt
step
studi
infect
center
assay
indic
primarili
interfer
coxsacki
cellular
attach
concentr
time
id
inhibit
adsorpt
coxsackieviru
complet
similar
concentr
effect
experi
neutral
viral
infect
thermal
stabil
demonstr
compound
abl
directli
inactiv
coxsackieviru
infecti
titer
restor
origin
valu
extract
compound
chloroform
howev
compound
protect
viral
infect
heat
inactiv
differ
concentr
use
bloodbrain
barrier
bbb
fulfil
vital
protect
function
limit
entri
potenti
pathogen
toxin
inflammatori
cell
central
nervou
system
cn
disrupt
bbb
common
compon
mani
cn
diseas
includ
viral
diseas
caus
west
nile
viru
wnv
transform
growth
previous
shown
improv
function
vitro
model
bbb
evalu
role
bbb
wnv
infect
mice
determin
abil
intraperiton
ip
administ
sodium
fluorescein
move
circul
blood
central
nervou
system
demonstr
bbb
permeabl
mean
normal
rang
permeabl
valu
determin
noninfect
mice
subsequ
experi
anim
express
permeabl
valu
greater
sd
mean
consid
abnorm
high
determin
elev
bbb
permeabl
detect
mice
day
subcutan
inocul
wnv
wnv
inocul
anim
treat
dose
ngkgday
drug
vehicl
daili
via
ip
rout
day
postviru
inocul
dpi
assay
bbb
permeabl
dpi
sixtytwo
percent
placebotr
anim
abnorm
high
permeabl
valu
anim
treat
ngkgday
anim
abnorm
high
permeabl
valu
respect
contrast
none
anim
treat
ngkg
express
abnorm
high
permeabl
valu
significantli
lower
p
placebotr
anim
result
suggest
may
improv
function
bloodbrain
barrier
wnv
infect
mice
acknowledg
support
grant
rocki
mountain
region
center
excel
nih
contract
virolog
branch
niaid
nih
peopl
infect
west
nile
viru
wnv
usual
see
physician
show
symptom
suggest
neurolog
infect
wnv
infect
central
nervou
system
cn
rodent
day
sc
viral
challeng
yet
publish
anim
studi
begin
therapeut
treatment
soon
viral
challeng
question
address
studi
neuroprotect
agent
efficaci
administ
earli
brain
infect
later
viru
demonstr
brain
drug
evalu
wnvinfect
rodent
nmda
ampa
receptor
antagonist
modul
nitric
oxid
synthas
no
nitric
oxid
product
riluzol
reduc
glutam
excitotox
serial
dose
diethyldithiocarbam
ddtc
n
g
monomethyllarginin
lnmma
induc
inhibitor
no
respect
administ
ip
daili
day
begin
h
viral
challeng
slightli
improv
surviv
mice
differ
statist
signific
toler
dose
two
nmdareceptor
antagonist
flupertin
mgkg
mgkg
one
ampareceptor
antagonist
gyki
mgkg
administ
twice
daili
bid
though
day
postviru
inocul
dpi
gyki
slightli
improv
mous
surviv
weight
gain
differ
statist
signific
talampanel
ampareceptor
antagonist
deriv
gyki
slightli
improv
hamster
surviv
p
treatment
began
dpi
repeat
experi
use
differ
dose
slightli
differ
protocol
gave
mix
result
riluzol
drug
shown
improv
surviv
amyotroph
later
sclerosi
al
presum
reduc
glutam
excitotox
effect
wnv
diseas
administ
bid
begin
dpi
overal
neuroprotect
agent
consist
improv
wnv
diseas
although
slight
improv
anim
surviv
might
relev
improv
neurolog
sequela
wnvpatient
acknowledg
support
contract
virolog
branch
niaid
nih
hamster
mous
model
west
nile
viru
wnv
diseas
use
studi
identifi
infect
cell
central
nervou
system
cn
earli
cours
infect
inform
may
relev
therapeut
strategi
sinc
wnvinfect
peopl
visit
physician
show
symptom
suggest
neurolog
infect
subcutan
infect
adult
mice
hamster
use
tissu
cultur
infecti
dose
wnv
tissu
infect
control
anim
day
postvir
inject
dpi
fix
cardiac
perfus
use
paraformaldehyd
local
wnv
neuron
astrogli
marker
paraffin
embed
tissu
section
immunofluoresc
imag
captur
use
confoc
microscop
biorad
mrc
observ
presenc
wnv
antigen
cn
tissu
mice
hamster
earli
dpi
respect
strong
wnvspecif
immunofluoresc
stain
observ
cytoplasm
neuron
spinal
cord
cerebellum
cerebr
cortex
midbrain
rodent
wnvspecif
stain
coloc
neuronspecif
marker
howev
astrogli
marker
coloc
wnv
antigen
brain
section
lack
tropism
wnv
astrocyt
also
confirm
primari
murin
astrocyt
cultur
interestingli
infect
neuron
midbrain
infect
hamster
coloc
calbindin
calciumbind
protein
mostli
express
interneuron
cn
therapi
evalu
hamster
mice
timepoint
wnvstain
neuron
identifi
cn
acknowledg
support
grant
rocki
mountain
region
center
excel
nih
laboratori
virolog
depart
biolog
chemistri
school
scienc
univers
bueno
air
argentina
dengu
viru
denv
arthropodborn
flaviviru
reemerg
recent
year
increasingli
import
public
health
threat
nearli
million
infect
occur
year
present
neither
specif
antivir
therapi
vaccin
exist
treatment
prevent
denv
infect
carrageenan
sulfat
galactan
extract
red
seawe
compris
divers
structur
wide
rang
biolog
properti
use
biomedicin
previou
studi
demonstr
antivir
activ
commercialand
carrageenan
denv
type
vero
monkey
kidney
cell
human
hepatoma
cell
show
inhibitori
concentr
ic
valu
rang
gml
select
index
cc
ic
rang
present
work
studi
mode
action
polysulf
vero
cell
first
analyz
influenc
time
addit
compound
antidenv
activ
infecti
centr
assay
highest
inhibitori
effect
observ
compound
ad
adsorpt
h
pi
ineffect
later
time
effect
compound
viru
adsorpt
intern
studi
separ
viru
yield
inhibit
assay
signific
antivir
efficaci
attain
compound
present
either
adsorpt
intern
possibl
effect
carrageenan
viral
protein
synthesi
subsequ
stage
viru
cycl
occur
first
hour
infect
analyz
pulselabel
methionin
alter
denv
protein
synthesi
carrageenantr
cell
observ
cell
transfect
purifi
rna
presenc
carrageenan
inhibit
fluoresc
cell
focu
format
viru
product
detect
besid
signific
direct
virucid
effect
shown
compound
result
indic
denv
adsorpt
intern
seem
main
target
compound
lack
effect
step
occur
viral
genom
insid
cell
vitro
infect
human
monkey
cell
multipl
member
flaviviru
genu
famili
flavivirida
caus
lethal
hemorrhag
fever
enceph
public
health
signific
hemorrhag
fever
enceph
caus
flavivirus
enorm
global
tremend
need
antivir
imino
sugar
glucosidas
inhibitor
shown
select
antivir
activ
virus
bovin
viral
diarrhea
viru
bvdv
west
nile
viru
wnv
common
requir
glycoprotein
process
viru
product
develop
imino
sugar
deoxynojirycin
dnj
deriv
chemic
synthesi
compound
variou
alkyl
side
chain
antivir
test
bvdv
wnv
well
wnv
subgenom
replicon
assay
briefli
use
singl
step
growth
viru
yield
reduct
assay
bvdv
wnv
seri
dnj
deriv
contain
variou
conform
lock
side
chain
shown
antivir
activ
preliminari
structureact
relationship
sar
obtain
modif
alkyl
side
chain
improv
dnj
deriv
activ
mechan
action
compound
present
sever
flavivirus
caus
lifethreaten
diseas
man
current
therapi
avail
infect
recent
year
sever
highli
select
inhibitor
replic
hepat
c
viru
hcv
design
small
molecul
inhibitor
hcv
preclin
clinic
develop
either
proteas
polymeras
inhibitor
compound
highli
select
hcv
unlik
exhibit
activ
flavivirus
nucleosid
polymeras
inhibitor
howev
may
potenti
inhibit
replic
flavivirus
well
evalu
vitro
whether
activ
compon
antihcv
compound
valopicitabin
ie
cmethylcytidin
inhibit
replic
flavivirus
cell
cultur
compound
found
exhibit
specif
antivir
activ
yellow
fever
viru
ec
gml
cpe
reduct
assay
reduct
gml
assess
qpcr
dengu
fever
viru
type
ec
gml
cpe
reduct
assay
compound
also
effici
inhibit
west
nile
viru
replic
gml
assess
qpcr
plaqu
reduct
neutral
test
gml
absenc
drug
treatment
flaviviru
infect
may
envisag
nucleosid
polymeras
inhibitor
market
treatment
hcv
infect
could
use
offlabel
treatment
lifethreaten
flaviviru
infect
even
drug
would
abl
complet
inhibit
flaviviru
replic
partial
reduct
viremia
acut
phase
infect
may
suffici
prevent
develop
fulmin
diseas
thu
protect
virusinduc
mortal
yuri
klimochkin
andrew
shiryaev
igor
moiseev
v
sabynin
larisa
rustamova
alexandr
petkevich
state
technic
univers
samara
russia
institut
epidemiolog
microbiolog
minsk
belaruss
arenavirus
one
danger
tool
bioterror
view
pathogen
epidemiolog
threat
purpos
search
new
remedi
treatment
arenavirus
infect
synthesi
new
deriv
cage
compound
carri
prepar
compound
bridgehead
deriv
cage
compound
bear
differ
function
group
hydroxi
acylamino
alkoxycarbonylamino
alkylthiocarbonylamino
group
well
iminoalkyl
adamantan
deriv
adamantyl
heterocycl
compound
contain
two
adamantan
moieti
molecul
antivir
activ
cage
compound
studi
respect
arenavirus
lassa
sierraleon
strain
pichind
strain
vero
cell
cultur
differ
level
antivir
activ
shown
compound
activ
compound
monosubstitut
adamantan
deriv
sufur
nitrogencontain
substitu
bridgehead
posit
data
activ
confirm
avail
search
inhibitor
arenavirus
reproduct
cage
compound
seri
brian
gowen
donald
smee
minhui
wong
ann
pace
kiehoon
jung
kevin
bailey
lawrenc
blatt
robert
sidwel
institut
antivir
research
utah
state
univers
logan
ut
usa
intermun
brisban
ca
usa
sever
arenavirus
endem
south
american
junin
machupo
guanarito
african
lassa
contin
known
caus
frequent
fatal
hemorrhag
fever
except
ribavirin
demonstr
efficaci
case
lassa
fever
effect
therapeut
treatment
arenavir
hemorrhag
fever
outcom
treatment
ultim
depend
upon
earli
diagnosi
toler
ribavirin
patient
high
dose
requir
effect
antivir
activ
recent
demonstr
consensu
interferonalpha
ifnalfacon
protect
hamster
lethal
pichind
viru
pcv
infect
gowen
et
al
antimicrob
agent
chemoth
serv
model
acut
arenavir
diseas
human
demonstr
highli
effect
therapi
combin
use
ribavirin
ifn
treatment
pcv
infect
hamster
ribavirin
given
oral
twice
per
day
day
ifn
administ
intraperiton
per
day
day
treatment
initi
day
postinfect
variou
dose
combin
mani
less
optim
drug
given
independ
combin
suboptim
dose
ribavirin
mgkgday
ifn
mgkgday
abl
show
increas
protect
mortal
reduc
viral
burden
liver
diseas
greatli
extend
surviv
time
compar
treatment
drug
administ
alon
data
indic
synergist
activ
result
combin
therapi
activ
may
slow
progress
diseas
decreas
fatal
rate
seen
sever
arenavir
infect
combin
therapi
reduc
effect
dosag
ribavirin
would
serv
limit
toxic
acknowledg
support
contract
virolog
branch
nation
institut
allergi
infecti
diseas
nation
institut
health
slobodan
paessler
laur
andrew
vaillant
jeanmarc
juteau
ramon
flick
depart
patholog
univers
texa
medic
branch
galveston
texa
usa
replicor
inc
laval
que
canada
rift
valley
fever
viru
rvfv
genu
phleboviru
famili
bunyavirida
arboviru
transmit
mani
speci
mosquito
viru
major
public
health
concern
subsaharan
africa
egypt
spread
yemen
saudi
arabia
area
rvfv
respons
dramat
epidemicsepizoot
underlin
need
effici
antiviralprophylact
measur
rep
mer
phosphorothio
oligonucleotid
previous
shown
broadspectrum
activ
sever
virus
vaillant
et
al
submit
public
use
vaccin
strain
well
wildtyp
rvfv
test
abil
rep
inhibit
bunyaviru
prolifer
vitro
data
show
reduct
viru
titer
strain
use
rep
nanomolar
concentr
moreov
absenc
phosphorothio
modif
stabil
rep
analog
result
loss
antivir
activ
suggest
virus
increas
hydrophob
rep
essenti
antivir
activ
base
inhibitori
activ
observ
vitro
start
vivo
efficaci
studi
util
valid
mous
model
use
laboratori
anim
experi
ongo
confirm
vitro
result
evalu
antivir
effect
rep
adriana
garozzo
rossella
timpanaro
aldo
stivala
gianna
tempera
christian
cc
angelo
castro
depart
microbiolog
scienc
univers
catania
via
andron
catania
itali
depart
pharmaceut
scienc
univers
catania
vial
doria
catania
itali
previou
studi
describ
synthesi
antivir
activ
isothiazol
deriv
found
particularli
effect
picornavirus
compound
exhibit
interest
antipolioviru
activ
high
select
index
present
studi
investig
mechan
action
compound
studi
time
addit
polioviru
type
infect
cell
suggest
compound
may
inhibit
earli
process
viral
replic
order
determin
mechan
action
evalu
rate
attach
intern
purifi
h
uridinelabel
polioviru
cell
presenc
absenc
effect
polioviru
adsorpt
intern
host
cell
detect
also
investig
influenc
compound
viru
uncoat
use
label
polioviru
measur
radioact
oligoribonucleotid
form
viral
rna
suscept
ribonucleas
experi
demonstr
polioviru
uncoat
influenc
action
justin
juland
aaron
olsen
john
morrey
lawrenc
blatt
kristiina
shafer
robert
sidwel
institut
antivir
research
utah
state
univers
logan
ut
usa
intermun
brisban
ca
usa
alpha
togavirus
medic
import
arbovirus
clinic
case
occur
year
north
south
central
america
recent
increas
threat
use
virus
bioterror
agent
led
increas
effort
develop
therapeut
agent
treatment
virus
venezuelan
vee
western
equin
enceph
wee
virus
list
categori
b
prioriti
pathogen
nation
institut
allergi
infecti
diseas
niaid
goal
studi
character
anim
model
vee
wee
use
evalu
antivir
therapi
mice
infect
intranas
rout
vaccin
strain
vee
viru
detect
brain
day
postvir
inject
dpi
brain
titer
increas
peak
titer
cell
cultur
infecti
dose
per
gram
tissu
ccid
g
dpi
maintain
titer
ccid
g
dpi
drop
slightli
ccid
g
dpi
viru
also
detect
spleen
liver
kidney
treatment
veeinfect
mice
interferon
alpha
bd
human
consensu
interferon
result
surviv
wherea
placebotr
anim
die
dpi
syrian
golden
hamster
infect
ccid
wee
intraperiton
ip
inject
morbid
includ
hind
limb
paralysi
tremor
nasal
bleed
hunch
mortal
seen
soon
dpi
major
death
occur
dpi
viru
detect
organ
assay
brain
liver
spleen
peak
titer
occur
dpi
interferon
alfacon
ifn
alfacon
human
consensu
interferon
activ
hamster
effect
significantli
reduc
mortal
p
compar
placebo
trend
reduct
brain
titer
ifn
alfacontr
anim
mean
titer
ccid
g
compar
placebo
mean
titer
ccid
g
although
differ
statist
signific
model
use
screen
potenti
antivir
agent
efficaci
vee
wee
acknowledg
support
contract
virolog
branch
niaid
nih
justin
juland
kristiina
shafer
john
morrey
lawrenc
blatt
robert
sidwel
institut
antivir
research
utah
state
univers
logan
ut
usa
intermun
brisban
ca
usa
yellow
fever
viru
yfv
caus
signific
morbid
mortal
centuri
primat
anim
model
viscer
yfv
recent
hamster
found
morbid
mortal
inject
hamsteradapt
jimenez
strain
yfv
tesh
et
al
j
infect
di
object
studi
character
model
yfv
viscerotrop
diseas
studi
effect
antivir
compound
test
compound
known
efficaci
use
posit
control
anim
challeng
dilut
dilut
previous
shown
caus
high
mortal
liver
homogen
made
liver
taken
day
postvir
inject
dpi
hamster
challeng
jimenez
strain
mortal
anim
challeng
viru
dpi
viru
titer
liver
peak
dpi
determin
qrtpcr
signific
increas
serum
level
alt
dpi
alkalin
phosphotas
dpi
bilirubin
dpi
signific
decreas
amylas
dpi
albumin
dpi
glucos
dpi
observ
hepat
icteru
observ
hamster
exhibit
diseas
sign
time
necropsi
hamster
treat
ribavirin
interferon
ifn
alfacon
consensu
interferon
ribavirin
ifn
alfacon
significantli
p
reduc
mortal
compar
placebotreat
also
signific
reduct
weight
loss
ribavirin
p
ifn
alfacon
p
treatment
compar
placebo
diseas
sign
lethargi
lie
prostrat
also
reduc
treatment
ribavirin
ifn
alfacon
viral
liver
titer
treat
anim
significantli
differ
titer
placebotr
anim
hamster
model
yfv
diseas
serv
suitabl
model
evalu
antivir
compound
efficaci
viru
acknowledg
support
contract
virolog
branch
niaid
nih
polyomavirus
small
dna
tumor
virus
depend
host
cellular
dna
polymeras
replic
three
polyomavirus
associ
tumor
format
human
jc
viru
jcv
bk
viru
bkv
simian
vacuol
viru
addit
associ
viral
diseas
jcv
caus
progress
multifoc
leukoencephalopathi
immunosuppress
patient
bkv
consid
caus
agent
polyomavirusassoci
nephropathi
lead
kidney
transplant
failur
associ
welldefin
diseas
viral
dna
sequenc
protein
express
detect
mostli
central
nervou
system
cn
tumor
strengthen
evid
associ
viru
human
cancer
activ
variou
acycl
nucleosid
phosphon
anp
cidofovir
adefovir
murin
polyomaviru
primat
vitro
alreadi
demonstr
andrei
et
al
antimicrob
agent
chemoth
activ
new
class
anp
name
phosphonomethoxi
alkoxi
polyomavirus
assess
confluent
cell
infect
either
four
murin
polyomaviru
strain
mnrde
toronto
pta
cell
infect
either
primat
strain
strain
ek
strain
dar
remov
residu
viru
serial
dilut
test
compound
ad
viral
cytopath
effect
record
microscop
day
murin
polyoma
viru
day
hpmpodapi
r
phosphonomethoxi
propoxi
pyrimidin
pmeodapi
phosphonomethoxi
ethoxi
pyrimidin
less
activeselect
cidofovir
adefovir
three
strain
test
hpmpodapi
pmeodapi
prove
equal
activ
cidofovir
adefovir
murin
polyomavirus
naresh
sunkara
sylvest
mosley
brian
bakk
joshua
sadler
katherin
seley
radtk
sunni
zhou
univers
marylandbaltimor
counti
baltimor
md
usa
washington
state
univers
pullman
wa
usa
inhibit
biolog
signific
enzym
critic
nucleotid
metabol
viral
replic
wellestablish
chemotherapeut
approach
treatment
mani
diseas
transcript
cap
viral
mrna
implic
elong
checkpoint
critic
replic
cycl
mani
virus
cap
process
accomplish
variou
methyltransferas
therefor
disrupt
methyl
becom
attract
target
therapi
accomplish
sever
way
particular
direct
inhibit
methyltransferas
metas
andor
indirect
inhibit
sadenosyllhomocystein
hydrolas
sahas
establish
cellular
target
antivir
antiparasit
anticanc
agent
modifi
nucleosid
particular
carbocycl
nucleosid
exhibit
potent
inhibitori
activ
sahas
metas
inspect
recent
literatur
reveal
close
correl
sahas
inhibit
potent
biolog
activ
neg
strand
rna
virus
ie
arenavirida
paramyxovirida
rhabdovirida
doubl
strand
rna
virus
reovirida
poxvirida
well
thu
support
import
sahas
viabl
chemotherapeut
target
herein
report
design
synthesi
preliminari
biolog
activ
new
class
structur
novel
carbocycl
nucleosid
phosphoryl
substitut
nucleosid
diphosph
charlotta
wennefor
mikhail
dobrikov
barbara
ramsay
shaw
chemistri
depart
duke
univers
durham
nc
usa
nucleosid
antivir
agent
requir
stepwis
phosphoryl
respect
triphosph
order
activ
cell
substitut
nucleosid
triphosph
interest
proven
good
substrat
revers
transcriptas
rt
may
therefor
use
antivir
agent
studi
laboratori
indic
substitut
dideoxycytidin
triphosph
ddctp
result
increas
effici
incorpor
mmlv
rt
compar
nonsubstitut
ddctp
howev
potenc
substitut
nucleosid
analog
antivir
drug
highli
depend
abil
activ
nucleosid
triphosph
ntp
phosphoryl
nucleosid
analog
diphosph
respect
triphosph
remain
larg
unexplor
role
sever
phosphoryl
enzym
examin
laboratori
nucleosid
diphosph
kinas
creatin
kinas
pyruv
kinas
evalu
specif
toward
nucleosid
analog
diphosph
effect
nucleobas
ribos
substitut
stereochemistri
boranophosph
group
interest
bind
affin
substrat
creatin
kinas
ck
pyruv
kinas
pk
determin
use
fluorescencequench
assay
allow
us
investig
substrat
affin
presteadi
state
rabbit
muscl
ck
pk
titrat
wide
rang
ndp
ntp
monitor
decreas
enzym
intrins
fluoresc
affin
substrat
determin
establish
structureact
relationship
ck
pk
evalu
effect
substrat
modif
ck
show
stereospecif
toward
sp
isom
wherea
pk
show
stereospecif
toward
rp
isom
neg
cooper
observ
studi
substrat
steadyst
experi
also
perform
directli
follow
product
format
use
uvvis
spectroscopi
high
perform
liquid
chromatographi
hplc
kinas
investig
may
serv
mean
activ
antivir
substitut
ndp
tradit
antivir
target
encod
small
human
papillomaviru
hpv
genom
lack
reason
chose
target
dna
sequenc
within
hpv
genom
effort
identifi
compound
would
block
viral
dna
replic
cell
chose
compound
known
polyamid
relat
distamycin
natur
product
dna
bind
agent
unlik
mani
literatur
studi
polyamid
design
block
format
transcript
complex
particular
gene
chose
target
sequenc
within
origin
replic
ori
thu
pyrroleimidazol
polyamid
contain
fluoresc
probe
aid
cell
local
studi
design
recogn
ori
principl
use
design
compound
describ
use
tradit
hairpin
polyamid
unusu
structur
relat
recent
literatur
report
focus
librari
prepar
two
highli
activ
molecul
identifi
rest
molecul
minim
zero
activ
cellular
toxic
observ
either
project
relat
program
polyamid
use
affect
transcript
subsequ
express
rheumatoid
synovi
fibroblast
particular
interest
differ
activ
molecul
two
close
relat
compound
inact
activ
speci
bind
recogn
two
hpv
dna
base
pair
relat
inact
structur
present
provid
detail
chemistri
background
structur
inform
complement
cell
work
also
present
meet
discoveri
chemokin
receptor
coreceptor
infect
reveal
novel
approach
treatment
prevent
member
famili
gprotein
coupl
receptor
thu
becam
attract
target
pursu
pharmaceut
industri
recent
success
develop
sever
small
molecul
clinic
antagonist
hold
great
promis
next
gener
antihiv
medicin
poster
describ
effort
ntermin
piperidin
ring
templat
improv
pharmacolog
properti
deriv
molecul
accord
current
model
proteolyt
process
gag
precursor
occur
within
virion
detach
infect
cell
meanwhil
viral
proteas
activ
much
earlier
gag
cleavag
initi
infect
cell
follow
fate
matrix
protein
cleav
infect
cell
cma
comparison
cleav
virion
vma
show
form
differ
local
infect
cell
virion
form
involv
viru
pathogenesi
repres
target
antivir
compound
cell
label
leucin
myrist
acid
h
label
proteas
inhibitor
ad
separ
cleavag
cma
vma
cma
found
nuclear
membran
fraction
infect
cell
cca
resid
cytoplasm
h
label
cma
found
virion
local
core
vma
locat
lipoprotein
envelop
virion
new
membranotrop
antivir
compound
base
adamantaneand
norbornenerel
deriv
toxic
host
cell
ad
cell
infect
h
later
concentr
ugml
block
revers
transcript
transport
cma
nuclei
product
infecti
viru
compound
inhibit
earli
step
viru
life
cycl
optim
candid
microbicid
enhanc
antivir
activ
plan
associ
polyanion
matrix
imit
peptid
cholesterollik
fragment
kurt
vermeir
thoma
bell
sreenivasa
anugu
noah
duffi
roger
le
grand
erik
de
clercq
dominiqu
schol
rega
institut
medic
research
katholiek
universiteit
leuven
leuven
belgium
depart
chemistri
univers
nevada
reno
usa
servic
de
neurovirologi
fontenayauxros
franc
cyclotriazadisulfonamid
cada
compound
shown
potent
inhibitor
hiv
replic
human
tcell
line
phastimul
pbmc
monocytesmacrophag
ec
prototyp
compound
cada
consist
activ
laboratori
adapt
primari
clinic
isol
irrespect
chemokin
receptor
prefer
cada
act
synergist
evalu
combin
variou
hiv
drug
revers
transcriptas
rt
proteas
viru
entri
inhibitor
flow
cytometr
analysi
reveal
signific
decreas
cell
surfac
intracellular
express
receptor
human
cell
cadatreat
moreov
antihiv
activ
cada
correl
abil
downmodul
receptor
human
tcell
report
consist
antivir
activ
cada
drugresist
virus
ie
virus
resist
rt
inhibitor
proteas
inhibitor
enfuvirtid
ii
differ
subtyp
b
c
ae
f
h
iii
variou
strain
examin
addit
cada
potent
inhibit
infect
pbmc
isol
macaqu
ec
compar
result
obtain
human
cell
infect
flow
cytometr
analysi
also
demonstr
signific
dosedepend
downregul
receptor
express
cell
surfac
simian
pbmc
treatment
cada
combin
cada
cellulos
acet
cap
enter
coat
polym
capsul
tablet
result
synergist
antivir
activ
summari
data
indic
cada
may
qualifi
potenti
antihiv
microbicid
drug
candid
prevent
sexual
transmiss
hiv
prepar
gel
formul
cada
singl
drug
combin
cap
vagin
administr
nonhuman
primat
current
investig
depart
micro
immuno
suni
upstat
medic
univers
syracus
ny
usa
varicella
zoster
viru
vzv
human
herpesviru
infect
caus
chicken
pox
latenc
establish
neuron
reactiv
lead
shingl
acyclovir
deriv
treatment
choic
manifest
vzv
new
therapeut
need
acyclovirresist
strain
exist
treatment
must
begin
within
h
studi
antivzv
properti
roscovitin
cyclin
depend
kinas
cdk
inhibitor
test
compound
block
cell
cycl
determin
vzv
acut
sensit
effect
vzv
replic
test
human
foreskin
fibroblast
hff
primari
cultur
normal
cell
cycl
unlik
tumor
cell
line
cytotox
drug
determin
neutral
red
dye
uptak
assay
hff
inocul
low
moi
vzvinfect
cell
remain
entir
cellassoci
treat
drug
diluent
h
vzv
spread
replic
measur
infecti
focu
assay
quantit
real
time
pcr
drug
test
acyclovir
acv
phosphonoacet
acid
paa
aphidicolin
aloisin
purvalanol
roscovitin
rroscovitin
sroscovitin
lmimosin
drb
antivzv
activ
select
indic
aphidicolin
purvalanol
greater
posit
control
acv
paa
aphidicolin
inhibit
mammalian
dna
polymeras
clinic
use
cancer
purvalanol
purin
primarili
inhibit
deriv
crucifer
veget
inhibit
cell
prolifer
concentr
compound
inhibit
vzv
replic
much
less
need
caus
cell
cycl
arrest
suggest
vzv
depend
enzym
activ
target
compound
cell
prolifer
per
se
three
drug
studi
next
skin
organ
cultur
scidhu
mous
model
vzv
pathogenesi
result
present
demonstr
target
cell
function
inhibit
vzv
replic
help
us
better
understand
virushost
interact
virus
could
identifi
suprabiopolymer
nanoscal
complex
parasit
intervent
cell
occur
interpolymer
reaction
level
antivir
safeti
fulli
provid
without
adequ
nanorespons
antivir
nav
discuss
strategi
methodolog
multifunct
nav
develop
ration
macromolecular
sarcooper
polyelectrolytespecif
interferon
induct
immunomodul
electrostaticselect
prevent
virus
absorpt
plasma
membran
membranetarget
block
postabsorpt
step
fusion
macromolecular
prevent
structurespecif
interact
viral
cellular
receptor
well
polymericassoci
disrupt
latest
stage
viral
replic
virion
assembl
matur
cooper
function
explor
synthesi
saroptim
succin
carbohydr
polymer
deriv
modifi
control
combin
anion
group
immunemedi
protector
tickborn
rabi
viral
infect
vivo
absorpt
inhibitor
vitro
develop
prenav
gener
use
macromolecular
platform
stepbystep
target
design
synthesi
toward
high
effect
multifunct
nav
virusrespons
nanoselect
achiev
ration
intraor
intermolecular
cooper
virusspecif
membranotrop
vector
bi
rafttarget
anchor
ci
peptidekind
mimick
viru
usabl
receptor
human
cell
pi
particularli
result
novel
nanosensit
system
possess
uniqu
wide
multisynergist
antivir
potenc
high
level
select
si
strain
creat
purpos
advanc
antivir
vaccin
drug
microbicid
marina
kukhanova
alexand
ivanov
georgii
galegov
valeria
andronova
maxim
jasko
engelhardt
institut
molecular
biolog
russian
academi
scienc
moscow
russia
centr
medic
studi
univers
oslo
moscow
russia
ivanovski
institut
virolog
russian
academi
medic
scienc
moscow
russia
novel
acycl
purin
phosphon
deriv
bear
doubl
bond
conjug
nucleic
base
name
z
e
phosphonomethoxi
purin
synthes
efficaci
evalu
cell
cultur
activ
z
isom
higher
hiv
refer
phosphonomethoxi
ethyl
adenin
adefovir
compar
respect
activ
adefovir
hsv
e
isom
show
low
antivir
activ
virus
compound
less
toxic
toward
cell
cultur
compar
adefovir
diphosph
z
e
phosphonomethoxi
purin
evalu
substrat
toward
revers
transcriptas
hsv
dna
polymeras
z
isom
shown
effici
substrat
enzym
e
isom
human
dna
polymeras
alpha
could
incorpor
neither
diphosph
end
grow
dna
chain
avail
viru
jev
genom
approxim
singlestrand
positivesens
rna
cap
structur
terminu
lack
poli
tail
terminu
code
region
genom
flank
untransl
region
utr
utr
plusand
minusstrand
jev
genom
contain
import
cisact
element
requir
replic
viral
rna
genom
peptid
nucleic
acid
pna
synthet
oligonucleotid
phosphodiest
backbon
dnarna
replac
polyamin
glycin
skeleton
pna
offer
potenti
power
approach
recognit
rna
silenc
gene
express
studi
investig
antivir
effect
pna
target
utr
region
jev
genom
evalu
pnamedi
inhibitori
effect
rna
synthesi
vitro
rnadepend
rna
polymeras
rdrp
jev
protein
play
major
role
replic
viral
genom
rna
express
escherichia
coli
purifi
near
homogen
sequenti
column
chromatographi
recombin
jev
protein
exhibit
primerdepend
rdrp
activ
vitro
homopolymer
templat
poli
addit
abl
accept
plusand
minusstrand
utr
templat
rna
synthesi
absenc
exogen
primer
could
util
end
jev
genom
minim
templat
vitro
rdrp
assay
use
function
recombin
jev
rdrp
presenc
pna
target
jev
utr
show
dosedepend
rna
synthesi
inhibit
deliveri
inhibitori
pna
jevinfect
cell
suppress
jev
replic
determin
westernblot
analys
plaqu
assay
result
show
sequenc
specif
inhibit
jev
replic
antisens
pna
suggest
possibl
applic
pna
novel
antijev
agent
julia
serkedjieva
reneta
toshkova
milena
nikolova
reneta
tsvetkova
stefka
antonova
ivana
roeva
munnev
sokmen
bekta
tepe
medin
gulluc
fikrettin
sahin
atalay
sokmen
institut
microbiolog
institut
experiment
patholog
parasitolog
institut
botani
bulgarian
academi
scienc
faculti
biolog
depart
microbiolog
sofia
univers
sofia
bulgaria
faculti
art
scienc
depart
biolog
cumhuriyet
univers
siva
turkey
faculti
art
scienc
depart
biolog
univers
erzurum
turkey
natur
product
import
sourc
new
pharmaceut
research
antivir
natur
origin
mainli
focus
plant
sinc
among
reason
select
basi
ethnobotan
use
plant
extract
natur
plant
product
exhibit
also
varieti
biolog
activ
pharmacophor
util
popul
balkan
peninsula
like
peopl
contin
long
appli
poultic
imbib
infus
hundr
indigen
plant
present
report
summar
antivir
screen
studi
plant
product
obtain
bulgarian
turkish
medicin
plant
test
inhibitori
effect
reproduct
select
influenza
viru
flu
strain
mdck
cell
herp
simplex
viru
hsv
strain
mdbk
cell
reduct
virusinduc
cpe
infecti
viru
yield
use
measur
viral
inhibit
fifteen
sampl
inhibit
flu
reproduct
twelv
sampl
activ
hsv
antiflu
activ
confirm
vivo
test
sampl
effect
product
test
antiproteolyt
antioxid
immunogen
capac
potenti
antibacteri
antifung
effect
follow
correl
among
varieti
biolog
pharmacolog
activ
plant
product
observ
antiflu
effect
associ
antihsv
effect
viceversa
antivir
effect
connect
antioxid
activ
antiflu
effect
associ
immunogen
properti
found
correl
antivir
effect
antiproteolyt
capac
antivir
properti
bacteri
fungal
inhibit
antivir
activ
polyphenol
content
previou
investig
reveal
antivir
activ
proteolysi
inhibitor
eaminocapro
acid
eaca
paraaminomethylbenzo
acid
pamba
vitro
vivo
clinic
construct
qsar
computerassist
hierarch
system
effect
antiherpet
antihsv
antiinfluenza
antiflu
agent
select
well
elabor
new
method
synthesi
perman
object
keen
interest
team
object
studi
investig
efficaci
pyridin
analog
combin
fragment
proteolysi
inhibitor
framework
qsar
approach
molecul
new
compound
consist
nucleu
py
ar
two
symmetr
fragment
eacacarbonyl
pambacarbonyl
taken
inhibitor
molecul
antiflu
activ
dose
studi
vitro
model
ahong
reproduct
tissu
cultur
chorioallanto
membran
day
old
chick
embryo
antihsv
activ
dose
studi
model
reproduct
cell
cultur
compound
pynucleu
contain
pambacarbonyl
eacacarbonyl
fragment
demonstr
suffici
antihsv
activ
reduct
intranucleu
virusspecif
inclus
infect
cell
account
accordingli
show
high
antihsv
activ
efficaci
design
antiherpet
compound
obtain
combin
effort
qsar
computerassist
design
properti
predict
synthesi
biolog
test
well
correct
introduc
iter
circl
passsag
proven
effici
modern
way
drug
design
acknowledg
research
support
part
stcu
grant
author
indebt
stcu
foundat
courtesi
lubomira
nikolaevaglomb
angelina
trifonova
stephan
filipov
angel
galabov
institut
microbiolog
bulgarian
academi
scienc
sofia
bulgaria
institut
organ
chemistri
bulgarian
academi
scienc
sofia
bulgaria
seri
aporphinoid
alkaloid
isol
glaucinum
flavum
l
obtain
synthet
test
vitro
antivir
activ
virus
belong
picorna
orthomyxo
paramyxoand
herpesvirus
one
oxoglaucin
manifest
wellpronounc
inhibitori
effect
polioviru
replic
fl
cell
measur
semiquantit
agardiffus
plaqueinhibit
test
virucid
activ
test
compound
show
direct
virucid
effect
extracellular
viru
oxoglaucin
inhibitori
concentr
polioviru
mahoney
found
gml
cpeinhibit
test
gml
classic
plaqueinhibit
test
similar
valu
obtain
vaccin
polioviru
type
strain
antivir
effect
oxoglaucin
replic
virus
belong
anoth
enteroviru
speci
test
ie
coxsacki
echovirus
hevb
six
coxsacki
b
virus
echovirus
test
sensit
antivir
effect
oxoglaucin
endpoint
dilut
method
multicycl
cpe
inhibit
setup
fl
cell
oxoglaucin
reveal
mark
inhibitori
effect
test
enterovirus
concentr
reduc
viru
titer
lg
rang
gml
select
index
greater
even
greater
virus
test
timeofaddit
studi
onestep
viru
growth
cycl
setup
show
strong
viru
inhibit
earli
period
viru
replic
milka
mileva
angel
galabov
depart
medic
physic
biophys
medic
univers
sofia
bulgaria
institut
microbiolog
bulgarian
academi
scienc
sofia
bulgaria
studi
investig
comparison
effect
plant
flavonoid
polyphenol
quercetin
sugarcontain
homologu
rutinosid
rutin
oxid
stress
liver
isol
influenza
viru
inocul
mice
carri
found
experiment
influenza
viru
infect
accompani
graduat
oxid
disturb
liver
mice
despit
absenc
viru
inflamm
tissu
found
experiment
influenza
viru
infect
accompani
signific
increas
lipid
peroxid
product
decreas
natur
antioxid
vitamin
e
glutathion
cyp
inhibit
cytochrom
creductas
liver
monooxygenas
analginndemethylas
amidopyrinendemethylas
compar
control
noninfect
anim
preliminari
day
supplement
mice
rutin
quercetin
combin
subsequ
viru
inocul
influenc
significantli
analyz
paramet
compar
control
protect
effect
rutin
influenza
virusinduc
lipid
peroxid
activ
cyp
liver
monooxygenas
liver
better
express
effect
quercetin
may
due
contain
rutinosid
part
differ
metabol
hyunjeong
lee
jisun
kwon
chiung
moon
jonghwan
kwak
younjeong
lee
changseon
song
avian
diseas
laboratori
colleg
veterinari
medicin
konkuk
univers
seoul
korea
hanyang
univers
seoul
korea
sungkyunkwan
univers
seoul
korea
nation
veterinari
research
quarantin
servic
seoul
korea
one
tradit
korean
medic
herb
extract
name
investig
determin
antiinfluenza
viru
activ
vitro
vivo
show
potent
antivir
activ
influenza
viru
effect
concentr
valu
gml
cytotox
concentr
valu
gml
mdck
cell
treatment
appear
capabl
significantli
amelior
influenza
viru
infect
mice
oral
gavag
treatment
treat
mice
show
significantli
higher
surviv
rate
lower
pathogen
index
well
lung
viru
titer
untreat
control
mice
extract
etoac
nbuoh
isol
activ
compound
antiinfluenza
effect
activ
compound
discuss
antivir
effect
aqeou
ethanol
extract
ocimum
gratissimum
og
terminalia
catappa
tc
gynostemma
pentaphyllum
gp
newbouldia
laevi
nl
aspilia
africana
aa
phyllantu
amaru
pa
leav
examin
cultiv
viru
extract
embryon
chicken
egg
extract
inocul
immedi
viru
zero
time
h
viru
inocul
viru
replic
compar
control
haemagglutin
assay
zero
time
aqeou
extract
og
tc
pa
gp
inhibit
viru
growth
respect
wherea
nl
aa
ethanol
extract
og
tc
pa
gp
time
inhibit
respect
wherea
nl
aa
two
h
viru
inocul
aqeou
extract
og
tc
pa
gp
inhibit
viru
growth
respect
wherea
nl
aa
effect
ethanol
extract
tc
pa
gp
inhibit
viru
respect
wherea
og
nl
aa
herb
studi
use
herbalist
treatment
human
infecti
diseas
intern
confer
antivir
research
held
palm
spring
california
area
confer
begin
sunday
april
end
thursday
afternoon
may
scientif
session
held
westin
mission
hill
resort
rancho
mirag
ca
purpos
intern
confer
antivir
research
provid
interdisciplinari
forum
investig
involv
basic
appli
clinic
research
worldwid
meet
review
recent
develop
area
antivir
research
specif
topic
cover
program
includ
synthesi
chemistri
biochemistri
mechan
action
molecular
biolog
drug
target
vitro
evalu
anim
model
pharmacokinet
toxicolog
clinic
trial
within
area
interest
invit
overview
speaker
oral
present
poster
present
famou
el
paseo
shop
district
palm
desert
downtown
palm
spring
offer
larg
varieti
galleri
boutiqu
shop
numer
mention
restaur
virtual
everi
palat
whether
tast
run
burger
sushi
pizza
escargot
steak
mexican
continent
find
california
flourish
everi
price
rang
hope
take
advantag
opportun
combin
import
learn
experi
magnific
travel
experi
join
us
palm
spring
california
th
intern
confer
antivir
research
isar
confer
committe
